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ABSTRACT 
 
The oral delivery of drugs has several disadvantages, particularly in pediatrics, geriatrics and other 
patients experiencing difficulty in swallowing tablets or capsules. A frequent approach to this problem 
is the use of liquid formulations or buccal drug delivery systems. However, with liquid formulations, 
many drugs have an undesirable solubility or stability in appropriate solvents and dosing accuracy is 
compromised due to the patient being required to measure doses. Current rapidly disintegrating 
buccal drug delivery systems, such as buccal tablets, are able to dissolve rapidly within the oral 
cavity; however the short residence time at the absorption surface is a limiting factor in the 
effectiveness of these delivery systems. Furthermore, buccal tablet and wafer systems tend to be 
brittle and fragile and hence require special protective packaging. A rapidly disintegrating, flexible, 
mucoadhesive fibrous matrix system (FMS) with drug-loaded electrospun fibers incorporated onto a 
polymeric backing film may be capable of overcoming some of the innate disadvantages of the non-
invasive delivery of various drugs, especially those requiring a rapid onset of action.  
 
Various electrospinnable polymers were investigated for suitability in the development of the 
electrospun fibrous layer of the FMS, and it was determined that polyvinylalcohol (PVA) produced 
drug-loaded fibers with the most acceptable morphology and a desirable disintegration time. An ideal 
drug-loaded fiber formulation was obtained by design of experiments and employed in further 
investigations. The original model drug, zidovudine (AZT), exhibited less than 1% permeation after 
90 minutes. Permeation was not adequately increased by penetration enhancers, and AZT was 
therefore tested against diphenhydramine (DPH), which exhibited 42-82% permeation after 5 
minutes. 
 
The polymeric backing film layer was developed by investigating various film-forming polymers and 
methods of film or membrane preparation. Acceptable films were produced by film-casting of 
solutions containing combinations of PVA and hydroxypropylmethylcellulose (HPMC), and variables 
for an Experimental Design were obtained. The variables were fill volume (40-100mL), HPMC 
concentration (0-0.5%
w
/v) and concentration of glycerol (10-15%
w
/w of total polymer mass). The film 
layer was optimized according to a Box-Behnken experimental design, employing the responses 
disintegration time, work of adhesion, maximum detachment force, dissolution and ex vivo 
permeation. 
 
In vitro physicochemical and physicomechanical characterization, as well as ex vivo analysis, was 
performed on the optimized FMS in order to assess the suitability of the system for rapid oramucosal 
drug delivery. The FMS was deemed to be suitable for buccal drug delivery and able to overcome 
some of the inherent limitations of current drug delivery systems. 
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CHAPTER 1 
INTRODUCTION 
 
1.1. Background to this Study 
 
Oral drug delivery in pediatric patients is an area of concern in the pharmaceutical 
industry. The majority of formulations designed for pediatric use are in the form of 
liquids. Liquid formulations have a few advantages over solid formulations. These 
advantages include a faster onset of action, due to drug that is either dissolved or 
suspended in the form of small particles, and convenience of pediatric administration. 
Liquid formulations are easier to swallow than large tablets or capsules, particularly for 
infants, young children and geriatric patients, who experience difficulty with swallowing. 
However, liquid formulations are not always ideal for drug delivery, especially when the 
drug to be delivered has an undesirable stability or is poorly soluble in an appropriate 
liquid, or where loss of drug may occur due to measurement (Winfield, 2004). Examples 
of such drugs include those used in the treatment of HIV/AIDS, Tuberculosis (TB) and 
Malaria. Liquid formulations are also not ideal in terms of dosing accuracy because of 
the necessity for the patient or care-giver to accurately measure the prescribed dose 
(Winfield, 2004; Dixit and Puthli, 2009). Furthermore, there are very few solid drug 
delivery systems designed for pediatric use (Standing and Tuleu, 2005). 
 
The oral administration of a drug, using a liquid or solid drug delivery system, poses 
several challenges. The patient is required to be compliant and able to swallow the drug 
delivery system. Swallowing tablets or capsules can be particularly challenging in 
HIV/AIDS patients who suffer from dysphagia, elderly patients and pediatric patients 
(Sastry et al., 2000). When administered orally, a drug is subjected to the harsh 
environment of the stomach and small intestine, where it comes into contact with 
varying pH and high enzymatic activity, and may be degraded. If the drug remains intact 
and is absorbed, it may then undergo hepatic first pass metabolism. Exposure to the 
harsh gastrointestinal environment and hepatic first pass metabolism may result in the 
drug having a low bioavailability and a lower than optimal plasma concentration 
(Sudhakar et al., 2006). If these factors are bypassed, a superior bioavailability may be 
achieved as well as the possibility of lowering doses and decreasing dosing frequencies 
(Sudhakar et al., 2006; Dixit and Puthli, 2009). There may also be a reduction in the 
 2 
side-effects related to high doses and gastrointestinal transit, and toxicity related to high 
doses (Stanley and Ashburn, 1992; Dixit and Puthli, 2009). 
 
One of the diseases of concern in this study was HIV/AIDS and the novel delivery of 
model drug, zidovudine (AZT). There is currently no cure for HIV/AIDS, and treatment, 
according to the World Health Organization (WHO), is aimed at preserving or restoring 
immunological function, keeping the viral load minimal, thereby reducing the incidence 
of opportunistic infections, and enhancing patient quality of life (WHO, 2007). The 
treatment for HIV/AIDS involves complicated regimens of antiretroviral agents, where 
the patient is required to take at least three different drugs at different times during the 
day (WHO, 2007). For the successful treatment of HIV/AIDS, the drug plasma 
concentration needs to be relatively high in order to completely suppress viral replication 
(Aungst, 1999). AZT is a nucleoside reverse transcriptase inhibitor (NRTI) that is often 
used in HIV treatment regimens (WHO, 2007). When selecting a first line regimen for 
the treatment of HIV in infants and children, the preferred option is a combination of two 
NRTIs and one non-nucleoside reverse transcriptase inhibitor (NNRTI), for example, 
AZT (NRTI), lamivudine (NRTI) and nevirapine (NNRTI) (WHO, 2007). Zidovudine has 
an oral bioavailability of approximately 65% that is relatively low due to hepatic first pass 
metabolism (Aungst, 1999). The World Health Organization (WHO) encourages the 
development of formulations, for the treatment of HIV, that are suited for use in pediatric 
patients, particularly solid formulations (WHO, 2007).  
 
Bypassing the harsh gastrointestinal environment and first pass metabolism can be 
achieved by formulating a drug delivery system that permits the dissolution and 
absorption of drug within the oral cavity (Cappello et al., 2006). The absorption sites 
within the oral cavity are the buccal (cheek), sublingual (under the tongue) and gingival 
(gums) areas. Drug is absorbed most readily from the sublingual area and least readily 
from the gingival area (Stanley and Ashburn, 1992). The oral mucosa is an attractive 
site for drug absorption due to good permeability, a high level of vascularization and 
minimal enzymatic activity compared to the enzymatic activity present in the stomach 
and small intestine that may result in degradation of certain drugs (Giannola et al., 
2007). Another advantage is the fact that a drug delivery system administered via the 
oramucosal route does not need to be swallowed (Hoogstraate and Wertz, 1998). The 
majority of the dose administered would be absorbed from the oral cavity. Drug that is 
not absorbed in the oramucosal region would pass into the gastric region and be 
absorbed via normal gastro-intestinal absorption, but this would be a minimal quantity. 
Current rapidly disintegrating buccal drug delivery systems, such as buccal tablets, are 
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able to dissolve rapidly within the oral cavity. However, the short residence time at the 
absorption surface is a limiting factor in the effectiveness of these delivery systems 
(Madhav et al., 2009). Furthermore, buccal tablet and wafer systems tend to be brittle 
and fragile and hence require special protective packaging (Dixit and Puthli, 2009). 
 
In previous studies, electrospun fibers have been loaded with drug and studied for their 
potential application in controlled drug delivery (Verreck et al., 2003a; Zeng et al., 2003; 
Kim et al., 2004; Kenawy et al., 2007; Tungprapa et al., 2007; Yang et al., 2007; 
Ranganath and Wang, 2008; Kenawy et al., 2009; Loh et al., 2010; Tiwari et al., 2010). 
It has been found that, depending on polymers or combination of polymers used, fibrous 
matrices may demonstrate controlled release of drug and therefore have the potential to 
control the delivery of drugs (Sill and von Recum, 2008). Furthermore, fine control over 
drug release kinetics may be achieved by the use of different electrospinning and drug-
loading techniques (Sill and von Recum, 2008). The incorporation of drug into a low 
density, porous carrier system may result in an enhanced matrix-solvent interaction, 
leading to faster drug dissolution, enhanced bioavailability and an improvement in 
therapeutic effect (Szepes et al., 2007). Methods of formulating porous matrix systems 
include lyophilization (Bredenberg et al., 2003), freeze-casting (Szepes et al., 2007), 
compaction (Carli et al., 1984), electrospinning (Liu et al., 2006) and use of a porogen 
(Vidaurre et al., 2007).  
 
This study therefore proposed to develop a novel, porous, polymeric fibrous matrix 
system (FMS) with electrospun fibers incorporated onto a mucoadhesive, flexible film for 
the oral transmucosal delivery of drugs to infants, children and geriatrics as well as 
other patients experiencing difficulty with swallowing or patients that may be in a 
comatose state. It should be noted that the aim of this study was to design a platform for 
the delivery of various drugs and it is not limited in its application to the delivery of AZT. 
It is proposed to be flexible and versatile enough for the oramucosal delivery of various 
other drugs requiring a rapid onset of action, such as anaglesics, anxiolytics and sleep 
inducers.  
 
1.2. Rationale for this Study 
 
The FMS comprised two components and was formed by electrospinning for the fibrous 
layer and film-casting for the backing film layer, which were proposed to result in high 
drug-loading, high mechanical strength, high porosity, large surface area for hydration, 
mucoadhesion and taste-masking. The high porosity was achieved by the fibrous 
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network that the electro-spun fibers formed. The formulation of the FMS may be an 
alternative to the formulation of low density, porous matrices, such as wafers, produced 
by other methods. The porous, low density matrices were proposed to enhance the 
dissolution of drugs that are sparingly soluble in an aqueous environment by increasing 
the surface area for hydration. The FMS is a solid drug delivery system, resulting in a 
greater dosing accuracy than that of a liquid formulation because the necessity for the 
patient or care-giver to measure doses is not required. The main area that was targeted 
for drug absorption was the buccal region of the oral cavity. Suitable excipients, such as 
citric acid, were employed to mask the taste of the drug. Absorption of drug via the 
buccal mucosa bypasses gastro-intestinal and first pass metabolism and therefore could 
result in a higher bioavailability. 
 
In general, the FMS incorporated drug into a fibrous matrix, from where it was released 
rapidly once in contact with saliva in the oral cavity. A flexible, mucoadhesive film 
enabled the FMS to adhere to the buccal mucosa and the membranes were fast 
dissolving, which resulted in rapid exposure of the drug to saliva (see Figure 1.1). It is 
considered suitable for the administration of drug to pediatric patients, patients suffering 
from dysphagia and the elderly, who experience problems with swallowing tablets, 
capsules and liquids. This was proposed to result in an increase in drug stability as well 
as patient compliance. The WHO strongly encourages the use of solid drug delivery 
systems in HIV patients (WHO, 2007). There is therefore a demand for a solid drug 
delivery system that can be used in pediatric patients, as well as others who experience 
difficulty with swallowing. 
 
Figure 1.1: Schematic representing the dissolution of the fibrous matrix system (FMS) 
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1.3. Aim and Objectives of this Study 
 
The overall aim of this study was to design and develop a porous polymeric Fibrous 
Matrix System (FMS) in the form of a film, which would allow for the immediate release 
of drugs so that they can be absorbed via the oral mucosa. The drug delivery system is 
intended to overcome many of the shortcomings of rapidly dissolving oral drug delivery 
systems, as well as liquid formulations that are designed for pediatric administration. 
 
In order to accomplish this, the following objectives have been outlined: 
 To review the application of electrospinning in drug delivery and, in doing so, 
validate the novelty of the FMS in buccal drug delivery. 
 To identify suitable polymers for the design and development of a rapidly 
disintegrating, porous, polymeric fibrous matrix system (FMS), allowing for the 
immediate release of drugs to be absorbed via the buccal mucosa.  
 To develop drug-loaded fibers by electrospinning and backing films by film-casting. 
 To combine the fibers and films in order to develop a FMS to deliver drug to the 
buccal mucosa. 
 To perform in vitro disintegration and dissolution studies to determine the 
disintegration and drug release characteristics of the system. 
 To perform ex vivo permeation studies to determine the permeation of the model 
drug through the oral mucosa. 
 To optimize the FMS, employing a three-level Box-Behnken experimental design. 
 To perform physicochemical and physicomechanical investigations on the 
formulated FMS. 
 
1.4. Novelty of this Study 
 
Porous matrices for oramucosal drug delivery have been formulated by numerous 
methods, however the FMS is novel in the fact that: 
 It comprises electrospun fibrous structures that are carefully engineered and highly 
porous.  
 Fibers were formed by an electrospinning technique, which is unique in buccal drug 
delivery. 
 The fibers were electrospun directly onto a polymeric film to form the FMS. 
 The FMS is mucoadhesive and intended for delivering drug to the buccal mucosa. 
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1.5. Overview of this Dissertation 
 
Chapter 1 provides an introduction and outlines the background to the study, 
delineating the challenges faced with current rapidly dissolving oramucosal drug 
delivery systems, particularly for pediatric and geriatric patients, and explores the 
rationale for the study. It also covers the aim and objectives of the study. 
 
Chapter 2 is a literature review, focusing on electrospinning and the employment of this 
technique in drug delivery. Solution and processing parameters affecting fiber formation 
during electrospinning are outlined. Furthermore, various methods of drug-loading and 
effects on drug release are elucidated. 
 
Chapter 3 describes the development of the drug-loaded fiber layer, by electrospinning, 
and the polymeric backing film layer, by film-casting, of the FMS. Preliminary 
investigations, where various polymers were assessed for suitability in the development 
of the components of the FMS, are outlined. Variables for an experimental design were 
obtained. Furthermore, the investigation into permeation enhancement is delineated in 
this chapter.  
 
Chapter 4 is a description of the analysis and optimization of the backing film layer 
produced according to three-factor Box-Behnken experimental design. The dependent 
variables assessed in the experimental design were the fill volume, HPMC 
concentration and glycerol concentration. Formulations were analyzed according to five 
responses, namely disintegration time, work of adhesion, maximum detachment force, 
dissolution and permeation. An optimized formulation was determined employing the 
quadratic model. 
 
Chapter 5 describes the in vitro physicochemical and physicomechanical analysis of the 
optimized FMS as well as ex vivo permeation studies.  
 
Chapter 6 expounds the conclusions and future recommendations of the study. 
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CHAPTER 2 
DRUG DELIVERY APPLICATIONS OF ELECTROSPINNING AND 
PROCESSING PARAMETERS AFFECTING FIBER PRODUCTION 
 
2.1. Introduction 
 
Electrospinning of polymers is a unique technology that is used to produce very fine 
fibers in the nano- and micrometer size range (Liang et al., 2007). Electrostatic repulsive 
forces result in a reduced fiber diameter and increased fiber length, unlike fibers 
produced by other methods such as conventional spinning or mechanical drawing (Li et 
al., 2004). Fibers produced by conventional spinning methods are lengthened and 
thinned by being subjected to rheological, gravitational, tensile, inertial and aerodynamic 
forces (Reneker and Chun, 1996). Electrospinning produces thin, continuous fibers 
without using contact, but rather by applying an electrical potential to a liquid (Reneker 
and Chun, 1996; Li et al., 2004; Baji et al., 2010). When an electrical potential is applied 
to a drop of polymer solution at the end of a capillary tube, the rounded drop elongates, 
becoming conical in shape (Baumgarten, 1971; Doshi and Reneker, 1995; Sill and von 
Recum, 2008), termed the Taylor cone (Figure 2.1) (Sill and von Recum, 2008). When 
the electrical field exceeds the surface tension of the liquid, a fine fiber jet is ejected 
from the tip of the Taylor cone (Zeleny, 1935; Liang et al., 2007; Sill and von Recum, 
2008; Baji et al., 2010), travelling through the atmosphere, the solvent evaporates, 
depositing solid polymer fibers on a grounded collector (Sill and von Recum, 2008). The 
gap between the capillary tube and the collector is closed by the charges carried in the 
fiber jet, thereby completing the circuit (Deitzel et al., 2001; Baji et al., 2010). The 
resultant product is a porous fibrous scaffold with a very high surface area to volume 
ratio (Liang et al., 2007; Reneker and Yarin, 2008). 
 
Electrospinning is related to the process of electrospraying, which involves the 
application of an electrical potential to a low viscosity liquid, causing a jet of the liquid to 
accelerate from a capillary tip towards a grounded collector (Deitzel et al., 2001). 
Electrospraying has been used in the production of very fine aerosol particles in the 
sub-micron size range (Jaworek, 2007). Due to the low viscosity of the liquid used in 
electrospraying, the jet will possess a low degree of chain entanglement (Shenoy et al., 
2005; Baji et al., 2010) and the surface tension will cause it to break up (Deitzel et al., 
2001; Hogan and Biswas 2008). Polymer chain entanglement increases with increasing 
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solution concentration and molecular weight (Shenoy et al., 2005; Munir et al., 2009, 
Bhardwaj and Kundu, 2010). A jet of polymer solution exhibiting a low viscosity will 
break up into droplets due to the insufficient chain entanglement density (McKee et al., 
2004; Munir et al., 2009; Baji et al., 2010). Conversely, when the viscosity of the solution 
is increased, and hence adequate chain overlap and entanglements occur, the jet will 
undergo a whipping motion, stretching the fiber and reducing the diameter (McKee et 
al., 2004; Shenoy et al., 2005; Munir et al., 2009). 
 
 
Figure 2.1: Schematic illustrating the set-up of the electrospinning process 
 
Zeleny (1914, 1917 and 1935) investigated the surface instability of liquids when 
subjected to an electrical potential and found that fine threads were produced from the 
conical surface of the drop at the end of a capillary when the applied potential was large 
enough, although the fine threads eventually broke up into fine droplets as they moved 
away from the capillary. However, it wasn’t until Formhals (1934) solved a few technical 
issues, that electrospinning became feasible. Formhals (1934) combined a moveable 
fiber-collecting device with the electrode that attracted the fibers so that the collecting 
device could attract the fibers, although due to the short distance between the jet and 
collector electrodes, fibers were not able to dry completely before reaching the collector, 
resulting in the fibers sticking together and to the collector. In 1939, Formhals improved 
on this (Formhals, 1939), which resulted in greater control over the length of the fibers 
that were produced and the possibility for the formation of composite fibers by an 
electrospinning process that involved the deposition of spun fibers onto a base fiber 
(Formhals, 1940) and succeeding to increase the fiber strength by drawing fibers 
through a rotating funnel (Formhals, 1943).  
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Electrospinning has been applied in several varied fields. In electronics, electrospun 
nanofibers have been used in electronic micro- and nano-devices (Xin et al., 2008), as 
fine conducting fibers (MacDiarmid et al., 2001; Viswanathamurthi et al., 2003; Allaoui et 
al., 2008), as magnetic materials (Ju et al., 2008), as anode material in lithium ion 
batteries (Yao et al., 2008a; Yao et al., 2008b) and as optical and electrical nano-
materials (Tan et al., 2008). In catalysis, electrospun fibers have application in the 
fabrication of catalytic electrodes (Gong et al., 2003; Bai et al., 2008; Li et al., 2008a). 
Electrospinning has been employed in the fabrication of High Efficiency Particulate Air 
(HEPA) filters (Park et al., 2003; Ahn et al., 2006) and filters with a high filtration 
efficiency and low air resistance (Tsai et al., 2002). Nanofibrous materials have been 
investigated for their superior potential in absorption and adsorption and may be applied 
for absorption of water (Ali, 2008) and adsorption of pollutants such as toluene and 
benzene (Oh et al., 2008), as well as for the fabrication of sensors for the detection of 
gases (Ding et al., 2004; Li et al., 2008c), substances such as urea (Sawicka et al., 
2005) or drugs (such as anti-cancer drug, daunorubicin) (Song et al., 2008). Electrospun 
polymer mats have been employed in the fabrication of micro-air vehicle wing skin 
(Pawlowski et al., 2003). Biomedically, electrospun fibers have received much attention 
in the areas of drug delivery (Kenaway et al., 2007; Tungprapa et al., 2007; Sill and von 
Recum, 2008), gene delivery (Liang et al., 2005; Chu et al., 2006; Sill and von Recum, 
2008), prevention of post-operative adhesions (Zong et al., 2004), wound dressing (Khil 
et al., 2003; Chen et al., 2008) and tissue engineering (Yoshimoto et al., 2003; Xu et al., 
2007; Sill and von Recum, 2008). Applications relating to tissue engineering include 
artificial vascular grafts (Xu et al., 2004; Ma et al., 2005; Vaz et al., 2005), neural tissue 
engineering (Yang et al., 2005; Schnell et al., 2007; Chew et al., 2008), tendon and 
ligament tissue engineering (Lee et al., 2005; Sahoo et al., 2006) and bone tissue 
engineering (Liao et al., 2008; Yang et al., 2008). This chapter will delve into the 
pharmaceutical applications of electrospinning as well as the processing parameters 
affecting the production of electrospun fibers.  
 
2.2. Process of Electrospinning 
 
2.2.1. Applied Voltage 
Taylor (1969) observed that the difference between the applied voltage that would 
cause a drop to become unstable and that which would cause it to become conical in 
shape is very small. In general, as the applied voltage increases, the fiber diameter 
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decreases initially and after a certain point, increases once again (Sill and von Recum, 
2008).  
 
In a study by Baumgarten (1971), the jet length of a polymer solution at the optimal feed 
rate increased when the applied voltage was increased. At a capillary-to-collector gap of 
50mm, the fiber diameter initially decreased to a minimum and then increased with 
increasing voltage. At a gap of 75mm, the decrease in fiber diameter to a minimum was 
not so apparent and the diameter increased slightly in response to an increase in 
applied voltage. The optimum capillary feed rate also increased with an increase in 
voltage. 
 
Deitzel and co-workers (2001) examined the effect of applied voltage on a poly(ethylene 
oxide) (PEO)/water system and observed that the applied voltage has a significant 
effect on the shape of the droplet from which the fiber jet originates. Charge is 
transported from the capillary to the collector by the flow of polymer and, if all other 
variables remain constant, an increase in the applied voltage, and hence current, would 
therefore generally reflect an increase in the flow-rate between the capillary and 
collector. An increase in applied voltage resulted in an increase in the spinning current 
for the PEO/water system. At an applied voltage of 5.5kV, jet initiation occurred and 
fibers were found to be straight and free of defects and, as the applied voltage 
increased to 7kV, the current slowly increased. At these lower voltages, the fiber jet was 
ejected from a cone which was formed at the bottom of the droplet on the end of the 
capillary and fibers had fewer bead defects and a cylindrical morphology. Although 
above 7kV, the current increased dramatically ejecting the jet from the liquid surface 
within the capillary tip. Beads on the fibers began to become prevalent and were found 
to be high in density at 9kV, where the jet was ejected from inside the capillary tip. 
Therefore it appears that bead defect formation may be related to current.  
 
In a study undertaken by Zong and co-workers (2002), the effect of applied voltage on 
the morphology of resulting electrospun poly(lactic acid) (PLA) fibers was investigated. 
Jet formation began to occur at 16kV; however the jet was not stable at voltages below 
20kV. At 20kV, the jet originated from the tip of the Taylor cone and very few beads 
were formed; as the voltage was increased to 25kV, the droplet volume became smaller 
and bead formation became more likely. The beads had smaller diameters and the 
distances between beads were shorter. When voltage was increased to 30kV, the 
droplet completely disappeared and the jet emerged from the tip of the capillary, with 
fibers possessing a larger diameter and beads becoming more spherical in shape. 
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Meechaisue and co-workers (2006) used desaminotyrosyl-tyrosine ethyl ester (DTE) to 
synthesize poly(DTE carbonate) and investigated the effect of the applied voltage on the 
electrospun fibers of the synthesized polymer. At applied voltages between 10 and 
15kV/10cm, mostly beaded fibers were formed with the bead density decreasing as the 
voltage increased, while, at voltages between 20 and 25kV/10cm, the produced fibers 
were generally smooth. It was found that the fiber diameter increased, while the fiber 
density decreased with increasing voltage.  
 
Beachley and Wen (2009) investigated the effect of the applied voltage on the diameter 
and length of electrospun polycaprolactone (PCL) fibers. It was observed that both the 
length and diameter of the fibers decreased with increasing voltage. There was also an 
increase in the uniformity of the electrospun fibers with increasing voltage. 
 
2.2.2. Solution Flow-Rate 
At a high applied voltage, where the fiber jet is ejected from inside the capillary and 
bead defects become more prevalent, it may be necessary to increase the pressure 
which causes the drop to protrude from the capillary, thereby replacing the solution 
which was lost when the fiber jet was ejected (Zeleny, 1935). As flow-rate increases, the 
pore size and fiber diameter increase, but when the flow-rate is too high, fibers are 
unable to dry completely before reaching the collector, resulting in one of two things, 
either bead defects occur or the fibers may become flattened (Sill and von Recum, 
2008). A study conducted by Baumgarten (1971), showed that solution flow-rate had 
little effect on fiber diameter, but an increase in flow-rate resulted in an increase in jet 
length.  
 
In a study by Zong and co-workers (2002), it was shown that the lower the solution flow-
rate, the smaller the diameter of the resultant electrospun fibers and beads. Beads and 
larger fiber diameters occurred at higher flow-rates. This could be attributed to the larger 
droplet at the end of the capillary, due to the higher flow-rate, resulting in the solution 
being carried away faster amounting to incomplete drying and formation of beads. 
Theron and co-workers (2004), investigated the effect of solution flow-rate on electric 
current and surface charge density. They found that, as flow-rate increased, electric 
current increased and surface charge density decreased. 
 
Beachley and Wen (2009) investigated the effect of the solution flow-rate on the length 
and diameter of PCL fibers formed by electrospinning. It was found that the flow-rate did 
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not have any significant effect on the length, diameter or uniformity of the fibers. 
Furthermore, it was concluded that once the flow-rate was great enough for fiber 
formation to occur, any further increases only resulted in more solution than necessary 
at the capillary tip. 
 
2.2.3. Polymer Concentration and Solution Viscosity 
It has been shown that the concentration of polymer in the solution to be electrospun 
has an effect on both the viscosity and surface tension of the liquid (Sill and von Recum, 
2008). A higher polymer concentration results in a greater viscosity (Baumgarten, 1971; 
Meechaisue et al., 2006), greater conductivity (Meechaisue et al., 2006), greater chain 
entanglement density (Shenoy et al., 2005; Munir et al., 2009) and a larger fiber 
diameter (Huang et al., 2003; Yang et al., 2004; Bhardwaj and Kundu, 2010).  
 
Doshi and Reneker (1995) investigated the effect of viscosity on the electrospinning of 
aqueous PEO solutions and found that fibers were formed from solutions with 
viscosities between 800 and 4000mPa.s. Below 800mPa.s, the fiber jet broke up into 
droplets and above 4000mPa.s, fiber formation was difficult because the solution dried 
at the tip of the capillary. Fong and co-workers (1999) investigated the effect of viscosity 
of PEO solutions on bead formation in electrospun fibers. They found that a more 
viscous solution was less likely to form beads, but as viscosity increased, the bead 
diameter and distance between beads increased with the bead shape becoming less 
spherical and more spindle-like. Viscoelastic forces competed with surface tension in 
the fiber jet and an increase in viscosity therefore favored the formation of smooth 
fibers. In another study, it was shown that fiber formation from polyacrylonitrile solutions 
occurred between 170 and 21500mPa.s, with viscosities in the upper range resulting in 
incomplete drying of the polymer fiber. As the viscosity increased, jet length and fiber 
diameter increased and the drop at the end of the capillary changed from a 
hemispherical to a conical shape (Baumgarten, 1971). 
 
Deitzel and co-workers (2001) found that electrospinning of aqueous PEO solutions 
between 4 and 10%w/v (~100-2000mPa.s) resulted in the formation of fibers. Whereas 
below 4%w/v, surface tension was the main determinant of fiber morphology and a 
combination of fibers and droplets was formed. At lower concentrations within this 
range, fibers were found to have irregular morphologies as well as bundles and 
junctions due to inadequate drying before reaching the collector. At higher 
concentrations within this range, the fibers were found to be straight and cylindrical, with 
fewer junctions and bundles because fibers were able to dry before reaching the 
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collector due to the lower solvent content. Above 10%w/v, the flow of polymer solution 
through the capillary could not be controlled due to cohesion, and fiber formation was 
inhibited by the high viscosity. It can therefore be concluded that viscosity and surface 
tension often determine the useful range of polymer concentrations in electrospinning 
for a given polymer.  
 
Zong and co-workers (2002) attempted to electrospin PLA solutions of different 
concentrations and then examined the effects on resulting fiber morphology. They 
observed that electrospinning solutions with concentrations below 20%w/v resulted in the 
formation of a mixture of large beads and fibers. Solutions with concentrations above 
40%w/v were highly viscous and difficult to electrospin. As the concentration, and hence 
viscosity, increased between these two extremes, the fibers produced became more 
uniform and the beads had larger diameters and became more spindle-shaped. 
 
Meechaisue and co-workers (2006) examined the effect of different poly(DTE 
carbonate) concentrations on electrospun fiber formation. At 5%w/v (25mPa.s), mainly 
droplets were formed because the viscoelastic force at this concentration was not large 
enough to overcome the repulsive forces of charge, resulting in the fiber jet breaking up 
into droplets. At higher polymer concentrations, the jet was more stable because the 
viscoelastic force exceeded the repulsive forces. Beaded and smooth fibers were 
formed at 10%w/v (148mPa.s) and almost completely smooth fibers were formed at 
15%w/v (505mPa.s). It was proposed that the repulsive forces from the charge within the 
fiber jet resulted in stretching and therefore a smaller diameter. At 20%w/v (1960mPa.s), 
the fiber jet could better resist the stretching repulsive forces of charge and fiber 
diameter was hence greater. In this instance, polymer concentration had little effect on 
surface tension. 
 
2.2.4 Solvent  
In order to allow for sufficient solvent evaporation to occur before the fiber reaches the 
collector, a volatile solvent is required. The choice of solvent therefore plays an 
important role in fiber formation (Sill and von Recum., 2008). Besides the actual 
formation of fibers, the choice of solvent also influences the morphology of the fibers 
(Megelski et al., 2002). The effect of commonly used solvents in electrospinning is 
highlighted in Table 2.1. 
 
 
 
 14 
Table 2.1: Solvent properties and the resulting fiber morphology in electrospinning 
Solvent Boiling 
Point (˚C) 
Fiber 
Morphology 
Other 
Properties 
Reference 
Dichloromethane 
(DCM) 
39.8 Beaded, large 
diameter 
Low 
dielectric 
constant, 
high surface 
tension 
Yang et al., 2004; 
Meechaisue et al., 
2006 
Chloroform 61.2 Beaded at 
very low 
polymer 
concentration, 
smooth at 
higher 
concentration 
High 
intrinsic 
viscosity 
Son et al., 2004 
Methanol 64.7 Small fiber 
diameter with 
↑ methanol 
concentration 
until 50% then 
↑ fiber 
diameter 
High 
dielectric 
constant 
Meechaisue et al., 
2006 
Tetrahydrofuran 
(THF) 
66 Smooth and 
beaded, 
ribbon-like, 
high pore 
density 
High dipole 
moment, 
good 
conductivity 
Jarusuwannapoom 
et al., 2005; 
Megelski et al., 
2002 
Ethylacetate 77.1 Smooth and 
beaded, 
ribbon-like 
High 
dielectric 
constant, 
fair 
conductivity 
Jarusuwannapoom 
et al., 2005 
Ethanol 78.3 Smooth, large 
diameter 
Low surface 
tension, high 
intrinsic 
viscosity 
Fong et al., 1999; 
Son et al., 2004; 
Yang et al., 2004 
Methylethylketone 
(MEK) 
79.6 Flat, ribbon-
like, very few 
beads 
High dipole 
moment, 
good 
conductivity 
Jarusuwannapoom 
et al., 2005 
Dichloroethane 83.5 Smooth and 
beaded, C-
shaped 
High dipole 
moment, fair 
conductivity 
Jarusuwannapoom 
et al., 2005 
Deionized Water 100 Beaded, small 
diameter 
Low intrinsic 
viscosity 
Fong et al., 1999; 
Son et al., 2004 
Dimethylformamide 
(DMF) 
153 Smooth and 
beaded, 
round 
High dipole 
moment, 
high 
conductivity, 
low intrinsic 
viscosity 
Son et al., 2004; 
Jarusuwannapoom 
et al., 2005 
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Fong and co-workers (1999) electrospun PEO fibers using pure water and a mixture of 
ethanol and water. By keeping the PEO concentration constant and increasing the ratio 
of ethanol to water, the solution viscosity increased, resulting in the formation of 
smoother fibers with larger diameters as depicted in Figure 2.2, where the electric field 
was 0.5kV/cm and the weight fraction of PEO was 3.0%. This is most probably due to 
the fact that ethanol is more volatile than water and therefore combinations with higher 
ethanol:water ratios would have evaporated faster, resulting in a greater viscosity, 
thereby facilitating fiber solidification, and a slower rate of bead formation (Theron et al., 
2004).  
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Figure 2.2: Varying PEO fiber morphology from beaded to smooth fibers as the ratio of 
ethanol is increased (Reproduced from Fong et al., 1999) 
 
Megelski and co-workers (2002) investigated the effect of different solvents on fiber 
diameter and pore formation in electrospun polymer fibers. Various solvents with 
different boiling points and vapor pressures were used to electrospin polymer fibers and 
the effect on the fiber diameter and porosity of the fibers was examined. Polystyrene 
fibers were electrospun from tetrahydrofuran (THF), dimethylformamide (DMF) and 
combinations of the two. Fibers electrospun using THF, the more volatile of the two, 
resulted in fibers with very high pore density whereas fibers obtained using DMF 
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resulted in almost completely smooth fibers. The combination of solvents in varying 
ratios resulted in a decrease in pore density as the ratio of DMF:THF was increased.  
 
Son and co-workers (2004) examined the influence of employing water, chloroform, 
DMF and ethanol as solvents on the electrospinning of PEO fibers. They observed that 
fibers that were electrospun using DMF required a higher applied voltage and a longer 
capillary to collector distance than when the other three solvents were used, which 
could be attributed to the higher boiling point of DMF. The minimum polymer 
concentrations for the formation of fibers that were free of beads were 3, 4, 7 and 
10%w/v for chloroform, ethanol, DMF and water, respectively. Employing water as the 
solvent resulted in the production of fibers with the smallest diameter in relation to the 
other three solvents. In another study by Yang and co-workers (2004), the effects of 
employing different solvents for the electrospinning of poly(vinyl pyrrolidone) (PVP) were 
investigated. The solvents investigated were DCM, ethanol and DMF. Ethanol produced 
smooth fibers, whereas beaded fibers were formed upon using DCM or DMF. A 
combination of ethanol and DMF resulted in fibers with diameters as small as 20nm. 
However, a combination of ethanol and DCM resulted in the formation of fibers with 
diameters as large as 300nm.  
 
Jarusuwannapoom and co-workers (2005) also investigated the effects of using different 
solvents on the electrospinning of polystyrene solutions. Of the eighteen solvents that 
were tested, only five of them (DMF, THF, ethylacetate, 1,2-dichloroethane and 
methylethylketone [MEK]) were optimal for electrospinning polystyrene. All the solvents 
had a high dipole moment value, displayed relatively good conductivity and their 
polystyrene solutions had relatively good conductivity values, which are important 
factors for electrospinnability. The qualitative differences in the morphology of the fibers 
formed using these solvents and various solution concentrations were as depicted in 
Figure 2.3.  
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Figure 2.3: Scanning electron micrographs of electrospun polystyrene fibers formed from solutions using 1,2-dichloroethane, 
dimethylformamide (DMF), ethylacetate, methylethylketone (MEK) and tetrahydrofuran (THF) as solvents (Reproduced from 
Jarusuwannapoom et al., 2005) 
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Meechaisue and co-workers (2006) investigated the use of methanol, dichloromethane 
(DCM) and a combination of the two in the electrospinning of poly(DTE-co-20%DT 
carbonate) fibers. Employing pure DCM, which is more volatile than methanol, resulted 
in the formation of beaded fibers; this can be attributed to its low dielectric constant and 
higher surface tension. As the methanol content increased, the fibers became smoother. 
When 10-30% methanol was used, the diameter of the fibers decreased due to the 
higher dielectric constant of methanol, leading to greater charge repulsion. However, 
when 50% of the solvent was methanol, the fiber diameter increased due to the 
increase in electrostatic force, causing the fiber to reach the collector faster. 
 
2.2.5. Solution Conductivity 
Generally, it has been observed that an increase in solution conductivity results in a 
decrease in fiber diameter (Sill and von Recum, 2008). A greater charge carrying 
capacity has been observed in solutions with high conductivity than those with low 
conductivity and the fiber jet produced from a solution of high conductivity is therefore 
subjected to a greater tensile force when exposed to an applied voltage (Sill and von 
Recum, 2008).  Thus, conductivity of a solution is a very important factor in determining 
whether a solution can be electrospun (Jarusuwannapoom et al., 2005).  
 
Fong and co-workers (1999) investigated the influence of adding sodium chloride (NaCl) 
to a solution of PEO in distilled water on electrospun fibers. The net charge density of 
the fiber jet was increased by the addition of NaCl to the solution. This resulted in a 
decrease in resistivity of the fiber jet due to the increased charge flowing into the jet. 
The increased charge resulted in an increased force within the jet and smooth fibers 
were formed. When the charge of the fiber jet was neutralized with ions of opposite 
polarity, electrical forces were reduced and beads were formed. 
 
Zong and co-workers (2002) conducted a study to investigate the effects of adding 
different salts (KH2PO4, NaH2PO4 and NaCl) to PLA solutions for electrospinning. Each 
salt was added separately at 1%w/v to PLA solutions. The resulting electrospun fibers 
were smooth, free of beads and had smaller diameters than fibers electrospun from salt-
free solutions. Solutions containing NaCl produced fibers with the smallest diameter, 
while KH2PO4-containing solutions produced fibers with the largest diameter. The size of 
the ions was found to have an effect on the fiber diameter, where ions with smaller radii 
have a higher charge density and impose greater forces of elongation on electrospun 
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fibers. The small diameter obtained by the addition of NaCl is due to the fact that 
sodium and chloride ions are smaller than potassium or phosphate ions.  
 
Son and co-workers (2004) investigated the influence of adding small amounts of 
polyelectrolytes, poly(allylamine hydrochloride) (PAH) and poly(acrylic acid) (PAA) on 
the conductivity of PEO in water solutions. The viscosity and surface tension of the 
formed solution increased only slightly, whereas conductivity and charge density 
increased significantly when small amounts of PAH and PAA were added. The 
diameters of the resulting electrospun fibers were decreased on addition of the 
polyelectrolytes. In a study by Beachley and Wen (2009), the effect of addition of NaCl 
to PCL solutions was investigated. It was observed that the electrospun fiber diameter 
decreased as the concentration of NaCl in the solution was increased. Solutions that 
were electrospun without NaCl produced beaded fibers, whereas fibers electrospun 
from NaCl-containing solutions were smooth. 
 
2.2.6. Distance between Capillary and Collector 
Generally, the diameter of electrospun fibers decreases as the distance between the 
capillary and the collector increases, which results in beaded fibers being formed at 
smaller distances (Sill and von Recum, 2008).  
 
In a study conducted by Baumgarten (1971), the effect of increasing the distance 
between the capillary and the collector on fiber diameter (when applied voltage was 
increased) was investigated. At a distance of 50mm between capillary and collector, the 
fiber diameter initially decreased to a minimum and then increased with increasing 
voltage. At a gap of 75mm, the decrease in fiber diameter to a minimum was not so 
apparent and the diameter increased slightly in response to an increase in applied 
voltage. Doshi and Reneker (1995) investigated the influence of the distance between 
the capillary and collector on the diameter of electrospun fibers. Fiber diameter 
decreased as the distance increased although at distances greater than 30mm, the fiber 
jet became too small and unstable. Megelski and co-workers (2002) noted no significant 
change in fiber diameter with a change in distance between the capillary and the 
collector. However, bead formation began to occur as the distance decreased.  
 
2.2.7. Addition of Surfactants 
Zeng and co-workers (2003) examined the influence of surfactants and drugs on the 
uniformity and diameter of electrospun PLA fibers. Various cationic, anionic and non-
ionic surfactants and drugs were added to the PLA solution. The surfactants employed 
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were triethyl benzyl ammonium chloride (TEBAC), sodium dodecyl sulfate (SDS) and 
aliphatic PPO-PEO ether (AEO10). Reduction of fiber diameter and improvement of 
fiber uniformity was observed with addition of all three types of surfactant.  
 
2.3. Electrospinning in Drug Delivery 
 
2.3.1. Drug-Loading and Drug Release 
Drug-loading of electrospun fibers can be achieved in various ways (Chew et al., 2005; 
Luong-Van et al., 2006; Tungprapa et al., 2007; Ranganath and Wang, 2008; He et al., 
2009). If the drug and the polymer are soluble in the same solvents, the drug can be 
dissolved directly into the polymer solution (Luong-Van et al., 2006; Tungprapa et al., 
2007; Ranganath and Wang, 2008). If the drug and polymer are not soluble in the same 
solvents, the drug can be solubilized in a small amount of another solvent before being 
added to the polymer solution (Luong-Van et al., 2006; Kenawy et al., 2007; Kim et al., 
2007) or the drug can be dissolved in a solvent that is immiscible with that in which the 
polymer is dissolved and emulsion electrospun (Xu et al., 2005; Li et al., 2008b), or the 
two solutions can be co-axial electrospun (He et al., 2006; Huang et al., 2006). 
Electrospun fibers can also be immersed in a drug solution for drug-loading (Chunder et 
al., 2007). 
 
2.3.1.1. Effect of Drug Dissolved in the Polymer Solution 
Figure 2.4 is a schematic of the drug-loading and electrospinning process when drug is 
dissolved in the same solution as the polymer prior to electrospinning, which results in 
the drug being encapsulated within the electrospun fibers. 
 
Figure 2.4: Schematic of the electrospinning process from drug-loaded polymer 
solutions 
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Zeng and co-workers (2005) investigated the influence of compatibility between the 
polymer solution and drug on the release kinetics of electrospun fiber formulations. 
Paclitaxel, doxorubicin hydrochloride and doxorubicin base were employed as model 
drugs. PLA was dissolved in a mixture of chloroform and acetone. The drugs were 
added to solutions separately. Drugs were encapsulated by PLA fibers and the 
encapsulation was studied. Paclitaxel and doxorubicin base were found to have a good 
compatibility with PLA and good solubility in the chloroform/acetone solvent that was 
used, which resulted in even drug encapsulation. Doxorubicin hydrochloride was not 
adequately encapsulated and was found near or on the surface of the PLA fibers. The 
release rate of paclitaxel and doxorubicin base was nearly zero-order due to fiber 
erosion. A burst release of doxorubicin hydrochloride was observed due to diffusion at 
the surface of the sample. It was concluded that drug solubility and compatibility with 
solvents and polymers are important factors to consider for encapsulation. Lipophilic 
polymers should be used to produce fibers for the encapsulation of lipophilic drugs and 
hydrophilic polymers for hydrophilic drugs in order to ensure that the drug is completely 
encapsulated and hence avoid burst release. 
 
Taepaiboon and co-workers (2006) incorporated four different non-steroidal anti-
inflammatory drugs (NSAIDs) into electrospun PVA fibrous mats for transdermal drug 
delivery. PVA was dissolved in distilled water and the model drugs, sodium salicylate, 
diclofenac sodium, naproxen and indomethacin, were added individually to PVA 
solutions. These solutions were electrospun and the fibers were collected on a rotating 
metal drum. Drug encapsulation efficiency ranged from 81 to 98%. Sodium salicylate-
loaded fibrous mats displayed a burst release due to its high water solubility. As the 
fibrous matrix absorbed water and swelled, the drug was solvated and rapidly leached 
out of the matrix. The total percentage of drug release from the fibrous mats at 24 hours 
was 98, 97, 76, and 42% for naproxen, sodium salicylate, diclofenac sodium and 
indomethacin, respectively. Drug-loaded PVA mats were assessed for potential in 
transdermal drug delivery by an ex vivo diffusion study. 
 
Suwantong and co-workers (2007) prepared curcumin-loaded cellulose acetate fibrous 
mats. Cellulose acetate was dissolved in a mixture of acetone and DMAc. Curcumin 
was dissolved in the polymer solution at 5, 10, 15 and 20%w/w based on the cellulose 
acetate content and the resulting solution was electrospun. Drug encapsulation 
efficiency was 101.9±0.8%, 95.6±2.5%, 91.4±0.4% and 90.8±0.4% for the 5, 10, 15 and 
20%w/v solutions respectively. The maximum curcumin release was greatest for the 
20%w/v solution and lowest for the 5%
w/v solution. An initial burst release of curcumin 
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occurred followed by a gradual increase in curcumin release over 50 hours. It was 
concluded, from the study, that curcumin-loaded fibrous mats may have potential 
application as transdermal or topical patches or as wound dressings. 
 
In another study conducted by Taepaiboon and co-workers (2007), cellulose acetate 
mats were loaded with vitamins and investigated for in vitro release characteristics. 
Solutions were made by dissolving 17%w/v cellulose acetate and vitamin A or vitamin E 
in a mixture of acetone and dimethylacetamide (DMAc). The solution was electrospun 
and fibers were collected on a rotating metal drum. Drug encapsulation efficiency was 
82.9±2.2% for vitamin E and 44.5±1.1% for vitamin A. There was a gradual increase in 
the rate of release of vitamin A and E from the fibrous mats. After 6 hours, a maximum 
of about 34% of vitamin A had been released. After 24 hours, a maximum of about 52% 
of vitamin E had been released. The proposed application of the vitamin-loaded fibrous 
mats was for transdermal drug delivery. 
 
Ranganath and Wang (2008) fabricated poly(lactic-co-glycolic acid) (PLGA) microfiber 
implants by electrospinning. PLGA was dissolved in a mixture of DCM and DMF at 
30%w/v. Paclitaxel, which was employed as the model drug, was dissolved in the 
polymer solution and the resulting solution was electrospun. Fibers were collected as 
mats on a rotating drum covered with aluminum foil. The mats were cut into sheets or 
punched as discs. Paclitaxel encapsulation efficiency was found to be 98±4.9% for 
PLGA 85:15 fibers and 94±0.57% for PLGA 50:50 fibers. Drug release occurred over 80 
days and there was low initial burst release. Paclitaxel release was nearly zero order for 
the discs, although drug was released faster from PLGA 50:50 fibers than from PLGA 
85:15 fibers due to the higher glycolic acid content of the former. From in vitro cellular 
apoptosis and in vivo tumor inhibition studies, it was concluded that PLGA mats may 
have application as implants for chemotherapy against brain tumors. 
 
2.3.1.2. Effect of Drug Solubilized Prior to Addition to Polymer Solution 
When the drug is not soluble in the same solvent as the one used for the polymer 
solution, it may be solubilized prior to addition to the polymer solution and the resulting 
solution then electrospun. 
 
Kenawy and co-workers (2002) investigated electrospun fiber mats as drug delivery 
systems for the controlled delivery of tetracycline hydrochloride which was used as a 
model drug. Poly(ethylene-co-vinyl acetate) (PEVA), poly(lactic acid) (PLA) and a 50:50 
blend of PEVA and polyvinylalcohol (PVA) were dissolved individually in chloroform. 
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Tetracycline was dissolved in a small amount of methanol for solubilization and then 
added to the polymer solutions. These solutions were electrospun and fibers were 
collected on a stainless steel sheet on a metal drum. PEVA mats had the fastest drug 
release rate. They released approximately 65% of drug content within 5 days. The 50:50 
PLA/PEVA mats released 50% of drug content within 5 days. PLA mats exhibited an 
initial burst release effect arising from the drug that was on the surface of fibers and 
thereafter a negligible release over the next 50 hours. 
 
Kim and co-workers (2004) investigated the release of hydrophilic drug, cefoxitin 
sodium, from PLGA-based electrospun fibrous scaffolds. PLGA was dissolved in DMF at 
33%w/v. Cefoxitin sodium was dissolved in a small amount of water and this aqueous 
drug solution was slowly added to the polymer solution. The drug/polymer solution was 
electrospun and the fibers were collected on a rotating metal drum. The drug 
concentration was found to influence the morphology and density of the scaffolds. As 
the drug concentration increased, the density decreased and the fiber morphology 
changed from beaded fibers to smooth fibers. Adding poly(ethylene glycol) (PEG)-PLA 
block copolymer resulted in sustaining of the drug release to up to one week. It was 
concluded that the scaffolds may have potential in the prevention of post-surgical 
infections and adhesions.  
 
In a study by Luong-Van and co-workers (2006), heparin loaded fibrous PCL mats were 
fabricated by electrospinning. Heparin was dissolved in a small amount of water and 
methanol was added. This solution was added to DCM and the resulting solution was 
used to dissolve PCL. The polymer/drug solution was electrospun and the fibers were 
collected on glass microscope slides. Heparin was released from the fibrous mats in a 
sustained manner over a period of 14 days. The released heparin was found to maintain 
biological functionality and it was concluded that the fibers had potential application for 
the delivery of heparin at the site of vascular grafts. 
 
In another study, Kenawy and co-workers (2007) developed new systems of controlled 
drug release by electrospinning. Partially and fully hydrolyzed PVA was dissolved in 
deionized water. Ketoprofen was dissolved in a small amount of methanol and the 
solution was added to the polymer solution. The surfactant, Triton X-100 was added to 
the fully hydrolyzed PVA solution before addition of the drug in methanol. The solutions 
were electrospun and the resulting fibers were collected on a metal collector as fibrous 
mats. It was found that fully hydrolyzed PVA with entrapped ketoprofen could only be 
electrospun when combined with a small amount of surfactant and acetic acid. 
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Stabilization treatment with methanol or ethanol resulted in crosslinks within the fibers. 
Fibers that were not treated with alcohol showed a fast initial release of a large 
percentage of the drug content. Fibers treated with methanol showed a fast initial 
release of a much lower percentage of the drug content as well as a slow drug release 
over a period of two weeks. However, the overall drug release was lower from treated 
fibers. The degree of hydrolysis of PVA also affected the drug release rate. 
 
Kim and co-workers (2007) examined the controlled release of a protein drug from 
electrospun fiber meshes composed of a blend of poly(ε-caprolactone) (PCL) and PEO. 
Lysozyme was employed as a model protein. A blend of PCL and PEO was dissolved in 
chloroform at varying ratios. Salt-free and dried lysozyme were dissolved in 
dimethylsulphoxide (DMSO) and the resulting solution was mixed with the polymer 
blend solution. The polymer/lysozyme solution was electrospun and the fiber meshes 
were collected on a rotating metal drum. Protein release studies were carried out and it 
was found that blends containing a high proportion of PEO demonstrated a more rapid 
protein release; therefore lysozyme release can be readily controlled by varying the 
polymer blend ratio. It was concluded that this protein delivery strategy may find 
application in wound dressing and tissue engineering. 
 
2.3.1.3. Effect of Co-Axial Electrospinning 
Co-axial electrospinning involves the electrospinning of two separate solutions 
simultaneously such that the inner solution is ejected from the capillary tip inside the 
outer solution to essentially produce a fiber within a fiber (Sill and von Recum, 2008). A 
schematic of the co-axial electrospinning process is shown in Figure 2.5. 
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Figure 2.5: Schematic of the drug-loading and electrospinning process for co-axial 
electrospinning 
 
In a study by He and co-workers (2006), drug loaded core-sheath fibers were produced 
by co-axial electrospinning. PLA was dissolved in a mixture of chloroform and acetone 
and the model drug, tetracycline hydrochloride, was dissolved in a mixture of methanol 
and chloroform with a small amount of PLA. Triallyl isocyanurate was added to the 
polymer solution as a crosslinking agent. Drug concentration was kept constant while 
polymer concentration was varied. The drug solution was fed through the inner needle 
and the polymer solution through the outer needle. The fibers were collected on a 
grounded metal screen. A lower polymer concentration resulted in the formation of more 
uniform fibers with narrower diameter distribution, whereas higher polymer 
concentrations resulted in the formation of fibers with larger diameters. Sustained drug 
release was observed over a period of 32 days. Thus, drug release rate may be 
adjusted by changing the polymer concentration and hence sheath thickness. It was 
concluded that these fibrous membranes may have potential application in drug delivery 
or as sutures and wound dressings. 
 
Huang and co-workers (2006) fabricated drug-loaded core-sheath poly(ε-caprolactone) 
(PCL) fibers by co-axial electrospinning for application in wound dressing. PCL was 
dissolved in a mixture of chloroform and ethanol and the model drugs, resveratrol and 
gentamycin sulfate were dissolved in ethanol and water, respectively. The polymer 
concentration was kept constant and the drug concentrations varied. The drug and 
polymer solutions were fed through co-axial needles, with the drug solution in the inner 
needle and the polymer solution in the outer needle. An electrical potential was applied 
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to the inner solution and nanofibers, with a drug core and an outer polymer sheath, were 
collected on a grounded metal screen. It was found that when the drug and polymer 
solutions were miscible (resveratrol loaded fibers), an increase in drug concentration 
resulted in a decrease in bead formation, but when the drug and polymer solutions were 
immiscible (gentamycin sulfate loaded fibers), the opposite was true. On testing the 
erosion and drug release rate, no burst release was observed for either drug and 
release was observed to be smooth over seven days. However, this study did not 
include tissue studies. 
 
2.3.1.4. Effect of Emulsion Electrospinning 
When the drug and polymer are not soluble in the same solvent or miscible solvents, the 
solutions of drug and polymer can be formulated into an emulsion and emulsion 
electrospun to form drug-loaded fibers. Figure 2.6 is a schematic of the emulsion 
electrospinning process. 
 
 
Figure 2.6: Schematic of the emulsion electrospinning process 
 
Xu and co-workers (2005) electrospun ultra-fine fibers containing a water-soluble drug 
from water-in-oil (W/O) emulsions. The model drug was doxorubicin hydrochloride, 
which was dissolved in water to form the aqueous phase. Amphiphilic PEG-PLA diblock 
copolymer was dissolved in chloroform to form the oily phase. Sodium dodecyl sulfate 
(SDS) was added to the polymer solution as an emulsifying agent. The drug solution 
was slowly added to the polymer solution and emulsified. The resulting W/O emulsion 
was electrospun and the fibers were collected on a grounded target. The drug was 
completely encapsulated inside the fibers because it was dissolved in the aqueous 
phase of a stable emulsion. The release of the drug was controlled by diffusion and 
enzymatic degradation and was found to occur slowly over 10 hours. An in vitro 
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cytotoxicity assay was performed and it was found that the doxorubicin hydrochloride 
fibers exhibited satisfactory cytotoxicity against tumor cells. 
 
Qi and co-workers (2006) produced PLA composite fibers through electrospinning from 
W/O emulsions. A surfactant called sodium bis(2-ethylhexyl) sulfosuccinate was 
dissolved in DCM. Alginate was dissolved in water to which bovine serum albumin 
(BSA), the model drug, was added. The aqueous solution was slowly added to the DCM 
phase and the mixture was vortexed. A calcium chloride solution was added to cross-
link the alginate to form calcium alginate gel beads. PLA was then added to this 
emulsion and dissolved in the DCM phase. The final emulsion was electrospun and 
fibers were collected as mats on grounded aluminum foil. The calcium alginate beads 
were the drug reservoirs within the fibers and became spindle-shaped on 
electrospinning. An initial burst release was observed due to protein adsorbed or loosely 
associated on the fiber surface. A slow release over 120 hours followed the burst 
release.  
 
In a study that was conducted by Li and co-workers (2008b), proteinase K was loaded 
inside PEG-PLA fibers by emulsion electrospinning. PEG-PLA and SDS were dissolved 
in chloroform, and an aqueous proteinase K solution was slowly added to the polymer 
solution to form a W/O emulsion. The emulsion was electrospun and fibers were 
collected on a metal drum covered with aluminum foil. The formed fibers were found to 
have a core-sheath structure, with proteinase K forming the core and PEG-PLA forming 
the sheath. The fiber, core and sheath diameters could be adjusted by changing the 
size of emulsion droplets before electrospinning. Almost 100% mass loss occurred after 
7 days of in vitro biodegradation. 
 
Maretschek and co-workers (2008) prepared highly hydrophobic nanofibers that were 
loaded with protein. Cytochrome C, the hydrophilic model protein was dissolved in water 
and PLA in chloroform. Hydrophilic polymers such as poly(ethylene imine) (PEI) or 
poly(l-lysine) (PLL) were added to the aqueous phase before emulsification in order to 
reduce the hydrophobicity of the fibers. Emulsions were prepared and electrospun, and 
fibers were collected on a round steel plate covered with aluminum foil. Protein 
encapsulation efficiency was between 85 and 95%. Generally, protein release appeared 
to be dependent on the surface tension of the release medium. PLA fibers 
demonstrated very slow controlled release behavior. Nanofibers prepared with higher 
PLA concentrations showed no burst release whereas lower concentrations resulted in 
an increased release rate. Incorporation of hydrophilic polymers into the aqueous phase 
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resulted in a larger fiber diameter and an adjustable protein release rate. However, 
potential drug delivery applications were not explored in this study. 
 
In another study, Xu and co-workers (2008) prepared doxorubicin hydrochloride-loaded 
PEG-PLA nanofibers by emulsion electrospinning. The model drug was doxorubicin 
hydrochloride which was dissolved in water at various concentrations. PEG-PLA was 
dissolved in chloroform with SDS as a surfactant. These two solutions were emulsified 
and homogenized to produce a homogenous W/O emulsion. The emulsion was 
electrospun and the fiber mats were collected and freeze-dried to remove residual 
chloroform. The drug was incorporated inside the nanofibers, which had a core-sheath 
structure. A higher doxorubicin concentration in the aqueous phase resulted in a thinner 
core, which was due to the inward movement of the aqueous phase being related to the 
drug content in the drops. The drug release rate was found to decrease as drug content 
increased because of the drug distribution within the fibers forming a reservoir-type 
system. 
 
2.3.1.5. Effect of Drug-Loading by Immersion in Drug Solution 
An alternative method of drug-loading is to immerse electrospun polymer fibers in a 
drug solution. Drug release from such systems may be controlled by coating of the 
fibers after drug-loading (Chunder et al., 2007). Figure 2.7 is a schematic of the 
immersion drug-loading process. 
 
Chunder and co-workers (2007) fabricated fibers by electrospinning PAA and PAH, both 
of which are weak polyelectrolytes. The fibers were studied for their potential in 
controlling the release of cationic molecules, using methylene blue as a model drug. 
The fibers were loaded with methylene blue by crosslinking, immersion in a sodium 
hydroxide solution, drying and then immersion in a solution containing methylene blue. 
Controlled drug release was due to the negatively charged carboxylate groups in the 
fibers bounded to the positively charged drug. The degree of ionization of PAA was 
dependent on the pH of the dissolving medium and therefore drug release could be 
controlled by pH. As the pH of the non-buffered dissolving medium decreased below 6, 
protons began to bind to carboxyl groups, resulting in methylene blue being released. 
When the fibers were placed in phosphate buffered saline (PBS), methylene blue 
underwent a fast release due to swelling caused by the PBS. It was also observed that 
drug release could be further controlled by coating the fiber surfaces. Coating the fibers 
with a perfluorosilane network, that would not swell in PBS, resulted in obstruction of the 
diffusion of methylene blue and therefore a sustained release. Coating the fibers with 
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multilayers of PAA and poly(N-isopropylacrylamide) (PNIPAAM), resulted in a 
temperature-controlled release of methylene blue. It was concluded that these 
polyelectrolyte fibers had potential application in drug delivery; however, specific 
applications were not explored. 
 
 
Figure 2.7: Schematic of immersion drug-loading of electrospun fibers 
 
2.3.2. Electrospun Fibers in Drug Delivery 
Electrospun fibers have been examined for various pharmaceutical applications. Drug 
delivery implants that release an anticancer drug in a sustained manner at a tumor site 
have been produced by electrospinning (Xu et al., 2005; Ranganath and Wang, 2008). 
Another example of a site specific drug delivery system fabricated by electrospinning is 
one where heparin can be delivered to the site of a vascular graft (Luong-Van et al., 
2006). Electrospun fibrous mats have been assessed for their application in trans-
dermal drug delivery systems or as wound dressings (Verreck et al., 2003a; He et al., 
2006; Taepaiboon et al., 2006; Suwantong et al., 2007; Taepaiboon et al., 2007; 
Tungprapa et al., 2007). The prevention of post-surgical abdominal adhesions and 
infections has been investigated using antibiotic-loaded electrospun fibrous scaffolds 
(Kim et al., 2004; Zong et al., 2004).  
 
2.3.3. Polymers Employed for Drug Delivery Applications 
Various polymers have been electrospun and applied in drug delivery as exemplified in 
Table 2.2. Polymer, solvent and drug compatibility are important parameters when 
attempting to achieve stable and reproducible drug delivery, as a general rule, lipophilic 
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polymers should be used with lipophilic drugs while hydrophilic polymers should be 
used with hydrophilic drugs in order to obtain a stable release profile (Zeng et al., 2005).  
 
2.3.4. Crosslinking of Fibers 
Yang and co-workers (2007) prepared gelatin/PVA nanofibers and investigated their 
potential application in controlled drug release. An aqueous solution of PVA was added 
to a gelatin/formic acid solution, using different ratios. Raspberry ketone, the model 
drug, was added to the gelatin/PVA solutions, which were subsequently electrospun. It 
was found that, as the ratio of PVA increased, fiber diameter and tensile strength 
increased. Due to the water solubility of raspberry ketone, gelatin and PVA, an initial 
burst drug release was obtained. It was further observed that when the drug 
concentration increased, the percentage release was lower. Glutaraldehyde was 
employed as a crosslinking agent and an increase in crosslinking time resulted in a 
decrease in the rate of drug release. It was concluded that these crosslinked 
electrospun fibers may have application in controlled drug delivery. Specific potential 
drug delivery applications were, however, not explored in this study. 
 
2.4. Other Applications of Electrospun Fibers 
 
2.4.1. Biomedical Applications 
2.4.1.1 Composite Scaffolds Prepared by Electrospinning  
Composite scaffolds are useful in tissue engineering for the reconstruction of structural 
tissues, multi-tissue organs and tissue interfaces (Maquet et al., 2004; Schek et al., 
2005; Chan and Leong, 2008). Hydroxyapatite/PLA composites have a high mechanical 
strength, good osteo-conductivity, osteo-inductivity and biodegradability (Liao et al., 
2005; Miao et al., 2008). An ideal three-dimensional scaffold for tissue engineering 
should have a highly porous structure with a large surface area (Chen et al., 2006; 
Viswanath and Ravishankar, 2007). Such a scaffold can be prepared by electrospinning 
(Deng et al., 2007; Xu et al., 2007).  
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Table 2.2: Polymers, drugs and solvents for application in drug delivery 
Polymer Solvent Drug(s) Reference 
Cellulose acetate 
 
2:1 Acetone/DMAc 
 
Naproxen, indomethacin, 
ibuprofen, sulindac 
Tungprapa et 
al., 2007 
Curcumin Suwantong et 
al., 2007 
Vitamin A, vitamin E Taepaiboon et 
al., 2007 
Poly(ε-
caprolactone) 
(PCL) 
7:3 DCM/methanol Heparin Luong-Van et 
al., 2006 
3:1 
Chloroform/ethanol 
Resveratrol, gentamycin 
sulfate 
Huang et al., 
2006 
Poly(ethylene 
oxide)/poly(ε-
caprolactone) 
(PEO/PCL) blend 
Chloroform Lysozyme Kim et al., 2007 
Poly(vinyl 
alcohol) (PVA) 
Deionized water Ketoprofen Kenawy et al., 
2007 
Sodium salicylate, 
diclofenac sodium, 
naproxen, indomethacin 
Taepaiboon et 
al., 2006 
Gelatin/PVA 
blend 
Gelatin in formic acid, 
PVA in deionized 
water 
Raspberry ketone Yang et al., 
2007 
Poly(lactic-co-
glycolic acid) 
(PLGA) 
DCM/DMF Paclitaxel Ranganath and 
Wang, 2008 
DMF Cefoxitin sodium Kim et al., 2004 
Polyurethane DMF Itraconazole Verreck et al., 
2003a DMAc Ketanserin 
Poly(lactic acid) 
(PLA) 
2:1 
Chloroform/acetone 
Doxorubicin 
hydrochloride 
Zeng et al., 
2005 
Tetracycline 
hydrochloride 
He et al., 2006 
Chloroform Cytochrome C Maretschek et 
al., 2008 
DCM Bovine serum albumin 
(BSA) 
Qi et al., 2006 
Poly(ethylene-co-
vinyl acetate) 
(PEVA) 
Chloroform Tetracycline 
hydrochloride 
Kenawy et al., 
2002 
Poly(ethylene 
glycol)- 
polylactide (PEG-
PLA) 
Chloroform Doxorubicin 
hydrochloride 
Xu et al., 2005, 
Xu et al., 2008 
Poly(acrylic 
acid)/poly(allylami
ne hydrochloride) 
(PAA/PAH) blend 
Deionized water Methylene blue Chunder et al., 
2007 
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Chu and co-workers (2006) attempted to develop a non-viral gene carrier for a specific 
target by electrospinning. It was proposed that developing a gene carrier would enable 
delivering of genes that represent growth factors which could aid the repairing of 
fractured bones. Plasmid DNA was condensed in a poor solvent mixture. The 
condensed DNA was then encapsulated in a tri-block copolymer of poly(lactide)-b-
poly(ethylene glycol)-b-poly(lactide) (LEL). PLGA and encapsulated DNA solutions were 
electrospun to form a nano-fibrous scaffold. Promising results were obtained. Thus, it is 
anticipated that an effective gene carrier could be developed in future using 
electrospinning. 
 
In a similar study, Deng and co-workers (2007) prepared poly(l-lactic 
acid)/hydroxyapatite (PLA/HAP) hybrid nanofibrous scaffolds by electrospinning. The 
structure and morphology of the scaffolds were investigated using SEM, differential 
scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FTIR). The 
results indicated that the average diameter of hybrid nanofibers was similar to that of 
pure poly(l-lactic acid) fibers, but a new surface bonding (COO-) was formed in hybrid 
nanofibers which resulted in the surface of the fibers becoming coarse. The weight loss 
and water uptake of hybrid scaffolds decreased while the viscosity-average molecular 
weight decreased in the phosphate buffer solution with time. This was as opposed to the 
results obtained with pure poly(l-lactic acid) scaffolds where weight loss and water 
uptake increased continuously and the viscosity-average molecular weight decreased in 
the phosphate buffer solution with time. A possible explanation is that the dissolving 
hydroxyapatite particles acted as a physical barrier and blocked off the entry of water. 
The biocompatibility of these scaffolds has been investigated on human osteosarcoma 
MG-63 cell culture and the results have shown that the cells could adhere well and 
proliferate better on the hybrid scaffolds than pure scaffolds.  
 
In a study undertaken by Xu and co-workers (2007), electrospun composite fibrous 
scaffolds, composed of poly(l-lactide)-grafted hydroxyapatite (PLA-g-HAP) nanoparticles 
and a polylactide (PLA) matrix were produced. The morphology of the composite fibers, 
as well as the distribution of PLA-g-HAP nanoparticles in the fibers, was investigated 
using environmental scanning electron microscope (ESEM) and transmission electron 
microscopy (TEM). Results showed that at a low PLA-g-HAP content (approximately 
4%w/v), the nanoparticles dispersed uniformly in the fibers and the composite fibrous 
mats exhibited higher strength properties, compared to the pristine PLA fiber mats and 
the simple hydroxyapatite/PLA blend fiber mats. However, as the content of PLA-g-HAP 
increased, the nanoparticles began to aggregate, which resulted in the deterioration of 
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the mechanical properties of the composite fiber mats. Thus, degradation behaviors of 
the composite fiber mats depended entirely on the PLA-g-HAP content. At a low PLA-g-
HAP content, degradation was delayed presumably due to the reduction of autocatalytic 
degradation of PLA while at high PLA-g-HAP content, degradation rate increased, most 
likely due to the enhanced wettability of the composite fibers and the escape of the 
nanoparticles from fiber surfaces during incubation. 
 
Ma and co-workers (2008) attempted to capture bone marrow-derived hematopoietic 
stem cells into nanofiber scaffolds. PLGA was mixed with collagen at a 1:1 ratio and 
solutions of varying concentrations were prepared. The solutions were electrospun and 
the resulting fiber scaffolds were dried. The bone marrow-derived hematopoietic stem 
cells were seeded into wells and exposed to the fiber scaffolds, onto which they became 
attached. This method of capturing cells showed potential in the design of artificial 
carriers of bone marrow-derived stem cells. 
 
2.4.2. Electronic Applications 
In a study by Bai and co-workers (2008), silver chloride nano-particles were 
incorporated into PVP nanofibers to produce organic-inorganic composite fibers by 
electrospinning. The silver chloride particles were dispersed successfully within the PVP 
matrix. The composite fiber matrices may have potential application as catalyst, 
electronic and photonic materials. Ju and co-workers (2008) prepared manganese 
ferrite (MnFe2O4) nanofibers by electrospinning a mixture of poly(vinyl acetate) (PVAc) 
and MnFe2O4. After collecting and drying the fibers at 80˚C for 6 hours, the fibers were 
oxidized by heating at 400, 600 and 800˚C for 4h to get manganese ferrite fibers. Due to 
the high electrical resistance and high magnetic permeability of manganese ferrite, it is 
expected that these fibers may have potential application as magnetic material that may 
be used in electronic devices, magnetic recording devices and magneto-optical 
recording.  
 
2.4.3. Adsorption Applications 
Oh and co-workers (2008) used electrospinning to produce nanofibers that, when 
activated, are able to adsorb toluene. Toluene, which is a volatile organic compound, is 
considered to be a pollutant and therefore the aim is to reduce its level in the 
atmosphere. Activated carbon nanofibers were prepared by electrospinning 
polyacrylonitrile-based fibers and activating the fibers at temperatures between 800 and 
1000˚C. The high surface area and large micro-pore volume of the activated carbon 
nanofibers resulted in an excellent toluene adsorption capacity. 
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2.4.4. Sensor and Drug Content Determination Applications 
Sawicka and co-workers (2005) developed an electrospun fibrous mat for urea 
biosensing. A mixture of urease and PVP was electrospun and the fibers were collected 
as mats. Urease converted urea to ammonia, which could be measured as a mV value. 
This system proved to be an excellent biosensing device. Kang and co-workers (2007) 
developed a method of extracting trazodone from human plasma with an electrospun 
nanofiber solid-phase extraction sorbent. A polystyrene solution was electrospun and 
the fiber web was collected on a copper grid. Samples were pushed through this 
sorbent and trazodone was extracted. The sorbent was then washed with water and 
analytes were eluted with methanol. The methanol used for elution was analyzed by 
high performance liquid chromatography (HPLC). This method of extraction and 
analysis of trazodone was found to be effective. 
 
2.4.5. Filtration Applications 
Ahn and co-workers (2006) developed nano-filters by electrospinning Nylon 6. Generally 
nanofibers have a very large surface area and small pore size compared to 
conventional textiles. Nylon 6 solutions with concentrations between 15 and 24%w/v 
were electrospun and the fibers were collected on a drum covered with steel mesh. The 
filtration efficiency and pressure drop of the nanofibers was compared to that of High 
Efficiency Particulate Air (HEPA) filters. The nylon 6 nano-filters were found to have a 
filtration efficiency that was greater than that of commercial HEPA filters. Thus, nylon 6 
nano-filters showed the potential for application as high efficiency filters.  
 
2.5. Concluding Remarks 
 
Electrospun fibers have shown great potential in many areas, including drug delivery. 
Altering the processing parameters and solution constituents used in the electrospinning 
process can greatly influence the morphology of the fibers formed. Research conducted 
thus far has shown that it is now possible to produce low-cost, high-value, high-strength 
fibers from biodegradable and renewable materials. In this regard, electrospun fibers 
have shown great potential for application in wound dressings, filtration, bone tissue 
engineering, catalyst supports, non-woven fabrics, reinforced fibers, support for 
enzymes, fuel cells, conducting polymers and composites, photonics, medicine, fiber 
mats serving as reinforcing component in composite systems,  fiber templates for the 
preparation of functional nanotubes and drug delivery systems. Drugs can be 
incorporated inside or on the surface of fibers, using various methods, and may be 
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released rapidly or in a controlled manner. Therefore electrospun fibers may display a 
considerable scope for use as potential drug delivery carriers for the treatment of 
various diseases. The use of electrospun fibers in rapid drug delivery has, however, not 
been extensively investigated in previous studies. 
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CHAPTER 3 
DEVELOPMENT AND PREFORMULATION OF A POLYMERIC, 
MUCOADHESIVE BACKING FILM LAYER AND A DRUG-LOADED 
ELECTROSPUN FIBROUS LAYER 
 
3.1. Introduction 
 
A drug delivery system intended for accelerated oramucosal drug delivery is required to 
be rapidly disintegrating, releasing drug almost instantaneously to the buccal mucosa 
for immediate absorption (Rossi et al., 2005). This may be achieved by the use of water-
soluble polymers and a large surface area exposed to the dissolution medium (Verreck 
et al., 2003b; Dokoumetzidis and Macheras, 2006). Electrospun fibers exhibit an 
exceedingly large surface area to mass ratio (Reneker and Yarin, 2008), which not only 
enhances the dissolution rate, but also increases the bioavailability and total amount of 
drug released in comparison to cast-films of the same composition (Agarwal et al., 
2008) and may therefore find application in rapid oramucosal drug delivery. 
 
Due to the relatively short residence time of an oramucosally administered drug delivery 
system at the site of absorption, mucoadhesion is often required (Ponchel, 1994). 
Mucoadhesive drug delivery systems are advantageous in that the entire system is 
rendered immobile, an intimate contact between the system and buccal mucosa is 
created (Andrews et al., 2009) and a high drug concentration at the absorption surface 
is achieved (Ponchel, 1994). This results in a reduction in the required drug 
concentration as well as an improved bioavailability (Andrews et al., 2009). Thin, 
mucoadhesive films are favorable for oramucosal drug delivery due to the flexible nature 
and high contact surface area of such films (Perioli et al., 2004; Ponchel, 1994). 
 
Several polymers have been electrospun for the purpose of drug delivery (Sill and von 
Recum, 2008; Bhardwaj and Kundu, 2010), including polyvinylalcohol (PVA) 
(Taepaiboon et al., 2006; Kenawy et al., 2007), cellulose acetate (Tungprapa et al., 
2007), poly (ε-caprolactone) (PCL) (Luong-Van et al., 2006), poly(ethylene oxide) (PEO) 
(Kim et al., 2007) and poly(acrylic acid) (PAA) (Chunder et al., 2007). Although, not 
specifically for application in drug delivery, hydroxypropylcellulose (HPC) fibers have 
also been electrospun and investigated by Shukla and co-workers (2005).  
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The buccal mucosa is more permeable than skin but less permeable than intestinal 
mucosa (Nicolazzo et al., 2005). A permeation barrier, composed of lipids, is believed to 
be present in the upper portion of the buccal epithelium, which results in reduced 
permeability of certain drugs (Şenel and Hıncal, 2001; Nicolazzo et al., 2005). For drugs 
with poor permeability, such as zidovudine (AZT), it therefore becomes advantageous to 
employ permeation enhancers in oramucosally administered formulations (Şenel and 
Hıncal, 2001). There are various categories of buccal permeation enhancing substances 
that have different suggested modes of action. These include surfactants, which disrupt 
the integrity of the protein domain and intercellular lipids; fatty acids, which enhance the 
fluidity of phospholipids; cyclodextrins, which act as drug inclusion carriers; chelators, 
which interfere with calcium ions; and cations and polymers with positive charge, which 
interact with negative ions on the surface of the buccal mucosa (Şenel and Hıncal, 
2001). 
 
This chapter details the development of a mucoadhesive polymeric backing film layer 
and a drug-loaded electrospun fiber layer with the aim of producing a flexible, 
mucoadhesive fibrous matrix system (FMS) by depositing the latter directly onto the 
former. The film layer provided a flexible, mucoadhesive backing layer with a large 
exposed surface area and the drug-loaded fiber layer exhibited an exceedingly high 
surface area, due to the fiber dimensions, allowing for more rapid disintegration and 
drug release than what could be achieved from a drug-loaded film formulation. Polymers 
investigated for the development of the backing layer were selected based on water-
solubility and film or membrane-forming propensity. The polymers investigated for the 
fibrous layer were selected based on water-solubility and electrospinnability. Various 
penetration enhancing substances were investigated for their effect on the buccal 
permeation of one of the model drugs, AZT. 
 
3.2. Materials and Methods 
 
3.2.1. Materials 
Polyvinylalcohol (PVA) (87-89% hydrolyzed, Mw 13,000-23,000g/mol), poly(ethylene 
oxide) (PEO), poly(acrylic acid) (PAA) (Mw 1,800g/mol), chitosan (medium molecular 
weight), β-cyclodextrin and diphenhydramine (DPH) were purchased from Sigma-
Aldrich (St. Louis, Missouri, USA). Propan-2-ol, glycerol, citric acid, sodium carbonate, 
sodium chloride, peppermint oil, spearmint oil, cod liver oil, lemon oil, aniseed oil, oleic 
acid and ethanol were purchased from Rochelle Chemicals (Johannesburg, South 
Africa). Hydroxypropylcellulose (HPC) (Klucel Type EF and Type HF) was purchased 
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from Hercules (Wilmington, Delaware, USA). Hydroxypropylmethylcellulose (HPMC) 
was purchased from Colorcon Limited (London, England). Zidovudine (3'-azido-3'-
deoxythymidine) (AZT) was purchased from Evershine Ind. (Naejar Malad, Mumbai, 
India). 
 
3.2.2. Preparation of Crosslinked HPC Membranes 
Crosslinked membranes were produced by a method based on a study by Pillay and co-
workers (2005). HPC (Type HF) was dissolved in deionized water at concentrations 
between 1 and 3%w/v and the solutions were homogenized. The polymer solution (2mL) 
was syringed onto the bases of round glass moulds (4cm diameter). The moulds were 
placed in beakers, into which 25mL of sodium carbonate (2.5-20%w/v) or sodium 
chloride (10-15%w/v) solutions were syringed separately. The beakers were covered and 
the solutions left to crosslink for 24-72 hours, after which the formed membranes were 
removed and left to dry under an extractor at 21°C. 
 
3.2.3. Preparation of Polymeric Films from High Concentration Polymer Solutions 
HPC (Type HF) and HPMC were employed in the preparation of polymeric films. 
Solutions were prepared by dissolving HPC or HPMC in a 2:1 mixture of 80% ethanol 
and water at concentrations of 5.5-7%w/v. The solutions were semi-solid and exhibited 
minimal flow properties. The polymer solutions were cast onto smooth, flat glass 
surfaces with a spatula and oven dried at 50°C for 2 hours. 
 
3.2.4. Preparation of Polymeric Films Employing a Molding and Film-Casting 
Technique 
3.2.4.1. HPC Films 
HPC films were prepared from solutions with lower polymer concentrations than those 
used previously in an attempt to form films with a more even surface morphology. HPC 
(Type EF) and glycerol were dissolved in a 2:1 mixture of propan-2-ol and water at 
concentrations of 15%w/v and 8%
w/v, respectively. The resulting solutions were placed in 
flat, smooth-surfaced molds and placed under an extractor at 21°C for 48 hours in order 
for complete solvent evaporation and film formation to occur. 
 
3.2.4.2. HPMC Films 
HPMC solutions with lower polymer concentrations than those employed previously 
were used to produce films with an improved surface morphology. HPMC was dissolved 
in a 2:1 mixture of deionized water and propan-2-ol at concentrations ranging between 
0.5%w/v and 3%
w/v. Glycerol was added to the solutions as a plasticizer at varying 
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concentrations between 5 and 70% of the HPMC mass. Solutions were placed in 
rectangular, flat-bottomed molds and placed under an extractor at 21°C for 48 hours for 
solvent evaporation and film formation to take place.  
 
3.2.4.3. PVA and HPMC Films 
PVA was employed in film preparation with the aim of improving the morphology of the 
films. PVA/HPMC films were developed by first producing film formulations containing 
PVA and adding one other component at a time, at varying concentrations, to 
subsequent formulations in order to determine acceptable ranges for the various 
constituents. Polymer solutions were prepared by dissolving PVA (0.5-2.5%w/v), HPMC 
(0-1%w/v) and glycerol (5-20%
w/w of combined polymer mass) in a 4:1 mixture of 
deionized water and propan-2-ol. Solutions were syringed into rectangular, flat-
bottomed molds and placed under an extractor at 21°C for 48 hours in order for 
complete solvent evaporation and film formation to occur. The feasible mold fill-volume 
was also investigated by dissolving PVA, at a constant concentration of 1%w/v, in the 
solvent mixture and filling the mold with different volumes ranging between 25-100mL. 
 
3.2.5. Preparation of Fibers by Electrospinning 
Solutions, employing different solvents and polymers at varying concentrations, were 
prepared in order to assess the production of fibers. Once appropriate solvent/polymer 
combinations were determined, either AZT or diphenhydramine (DPH) was dissolved in 
the polymer solution in order to assess drug-loading and permeation. Solutions were 
placed in a 5mL pipette, which was fitted into the adjustable supporting bracket of an 
electrospinning device. Electrospinning of the solutions was performed at 10-20kV with 
a tip-to-collector distance of 5-15cm, using a custom-built electrospinning device (RGC 
Engineering, Johannesburg, South Africa) equipped with a voltmeter and MJ Series 
High Voltage Power Supply (Glassman High Voltage Inc., New Jersey, USA). Fibers 
were collected on aluminum foil-lined board or on polymeric backing films secured to the 
board. 
 
3.2.6. Investigation of Various Polymers for Electrospinning  
3.2.6.1. PVA in Water 
PVA was dissolved in deionized water at concentrations of 10, 15, 20 and 25%w/v, and 
the solutions were electrospun across distances of 5 and 11cm with applied potentials 
of 15, 17 and 20kV and investigated for fiber production potential. Drug-loaded and 
plasticizer-containing solutions were also produced by adding AZT and glycerin to 
polymer solutions, respectively. Tip-to-collector distances and applied potentials were 
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dependent on the formation of a Taylor cone at the tip of the pipette, and were adjusted 
accordingly during the process of electrospinning.  
 
3.2.6.2. PVA in a 2:1 Mixture of Water and Propan-2-ol 
PVA was dissolved in a 2:1 mixture of deionized water and propan-2-ol at 
concentrations of 15, 20, 22, 25 and 30%w/v, and solutions were electrospun with tip-to-
collector distances of 5 and 11cm at applied potentials of 15, 17, 18, and 20kV. Drug-
loaded solutions were produced by dissolving either AZT or DPH in PVA solutions at 
various concentrations. Glycerol and glycerin were added to the PVA solutions as 
plasticizers in order to assess their effect on fiber production. Citric acid was employed 
as a taste-masking agent. 
 
3.2.6.3. HPC in Water 
HPC was dissolved in deionized water to make a 15%w/v solution, which was 
electrospun at an applied voltage of 10kV and a tip-to-collector distance of 10cm. The 
applied voltage and tip-to-collector distance was determined by the formation of a Taylor 
cone. 
 
3.2.6.4. HPC in a 2:1 Mixture of Water and Propan-2-ol 
HPC was dissolved in a 2:1 mixture of deionized water and propan-2-ol at a 
concentration of 10%w/v. The solution was electrospun with a tip-to-collector distance of 
5cm and at an applied voltage of 20kV. Drug-loaded solutions were produced by 
dissolving AZT and DPH in the solutions, both at concentrations of 2 and 3%w/v. 
 
3.2.6.5. PEO in Water 
PEO was dissolved in deionized water at a concentration of 10%w/v and electrospun at 
an applied voltage of 20kV, over a tip-to-collector distance of 10cm. Glycerin was added 
to the PEO solution at a concentration of 5%v/v in order to assess the effect of plasticizer 
on fiber formation. This solution was electrospun at an applied voltage of 18kV, across a 
distance of 7cm. 
 
3.2.6.6. PAA in Water 
PAA was dissolved in deionized water at a concentration of 25%w/v and electrospun 
across a tip-to-collector distance of 10cm at an applied voltage of 15kV. 
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Further investigations were carried out only on PVA solutions electrospun fibers formed 
from PVA solutions as this polymer was deemed most suitable for the purposes of this 
study. 
 
3.2.7. Morphological Surface Structure Analysis of the Electrospun Fiber Layer 
The surface morphology of the electrospun fiber layer was analyzed by images 
produced by scanning electron microscopy (SEM), using a Phenom Microscope (FEI 
Company, Hillsboro, Oregon, USA). This was also used to confirm the presence of 
fibers.  
 
3.2.8. Rheological Characterization of PVA Solutions Employed in Electrospinning 
The rheological properties of PVA solutions at various concentrations were determined 
with the use of a Haake Modular Advanced Rheometer System (ThermoFisher 
Scientific, Karlsruhe, Germany). The stress-strain rheological parameters of the polymer 
solution have an influence on electrospinning, and are important factors when 
considering the desired characteristics of a solution to be electrospun. Samples were 
analyzed by placing the polymer solution on the sample stage and immersing the 
C35/1° titanium rotor in the fluid while the temperature was maintained at 25°C. The 
shear rate was ramped from 0 to 500/s and viscosity and shear force were quantified for 
each solution. 
 
3.2.9. Calibration Curves for UV Spectrophotometric Determination of AZT and 
DPH 
Calibration curves were generated by dissolving known concentrations of AZT and DPH 
in simulated saliva (pH 6.75) and phosphate buffered saline (PBS) (pH 7.4) and 
measuring the absorbance using a UV spectrophotometer (Specord 40, Analytik Jena, 
AG, Germany). Absorbances of AZT and DPH were analyzed at λ267nm and λ254nm, 
respectively. Concentration was plotted on the x-axis and absorbance on the y-axis to 
generate a linear curve with R2 > 0.95. 
 
3.2.10. Drug Entrapment 
Samples of the drug-loaded fiber layer were cut into sections, dissolved in simulated 
saliva (pH 6.75) and the drug content of each section was analyzed by UV 
spectrophotometry (Specord 40, Analytik Jena, AG, Germany).  
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3.2.11. Disintegration Time of the PVA Fiber Layer and Backing Film Layer 
The in vitro disintegration times of the PVA fiber layer and film formulations were 
determined according to a modified method based on the United States Pharmacopoeia 
(USP) method for tablet disintegration testing using a Type PTZ 1 basket-rack assembly 
disintegration apparatus (Pharma Test, Hainburg, Germany). According to the USP 32, 
disintegration is considered to have occurred when there is no longer any solid residue 
left on the mesh of the basket-rack assembly apparatus (USP 32, 2009). The 
disintegration medium was 150mL simulated saliva (pH 6.75) in a glass jar placed in a 
water bath maintained at 37˚C. Samples were cut into sections and placed on the mesh 
of the basket rack assembly, with a mesh disc placed on top. The basket rack assembly 
was raised and lowered through a distance of 55mm and at a frequency of 25 cycles per 
minute and the time taken for sample disintegration to occur was determined by 
observation and recorded.  
 
3.2.12. Drug Permeation by ex vivo Studies 
PVA fiber layers, loaded with AZT or DPH, were electrospun directly onto films made up 
of either PVA or a combination of PVA and HPMC. Chitosan and β-cyclodextrin were 
incorporated into formulations containing AZT, as permeation enhancers, in an attempt 
to improve permeation. The resulting fiber-on-film systems were cut into sections and 
assessed for ex vivo drug permeation characteristics. Ex vivo drug permeation testing 
was performed using freshly excised porcine buccal tissue, which is considered to have 
a closer resemblance to human buccal mucosa than other animal tissues (Langoth et 
al., 2005; Figueiras et al., 2009). Sections of mucosa were mounted in Franz Type 
Diffusion Cells (Perme Gear, Inc., Hellertown, Pennsylvania, USA) and equilibrated for 
0.5 hours at 37˚C by adding PBS (pH 7.4) to both the acceptor and donor 
compartments. After equilibration, the PBS in the donor compartment was removed and 
replaced with a drug-loaded sample in simulated saliva (pH 6.75). Samples were drawn 
from the acceptor compartment at 20 seconds, 1, 3, 5, 10, 30, 60 and 90 minutes and 
analyzed by UV spectrophotometry, and the volume removed was replaced with fresh 
PBS. 
 
3.3. Results and Discussion 
 
3.3.1. Crosslinked HPC Membranes 
HPC at 2.5%w/v and sodium carbonate at 15%
w/v were recognized as the most ideal 
reaction components for membrane formation. However, the membranes produced 
were porous and fragile, and deemed unsuitable for the purposes of this study. Due to 
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their malapropos nature, no further investigations were carried out on the crosslinked 
HPC membranes. 
 
3.3.2. Polymeric Films Prepared from Viscous Polymer Solutions 
The HPC and HPMC films, which were prepared from 5.5%w/v polymer solutions, 
displayed an uneven morphology due to the process of film formation by casting with a 
spatula. HPMC films were slightly more even than HPC films, which exhibited large 
pores but were poorly formed. Solutions with polymer concentrations above 5.5%w/v 
were too viscous to be adequately spread onto a flat surface and film formation could 
therefore not occur. The production of films from less viscous solutions that could be 
poured into moulds was therefore investigated. 
 
3.3.3. Polymeric Films Prepared Employing a Molding and Film-Casting Technique 
3.3.3.1. HPC Films 
Films were removed from molds and found to be thin, clear, even and extremely 
adhesive. Due to the adhesive nature of the HPC films, they were considered unsuitable 
for the purposes of the present study and no further investigation was carried out. 
 
3.3.3.2. HPMC Films 
For the production of HPMC films displaying a desirable thickness and uniformity, 
HPMC concentrations were found to be between 1 and 2%w/v. Without plasticizer, the 
films were brittle and fragile and the ideal glycerol concentration for the formation of 
flexible films was found to be between 15 and 30%w/w of the polymer mass. HPMC films 
were easily torn, which made removal from molds problematic. Further studies, 
including other polymers in the film formulation, were therefore conducted. 
 
3.3.3.3. PVA and HPMC Films 
The films produced were thin, even in thickness and clear or cloudy, depending on the 
solution constituents. PVA concentrations between 0.5 and 2%w/v produced films of a 
desirable thickness at a fill volume of 50mL. Films containing more than 2%w/v PVA 
(50mL fill volume) were too thick for electrospinning as fiber deposition was not uniform 
on these films. It was found that the optimal glycerol concentration was between 10 and 
15%w/w of the total polymer mass. Lower than this, the films were fragile and higher than 
this, the films were difficult to work with. HPMC could be incorporated into the films at 
concentrations between 0 and 0.5%w/v without causing breakage on removal of films 
from molds. The acceptable fill volume was found to be between 40 and 100mL. Below 
40mL, film formation was not particularly even. 
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3.3.4. Investigation into Various Polymers for Electrospinning 
3.3.4.1. PVA in Water 
The solutions were visibly thin in consistency, particularly at 10%w/v PVA, and fiber 
formation was generally poor, with a considerable quantity of spraying occurring during 
electrospinning. Where fibers were formed, they were visible only as a fine layer of 
discoloration on the aluminum foil, which is not adequate for drug delivery on account of 
the exceedingly high drug-loading that would be required so that a sufficient dose may 
be achieved. 
 
3.3.4.2. PVA in a 2:1 Mixture of Water and Propan-2-ol 
Solutions of PVA dissolved in a 2:1 mixture of deionized water and propan-2-ol were 
observed to exhibit the most desirable fiber formation on electrospinning. The solutions 
were visually thicker than those of PVA dissolved in deionized water and the produced 
fibers formed a thick layer on the foil or film onto which they were electrospun, which is 
adequate for drug-loading. Addition of plasticizers to the electrospinning solutions had a 
significant effect on fiber formation at higher plasticizer concentrations, hindering the 
production of fibers, whereas at lower concentrations, plasticizer addition resulted in the 
formation of a more flexible fiber layer without a marked effect on fiber production. The 
presence of drug in PVA solutions had little or no effect on fiber formation, and PVA 
fibers, electrospun from solutions using a 2:1 mixture of deionized water and propan-2-
ol as the solvent, were therefore deemed to be satisfactory for drug delivery. The ideal 
PVA concentration for the electrospinning solution was determined to be 25%w/v, the 
DPH concentration was 10%w/v and the excipients were citric acid and glycerol at 2%
w/v 
and 5%v/v, respectively. 
 
3.3.4.3. HPC in Water 
The formation of fibers from solutions containing HPC dissolved in deionized water was 
observed as a thin white layer on the film onto which the fibers were electrospun. Fiber 
production was preferable to that from PVA in water solutions; however, it was not 
sufficient to be applied in drug delivery. 
 
3.3.4.4. HPC in a 2:1 Mixture of Water and Propan-2-ol 
Fiber production from solutions of HPC dissolved in a 2:1 mixture of deionized water 
and propan-2-ol was somewhat superior to fiber production from HPC in water 
solutions. A fairly thick, white layer was formed on the collecting surface, suggesting 
that adequate fiber production had occurred. However, drug-loading of the HPC 
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solutions with AZT or DPH hindered both fiber production and formation considerably. 
Therefore, no further studies were conducted on HPC for electrospinning. 
 
3.3.4.5. PEO in Water 
Fibers electrospun from PEO solutions formed a thick, white layer on the collecting 
surface. Nevertheless, fiber deposition was observed to be erratic, with a large amount 
of deposition occurring in some regions and little or none in others and showing no clear 
pattern. The erratic nature of fiber deposition obviates the application of PEO in drug 
delivery for the purposes of this study and no further investigations were conducted. 
 
3.3.4.6. PAA in Water 
The PAA solution was not viscous enough for fiber formation to occur. Visually, the 
polymer solution appeared to have a similar consistency to water, whereas solutions 
that were adequately electrospun had consistencies similar to that of syrup. During 
electrospinning, the Taylor cone was not formed and the solution sprayed, in the form of 
droplets, onto the collecting surface. It was concluded that fiber formation did not occur 
at a concentration of 25%w/v and no further studies were conducted. 
 
3.3.5. Morphological and Surface Structure Analysis of the Electrospun Fiber 
Layer 
The presence of PVA fibers in the electrospun fiber layer was confirmed by SEM 
analysis. Figure 3.1 clearly displays fibrous structures. Fibers formed were in the less 
than 500nm thick and appeared to be somewhat uniform in diameter and structure. 
Pores were also apparent between individual fibers. 
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Figure 3.1: Scanning electron micrograph of PVA fibers 
 
3.3.6. Rheological Characterization of PVA Solutions Employed in Electrospinning 
The rheological properties of a solution employed for electrospinning can have a 
substantial effect on the process of electrospinning as well as the quality and 
morphology of fibers that are formed (Tao and Shivkumar, 2007). The degree of 
polymer chain entanglements, and hence the polymer concentration, has a considerable 
influence over the viscosity and electrospinnability of a solution (Ramakrishna et al., 
2005). The actual conformation of individual polymer chains also has a significant 
influence on solution viscosity, considering that solutions containing coiled chains have 
a lower viscosity than those with extended chains (Ramakrishna et al., 2005). It is 
therefore important to investigate the rheological properties of polymeric solutions 
employed in electrospinning. 
 
The rheological properties of PVA solutions for electrospinning were quantified at 
various PVA concentrations by ramping the shear rate ( ) from 0 to 500/s. The 
rheological profiles of the 15, 20, 25 and 30%w/v PVA solutions in 2:1 deionized water 
and propan-2-ol are depicted in Figure 3.2 a, b, c and d, respectively. The rheological 
profile of the 25%w/v PVA in water solution is depicted in Figure 3.3. The viscosity of the 
solutions increased with increasing shear rate and appeared to exhibit non-Newtonian, 
dilatant flow properties.  
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           a)               b) 
 
          c)                d) 
 
Figure 3.2: Rheological profiles of (a) 15%w/v, (b) 20%
w/v, (c) 25%
w/v and (d) 30%
w/v PVA solutions in 2:1 deionized water and propan-2-ol 
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Figure 3.3: Rheological profile of 25%w/v PVA solution in deionized water 
 
The average shear force (τ) and viscosity (η), over the shear rate range, were calculated 
and plotted against concentration in Figures 3.4 and 3.5, respectively. Figures 3.4 and 
3.5 appear to display a similar shaped curve, suggesting that the increase in average 
viscosity with increasing polymer concentration is proportional to the increase in shear 
force. At lower PVA concentrations (below 25%w/v) and when the solvent used was 
deionized water, electrospun fibers did form, but spraying of solution droplets also 
occurred intermittently where the viscosity was too low for constant fiber jet formation. At 
PVA concentrations above 25%w/v, the solution was too viscous to pass through the 
capillary tip of the pipette consistently. At a PVA concentration of 25%w/v, fiber formation 
was satisfactory and minimal spraying occurred. 
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Figure 3.4: Comparison of average shear force for the electrospinning solutions with 
varying PVA concentrations 
 
Figure 3.5: Comparison of average viscosity for the electrospinning solutions with 
varying PVA concentrations 
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3.3.7. Calibration Curves for UV Spectrophotometric Determination of AZT and 
DPH 
3.3.7.1. AZT in Simulated Saliva (pH 6.75) 
The calibration curve for AZT dissolved in simulated saliva (pH 6.75) at λ267nm is 
displayed in Figure 3.6. 
 
Figure 3.6: Calibration curve for AZT dissolved in simulated saliva (pH 6.75) at λ267nm (in 
all cases SDs < 0.02, N = 3) 
 
3.3.7.2. AZT in PBS (pH 7.4) 
The calibration curve for AZT dissolved in PBS (pH 7.4) at λ267nm is displayed in Figure 
3.7. 
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Figure 3.7: Calibration curve for AZT dissolved in PBS (pH 7.4) at λ267nm (in all cases 
SDs < 0.02, N = 3) 
 
3.3.7.3. DPH in Simulated Saliva (pH 6.75) 
The calibration curve for DPH dissolved in simulated saliva (pH 6.75) at λ254nm is 
depicted in Figure 3.8. 
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Figure 3.8: Calibration curve for DPH dissolved in simulated saliva (pH 6.75) at λ254nm 
(in all cases SDs < 0.02, N = 3) 
 
3.3.7.4. DPH in PBS (pH 7.4) 
The calibration curve for DPH dissolved in PBS (pH 7.4) at λ254nm is depicted in Figure 
3.9. 
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Figure 3.9: Calibration curve for DPH dissolved in PBS (pH 7.4) at λ254nm (in all cases 
SDs < 0.02, N = 3) 
 
3.3.8. Drug Entrapment 
On analysis of the drug entrapment of the electrospun fiber layer, it was found that the 
average quantity of drug per 1.5cm2 section varied according to PVA and drug 
concentrations in the electrospinning solutions and time of electrospinning. When these 
factors were increased, drug entrapment tended to increase linearly. The average 
quantity of drug entrapped per section ranged between 0.3-7mg. Drug entrapment and 
fiber production was observed to be greater at low humidity. Tripatanasuwan and co-
workers (2007) found that as the relative humidity was increased, fiber diameter 
decreased and bead-formation started occurring because solvent evaporation was 
retarded at higher humidity. It has also been found that small pores form on the surfaces 
of electrospun fibers at high humidity (Casper et al., 2004), which may also affect the 
overall fiber morphology and quality. Furthermore, when humidity is high, the charge on 
the fiber jet may be lost to the moisture in the air (Nieh and Nguyen, 1988; Kalayci et al., 
2005; Ramakrishna et al., 2005), resulting in a decrease in fiber production. The 
technique of electrospinning is therefore sensitive to environmental conditions and, 
hence, must be conducted in a controlled environment. 
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3.3.9. Disintegration Time of the PVA Fiber Layer and Backing Film Layer 
The average disintegration time of the electrospun PVA fiber layer was 5 seconds, which is 
desirable for a rapidly disintegrating drug delivery system. The average disintegration time 
for the backing film layer ranged between 7-60 seconds, depending on constituents, for 
formulations in the range used as variables for optimization. In order to keep the drug at the 
surface of absorption and prevent swallowing of the drug, the backing film layer should 
remain intact for a longer period of time than the fiber layer. However, if the film remains 
intact for too long, it may result in poor mouth feel and affect patient acceptability. 
 
3.3.10. Drug Permeation by ex vivo Studies 
The total fraction of permeated drug after 90 minutes for the various formulations that were 
prepared is outlined in Table 3.1. It is evident in Table 3.1 that the total buccal permeation of 
AZT was notably low after 90 minutes. Less than 1% of the loaded dose had passed through 
the buccal mucosal tissue during the testing period, as opposed to 42-82% of DPH. Figure 
3.10 depicts the flux profiles of both AZT and DPH, clearly displaying a greater flux for DPH 
during the period of testing. The poor permeability of AZT, in comparison with DPH, may be 
a result of the fact that it is sparingly soluble in water (WHO, 2008) and, hence, is not fully 
dissolved in the relatively small volume of saliva when it comes into contact with the 
absorptive buccal surface. The addition of permeation enhancers, β-cyclodextrin and 
chitosan, to the formulations at varying concentrations had little or no effect on the 
permeation of AZT. In a further endeavor to improve permeation, various oils, such as 
peppermint oil, spearmint oil, cod liver oil, lemon oil, aniseed oil and oleic acid, were 
employed in an attempt to solubilize AZT prior to electrospinning. However, the presence of 
these oils in the electrospinning solutions hindered fiber formation considerably.  
 
Table 3.1: Total percentage of drug permeated after 90 minutes 
Film 
Composition 
Drug Permeation 
Enhancer 
Total Percentage 
Permeated 
PVA + HPMC Zidovudine None 0.72 
PVA Zidovudine None 0.73 
PVA Zidovudine β-cyclodextrin (1%) 0.74 
PVA Zidovudine β-cyclodextrin (25%) 0.43 
PVA Zidovudine Chitosan (1%) 0.59 
PVA Zidovudine Chitosan (3%) 0.60 
PVA + HPMC Diphenhydramine None 42 
PVA Diphenhydramine None 82 
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Figure 3.10: Flux profiles of diphenhydramine (DPH) and zidovudine (AZT) (in all cases 
SDs < 0.02, N = 3) 
 
3.4. Concluding Remarks 
 
A preliminary polymeric backing film layer, containing PVA, HPMC and glycerol, was 
developed and variables for an experimental design were obtained. A PVA 
concentration of 1%w/v, fill volume of 40-100mL, HPMC concentration of 0-0.5%
w/v and 
glycerol concentration of 10-15%w/w (of total polymer mass) were deemed acceptable 
for film production and these variables were employed in an experimental design. 
Various polymers were investigated in order to develop a drug-loaded electrospun fiber 
layer for application in the FMS. PVA was identified as the most suitable polymer and 
further studies were therefore undertaken on formulation design using this polymer. On 
execution of permeation studies, it was discovered that less than 1% of the loaded dose 
of model drug, AZT, permeated during the testing period. DPH was therefore adopted 
as the model drug for the purposes of further studies as it exhibited 42-82% permeation 
during the testing period. The ideal PVA concentration for the electrospinning solution 
was determined to be 25%w/v, the DPH concentration was 10%
w/v and the excipients 
were citric acid and glycerol at 2%w/v and 5%
v/v, respectively. This ideal formulation was 
employed in the optimization and further investigations in the design of the FMS. 
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CHAPTER 4 
PREPARATION, CHARACTERIZATION AND OPTIMIZATION OF AN 
ELECTROSPUN FIBROUS MATRIX SYSTEM FOR RAPID 
ORAMUCOSAL DRUG DELIVERY 
 
4.1. Introduction 
 
Electrospinning has gleaned considerable interest in the field of drug delivery due to its 
proficiency in producing fibers with eminently small diameters (Sill and von Recum, 
2008). The process of electrospinning involves applying an electrical potential to a 
polymer solution in order to produce very fine fibers in the nano- and micrometer size 
range (Liang et al., 2007). When a drop of polymer solution at the end of a capillary tube 
is subjected to an electrical potential, the drop elongates, becoming conical in shape 
(Doshi and Reneker, 1995; Sill and von Recum, 2008) and, once the electrical field 
exceeds surface tension, a fiber jet is ejected from the tip of the cone (Liang et al., 2007; 
Sill and von Recum, 2008). As the fiber jet travels through the atmosphere, the solvent 
evaporates and solid polymer fibers are deposited on a grounded collector (Sill and von 
Recum, 2008), closing the gap between the capillary and collector, and hence 
completing the circuit (Deitzel et al., 2001). If the polymer concentration, and hence 
viscosity and chain entanglements, is too low, the jet will break up into droplets before 
reaching the collector (McKee et al., 2004; Shenoy et al., 2005). However, as the 
concentration is increased, the viscosity will increase and chain entanglements will 
become sufficient for fiber formation, resulting in a whipping motion of the jet and 
stretching and thinning of the fiber on application of a potential (McKee et al., 2004; 
Shenoy et al., 2005). 
 
Electrospun fibers display a small diameter and extremely high surface area to mass 
ratio (Frenot and Chronakis, 2003; Reneker and Yarin, 2008). This is advantageous in 
drug delivery as it results in an increase in the total drug release from drug-loaded fibers 
when compared to cast-films of the same composition, which have a considerably 
smaller surface area (Zong et al., 2002; Agarwal et al., 2008). Furthermore, a large 
exposed surface area can greatly improve the dissolution rate, and hence bioavailability, 
of a drug (Bruner and Tolloczko, 1901; Sjökvist and Nyström, 1991; Verreck et al., 
2003b; Dokoumetzidis and Macheras, 2006). 
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In order for adequate drug absorption to occur via the buccal mucosa, it is necessary for 
the drug concentration within the oral cavity to be high (Ponchel, 1994). Accelerated 
disintegration of an orally dissolving drug delivery system results in a high concentration 
of drug at the surface of absorption and therefore rapid and extensive absorption 
(Ponchel, 1994; Rossi et al., 2005). Furthermore, rapid absorption leads to expeditious 
blood levels (Rathbone et al., 1994) and hence a prompt onset of action (Abrams, 1983; 
Simpson et al., 2007; Scholz et al., 2008). It has been demonstrated that the in vivo 
availability of a drug administered via the oramucosal route is greatly dependent on the 
disintegration rate of the drug delivery system (Ponchel, 1994).  
 
Due to the relatively short residence time of an oramucosally administered drug delivery 
system at the site of absorption, mucoadhesion is often required (Ponchel, 1994). 
Mucoadhesive drug delivery systems are advantageous in that the entire system is 
rendered immobile, an intimate contact between the system and buccal mucosa is 
created (Andrews et al., 2009) and a high drug concentration at the absorption surface 
is achieved (Ponchel, 1994). This results in a reduction in the required drug 
concentration as well as an improved bioavailability (Andrews et al., 2009). Thin, 
mucoadhesive films are favorable for oramucosal drug delivery due to the flexible nature 
and high contact surface area of such films (Ponchel, 1994; Perioli et al., 2004). 
 
Statistical optimization, by experimental design, employs mathematical and statistical 
analysis in order to characterize and assess the effects of independent variables on 
measured responses. In contrast to traditional approaches to formulation optimization, 
where one variable is assessed at a time, statistical optimization utilizes fewer 
experimental runs, is less time consuming and provides a true optimized formulation by 
a systematic approach (Singh et al., 2004). 
 
Therefore the aim of the studies outlined in this chapter was to statistically optimize the 
polymeric backing film layer of the porous, fibrous matrix system (FMS), for oramucosal 
drug delivery, developed in Chapter 3. In order to do this, drug-loaded fibers were 
electrospun directly onto polymeric backing films, produced according to a Box-Behnken 
experimental design. Polyvinylalcohol (PVA) fibers were produced, according to a 
formula determined by preliminary experimentation, and loaded with model drug, 
diphenhydramine, in order to assess drug release and permeation characteristics. The 
effect of varying polymeric constituents on drug release, drug permeation, 
mucoadhesion and disintegration was investigated in order to produce an optimized 
drug delivery system. 
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4.2. Materials and Methods 
 
4.2.1. Materials 
Polyvinylalcohol (PVA) (87-89% hydrolyzed, Mw 13,000-23,000g/mol) and 
diphenhydramine (DPH) were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). 
Propan-2-ol, glycerol and citric acid were purchased from Rochelle Chemicals 
(Johannesburg, South Africa). Hydroxypropylmethylcellulose (HPMC) was purchased 
from Colorcon Limited (London, England). 
 
4.2.2. Preparation of polymeric backing films by film-casting 
Films intended as backing and mucoadhesive layers for electrospun fibers were 
prepared according to a Box-Behnken experimental design. Polymer solutions were 
prepared by dissolving glycerol, PVA and HPMC in a 4:1 mixture of deionized water and 
propan-2-ol. The concentrations and volumes used were as outlined in Table 4.1. 
Solutions were syringed into rectangular flat-bottomed moulds and left under an 
extractor at 21°C for 48 hours in order that complete solvent evaporation and film-
formation could occur.  
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Table 4.1: Polymer concentrations and volumes used in film preparation according to 
the Box-Behnken design 
Formulation 
number 
Fill Volume 
(mL) 
HPMC (%w/v) Glycerol (%
w/w of 
PVA + HPMC) 
F1 40 0.50 12.5 
F2 100 0.25 15.0 
F3 40 0.25 15.0 
F4 70 0.25 12.5 
F5 70 0.50 10.0 
F6 100 0.50 12.5 
F7 40 0.25 10.0 
F8 70 0.25 12.5 
F9 70 0.00 10.0 
F10 100 0.00 12.5 
F11 70 0.00 15.0 
F12 70 0.25 12.5 
F13 70 0.50 15.0 
F14 40 0.00 12.5 
F15 100 0.25 10.0 
 
4.2.3. Experimental Design 
A 3-factor Box-Behnken experimental design was generated by Minitab®, V15 (Minitab® 
Inc, Pennsylvania, USA) in order to statistically optimize the polymeric film layer and 
analyze the effect of formulation variables on system disintegration, drug release from 
the electrospun fiber layer, by dissolution and permeation, and mucoadhesiveness. The 
Box-Behnken design is a rotatable, or nearly rotatable, response surface design, which, 
for three factors, can be visualized by a cube with points in the center and the middle of 
each edge (Ferreira et al., 2007), as depicted in Figure 4.1. All points on the edges are 
therefore equidistant from the central point (Box and Behnken, 1960). This type of 
design was expressly selected for the purposes of this study as it is favored over the 
Central Composite Design due to the fact that it is considered to be more efficient 
(Ferreira et al., 2007) and it requires fewer experimental runs (Chopra et al., 2007), 
which makes the formulation process less expensive. The independent variables, X1, X2 
and X3, were selected based on preliminary studies in Chapter 3, and are outlined in 
Table 4.2. Y1 through to Y5, the dependent variables, were disintegration time, work of 
adhesion (WA), maximum detachment force (MDF), dissolution area under the curve 
(AUC) at 1 minute (AUCD)  and permeation AUC at 3 minutes (AUCP), respectively. 
 61 
 
 
Figure 4.1: Visualization of a Box-Behnken cube with points on the middle of each edge 
and in the center. X1, X2 and X3 represent the independent variables in the design 
(Adapted from Ferreira et al., 2007) 
 
Table 4.2: Variables employed in the Box-Behnken design 
Variable Levels 
Low (-1) High (1) 
X1 – Fill Volume (mL) 40 100 
X2 – HPMC concentration (%
w/v) 0.00 0.50 
X3 – Glycerol concentration (%
w/w of PVA + HPMC) 10.0 15.0 
 
4.2.4. Preparation of fibers by electrospinning 
A drug-loaded solution for electrospinning was produced by dissolving PVA, citric acid, 
DPH and glycerol in a 2:1 mixture of deionized water and propan-2-ol at concentrations 
of 25%w/v, 2%
w/v, 10%
w/v and 0.5%
v/v, respectively. These quantities were based on 
optimal fiber production, reproducibility and drug-loading proficiencies, determined in 
Chapter 3. The solution was placed in a 5mL pipette, which was fitted into the 
adjustable supporting bracket of an electrospinning device. Electrospinning of the 
solutions was performed at 20kV with a tip-to-collector distance of 11cm, using a 
custom-built electrospinning device (RGC Engineering, Johannesburg, South Africa) 
equipped with a voltmeter and MJ Series High Voltage Power Supply (Glassman High 
Voltage Inc., New Jersey, USA). Fibers were collected on polymeric backing films 
secured on aluminum foil-lined board. Samples were cut into sections.  
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4.2.5. Morphological and Surface Structure Analysis of the Drug-loaded Fiber 
Layer 
The surface structure of the electrospun fibers was analyzed by images produced by 
scanning electron microscopy (SEM), using a Phenom Microscope (FEI Company, 
Hillsboro, Oregon, USA). Samples were mounted on stubs and sputter-coated with gold 
prior to examination. 
 
4.2.6. Drug Entrapment of Experimental Design Formulations 
Individual drug-loaded FMS samples were cut into 1.5cm2 sections, dissolved in 
simulated saliva (pH 6.75) and the drug content of each section was analyzed by UV 
spectrophotometry.  
 
4.2.7. Disintegration Time of Experimental Design Formulations 
The in vitro disintegration time of individual FMS samples was determined according to 
a modified method based on the United States Pharmacopoeia (USP) method for tablet 
disintegration testing using a Type PTZ 1 basket-rack assembly disintegration 
apparatus (Pharma Test, Hainburg, Germany). According to the USP 32, disintegration 
is considered to have occurred when there is no longer any solid residue left on the 
mesh of the basket-rack assembly apparatus (USP 32, 2009). The disintegration 
medium was 150mL simulated saliva (pH 6.75) in a glass jar placed in a water bath 
maintained at 37˚C. FMS samples were cut into 1.5cm2 sections and placed on the 
mesh of the basket rack assembly, with a mesh disc placed on top. The basket rack 
assembly was raised and lowered through a distance of 55mm and at a frequency of 25 
cycles per minute and the time taken for sample disintegration to occur was determined 
by observation and recorded.  
 
4.2.8. In vitro Drug Release 
Standard USP tests and apparatuses for in vitro dissolution and drug release testing 
require large volumes of fluid, which do not accurately reflect the in vivo conditions 
within the oral cavity, where there is only a small volume of fluid available for the 
dissolution of a drug delivery system (Azarmi et al., 2007). A modified drug release 
testing method was therefore developed for the purposes of this study. In vitro drug 
release was tested using a 10mm-long magnet in a 35mm diameter petri-dish, placed 
on a temperature-controlled magnetic stirrer. Simulated saliva (pH 6.75) (2mL) was 
placed in the petri-dish, maintained at 37˚C and stirred at a constant rate to ensure 
circulation of buffer. FMS samples were cut into sections and placed in the buffer. 1mL 
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samples were drawn at 5, 15, 30 seconds, 1, 3, 5, 10 and 15 minutes, analyzed by UV 
spectrophotometry and replaced by fresh buffer. 
 
4.2.9. Ex vivo Drug Permeation Studies 
Ex vivo drug permeation testing and tissue preparation were performed as outlined in 
Chapter 3. Samples were drawn from the acceptor compartment at 20 seconds, 1, 2, 3, 
5, 10, 15 and 30 minutes and analyzed by UV spectrophotometry, and the removed 
volume replaced with fresh PBS. The apparent permeability coefficient (Papp) and 
steady-state flux (Jss) values were calculated using Equations 4.1 and 4.2, respectively. 
 
t c  A 
Q
 P   app     (Equation 4.1) 
 
t A 
M
  Jss      (Equation 4.2) 
 
Where Q is the total amount of drug permeated during the testing time (μg), A is the 
diffusional area (cm2), c is the initial drug concentration in the donor compartment 
(μg/mL), t is the total time that the experiment was run for (seconds) and ΔM is the 
amount of drug that had permeated through the mucosal tissue during time Δt. 
 
4.2.10. Mucoadhesion of Experimental Design Formulations 
Mucoadhesion testing was performed on FMS sections using a TA.XTplus Texture 
Analyser (Stable Micro Systems, England) fitted with a cylindrical probe. Porcine buccal 
mucosal tissue was attached to the probe, using rubber bands, and exposed to 
simulated saliva (pH 6.75). The FMS samples were attached to the stage directly below 
the probe. Mucoadhesion was tested by measuring the maximum detachment force 
(MDF) and the work of adhesion (WA) (AUCFD) between the buccal mucosa and the 
fibrous membranes. The pre-test, test and post-test speeds were 2, 2, and 10mm/s, 
respectively. An applied force of 50g, a trigger force of 5g and contact time of 5 seconds 
were used for the test.  
 
4.3. Results and Discussion 
 
The films produced were even, thin, transparent or cloudy and pliable. The fibers formed 
a white layer on the films.  
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4.3.1. Morphological and Surface Structure Analysis of the Drug-loaded Fiber 
Layer 
On SEM analysis, it was observed that the fibers produced were randomly arranged and 
had uniform diameters on average. The fiber diameter was approximately 0.36µm, as 
depicted in Figure 4.2. 
 
 
Figure 4.2: SEM image of electrospun PVA fibers loaded with DPH 
 
4.3.1. Drug Entrapment of Experimental Design Formulations 
The average drug entrapment and standard deviations for sections of each formulation 
was as outlined in Table 4.3. Samples were analyzed in triplicate. Inter-sample and 
inter-formulation variation was high due to uneven deposition of drug-loaded fibers 
during the electrospinning process. 
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Table 4.3: Drug entrapment per 1.5cm2 section of electrospun fibrous membrane 
system (FMS) 
Formulation Drug Entrapment (mg) ± 
SD 
F1 3.2 ± 2.4 
F2 1.5 ± 0.19 
F3 1.9 ± 0.56 
F4 2.0 ± 0.21 
F5 2.3 ± 0.73 
F6 2.1 ± 1.2 
F7 2.0 ± 0.98 
F8 1.8 ± 0.23 
F9 3.4 ± 1.6 
F10 3.7 ± 2.2 
F11 4.3 ± 1.1 
F12 1.9 ± 0.22 
F13 4.7 ± 1.9 
F14 4.1 ± 1.6 
F15 2.6 ± 0.46 
 
4.3.2. Disintegration Time of Experimental Design Formulations 
The average disintegration time for each formulation was as depicted in Figure 4.3. 
Formulations 5 and 6 exhibited the longest disintegration times, whereas formulations 1, 
9, 14 and 15 took the shortest time for disintegration. Figure 4.4 is a contour plot 
displaying the relationship between the disintegration time and HPMC concentration and 
fill volume. It was observed that the time for disintegration was greater for formulations 
with a higher HPMC content. This can be attributed to the relatively slow rate of 
disintegration of HPMC (Rodriguez et al., 2000; Nafee et al., 2003). Formulations with 
both a high HPMC content and a large fill volume exhibited an exceedingly longer 
disintegration time. The anomalous results, where formulations with a larger HPMC 
concentration displayed a similar disintegration time to those with lower concentrations, 
may be rationalized by the idiosyncrasies involved in the subjective observation of 
perceived formulation disintegration (Chandrasekhar et al., 2009). 
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Figure 4.3: Vertical bar chart depicting the average disintegration times of the 
experimental design formulations (in all cases SDs < 0.02, N = 3) 
 
 
Figure 4.4: Contour plot depicting the relationship between the disintegration time, 
HPMC concentration and fill volume 
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4.3.3. In vitro Drug Release by Dissolution 
The DPH-loaded experimental design FMS samples displayed rapid drug release, with 
24-65% of the loaded dose releasing after 1 minute, depending on the formulation. 
Figure 4.5a, b and c depicts the drug release profiles of formulations 1-5, 6-10 and 11-
15, respectively. No significant differences were noted between the drug release profiles 
of the first five formulations (Figure 4.5a). Formulation 2 exhibited the largest fractional 
drug release after the first minute and formulation 4 the smallest. Formulations 6-10 
(Figure 4.5b) displayed slightly more variance than the first five formulations, with 
formulation 9 exhibiting the slowest drug release and formulation 7 the most rapid. On 
analysis of the drug release profiles of the last five formulations (Figure 4.5c), it was 
noted that formulation 14 exhibited significantly slower drug release than the other five 
formulations. 
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Figure 4.5: Drug release profiles of formulations (a) 1-5, (b) 6-10 and (c) 11-15 (in all 
cases SDs < 0.02, N = 3) 
 
AUCD at 1 minute was calculated for all formulations and was plotted as in Figure 4.6. 
Formulation 2 had the largest AUCD at 1 minute and, hence, the most rapid drug 
release, whereas formulation 14 had the smallest AUCD and, as a deduction, the 
slowest drug release. This is in agreement with the observations noted on analysis of 
the drug release profiles. During dissolution testing, it was observed that films consisting 
of smaller quantities of polymers disintegrated rapidly and often left fragmented clumps 
of the drug-loaded fiber layer, which tended to dissolve and release drug slower than 
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fibers on films that remained intact for a longer period of time. Films that took 
significantly longer to disintegrate hindered dissolution only slightly when compared to 
films with an intermediate disintegration time. Figure 4.7 displays a contour plot 
depicting the relationship between HPMC concentration, fill volume and AUCD at 1 
minute. Formulations with both a large fill volume and HPMC concentration displayed a 
large AUCD, whereas formulations with a small fill volume revealed an increase in AUCD 
with increasing fill volume.  
 
The dissolution testing method that was adopted for the purposes of this study was 
deemed to be reproducible and indicative of in vivo conditions within the oral cavity. 
 
Figure 4.6: Scatter plot depicting AUC of dissolution (AUCD) at 1 minute for the 15 
experimental design formulations 
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Figure 4.7: Contour plot depicting the relationship between the HPMC concentration in 
film formulations, fill volume and AUCD at 1 minute 
 
4.3.4. Drug Permeation by ex vivo Studies 
Ex vivo drug permeation, where conditions are as similar as possible to in vivo 
circumstances (Figueiras et al., 2009), is a valuable study to conduct in order to 
determine the expediency of employing a particular drug or drug delivery system for 
buccal administration (Sudhakar et al., 2006).  
 
The flux at each time point was calculated and was plotted against time as depicted in 
Figure 4.8. Formulations 4, 8 and 14 exhibited the lowest flux values in the three groups 
and formulations 2, 9 and 15 the greatest. Flux was greatest between 20 seconds and 5 
minutes, after which it was considerably reduced. AUCP at 3 minutes was calculated 
from permeation data for each formulation and the values were plotted, as depicted in 
Figure 4.9. Formulations 2, 7 and 15 exhibited the greatest AUCP and, hence, the most 
rapid rate of permeation, whereas formulation 14 had the lowest AUCP and the slowest 
permeation. This is in agreement with the in vitro dissolution data, where formulation 2 
displayed the most rapid drug release, formulations 7 and 15 also showed relatively 
rapid dissolution rates, and formulation 14 had the smallest AUCD at 1 minute. The 
apparent permeability coefficient (Papp) and steady-state flux (Jss) values were calculated 
for the 15 experimental design formulations and are outlined in Table 4.4. These values 
are somewhat anomalous, possibly due, in part, to the disparities in drug-loading for the 
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experimental design formulations, as well as the variations between individual buccal 
mucosal specimens. 
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Figure 4.8: Flux profiles displaying the flux over time of formulations (a) 1-5, (b) 6-10 
and (c) 11-15 
 
Figure 4.9: Scatter plot depicting AUC of permeation (AUCP) at 3 minutes for the 15 
experimental design formulations 
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Table 4.4: Calculated apparent permeability coefficient (Papp) and steady-state flux 
values (Jss) for the 15 experimental design formulations. 
Formulation Papp Jss 
F1 4.34 × 10-4 4.17 
F2 5.34 × 10-4 2.40 
F3 4.68 × 10-4 2.67 
F4 4.02 × 10-4 2.41 
F5 4.84 × 10-4 3.34 
F6 4.48 × 10-4 2.82 
F7 4.62 × 10-4 2.77 
F8 3.56 × 10-4 1.92 
F9 5.11 × 10-4 5.21 
F10 4.31 × 10-4 4.78 
F11 3.96 × 10-4 5.11 
F12 3.58× 10-4 2.04 
F13 4.67 × 10-4 6.58 
F14 4.32 × 10-4 5.32 
F15 4.73 × 10-4 3.69 
 
4.3.5. Mucoadhesion of Experimental Design Formulations 
The affixment of a polymer to a mucosal surface, such as the buccal mucosa, is termed 
mucoadhesion. Mucoadhesiveness is an eminent factor to consider in oramucosal drug 
delivery because the retention of a drug delivery system at a specific site influences 
drug absorption at that site (Andrews et al., 2009). The average work of adhesion (WA) 
and maximum detachment force (MDF) for the 15 experimental design formulations 
were calculated from textural profiles, an example of which is depicted in Figure 4.10. 
The calculated values were as depicted in Figures 4.11 and 4.12, respectively. The 
largest WA and MDF values were exhibited by formulations 9, 14 and 15 and the 
smallest values by formulations 1, 5 and 6. 
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Figure 4.10: Typical textural profile showing the peak force (MDF) (N) and work of 
adhesion (AUCFD) (mJ) used to determine mucoadhesive properties of the experimental 
design formulations 
 
Figure 4.11: Vertical bar chart depicting the average work of adhesion (WA) 
 
Formulation
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15
W
o
rk
 o
f 
A
d
h
e
s
io
n
 (
m
J
)
0.0
0.2
0.4
0.6
0.8
 75 
 
Figure 4.12: Vertical bar chart depicting the average maximum detachment force (MDF) 
 
Figure 4.13 depicts the relationship between WA, HPMC concentration and fill volume. 
As HPMC concentration in the formulations increased, the average WA decreased. The 
process of mucoadhesion occurs largely through interpenetration and hydrogen bonding 
between the polymeric system and the mucosal surface. In order for interpenetration to 
occur between these two surfaces, the polymer chains are required to be flexible 
(Andrews et al., 2009). HPMC is able to form weak hydrogen bonds with mucosal 
surfaces and an adherent gel upon hydration, which both make it a strongly 
mucoadhesive polymer in theory. Notwithstanding this, it has a high glass transition 
temperature (>200˚C), which results in poor chain flexibility and therefore poor 
experimental mucoadhesion (Karavas et al., 2006). This elucidates the observed 
decrease in WA with an increase in HPMC concentration. 
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Figure 4.13: Contour plot depicting the relationship between the HPMC concentration in 
film formulations, fill volume and work of adhesion 
 
Figure 4.14 depicts the relationship between WA, HPMC concentration and glycerol 
concentration. As can be seen in Figure 4.14, an aberrant trend occurred with varying 
glycerol concentration. For formulations containing HPMC at 0.25%w/v or less, the 
average WA decreased with increasing glycerol concentration. However, formulations 
containing 0.5%w/v HPMC displayed an increase in WA with an increase in glycerol 
concentration. At HPMC concentration of 0.25%w/v or less (where the fraction of PVA 
was greater), the disintegration time was relatively short compared to that at 0.5%w/v, 
thus suggesting that PVA has a faster rate of disintegration than HPMC. With a 
disintegration rate that is already elevated, the addition of increasing concentrations of 
glycerol to formulations with a large proportion of PVA enhances the rate of 
disintegration even further (McCarron et al., 2005). When a formulation disintegrates 
rapidly, there may be less of it available in its original form at the point in time when 
mucoadhesive strength is measured and hence the decreasing WA with increasing 
glycerol concentration may be accounted for. At the higher HPMC concentration, the 
increase in WA with increasing glycerol concentration may be attributed to the pliability 
of poorly-flexible HPMC chains being enhanced, hence resulting in an increased WA as 
the glycerol concentration was increased (Llabot et al., 2007). 
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Figure 4.14: Contour plot depicting the relationship between HPMC concentration, 
glycerol concentration and work of adhesion 
 
4.3.6. Analysis of Main Effects and Interaction Effects on Responses 
4.3.6.1. Disintegration Time 
The main effects plot for disintegration time (Figure 4.15a) showed that both fill volume 
and HPMC concentration had positive effects on disintegration time, i.e. increasing the 
values of these two variables resulted in an increase in disintegration time. Glycerol 
concentration imparted a negative effect on the disintegration time, decreasing the 
response for an increase in concentration. HPMC concentration imparted the most 
significant effect on disintegration time (p = 0.015). The interactions plot (Figure 4.15b) 
suggested that interactions occurred between variables, observed where the lines were 
not parallel. From this, it was deduced that the effect of HPMC concentration on 
disintegration time was dependent on fill volume. The effect of glycerol concentration on 
disintegration time was presumed to be dependent on fill volume at a high fill volume, 
but there was little interaction between these two variables at fill volumes of 70mL or 
below. The effect of glycerol concentration on disintegration rate appeared to be 
dependent on HPMC concentration when HPMC concentration was high; however, little 
interaction was observed at HPMC concentration of 0.25%w/v or less.  
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Figure 4.15: Diagnostic plots of the design showing (a) main effects plot and (b) 
interactions plot for disintegration time 
 
4.3.6.2. Work of Adhesion 
Analysis of the main effects plot for WA (Figure 4.16a) revealed that WA increased with 
increasing fill volume, decreasing HPMC concentration and glycerol concentration 
above and below 12.5%w/w; however, it decreased at glycerol concentration of 12.5%
w/w. 
The most significant effect on WA was from HPMC concentration (p = 0.004). The 
interactions plot (Figure 4.16b) suggested that the effect of all three individual variables 
on WA depended on the other independent variables. 
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Figure 4.16: Diagnostic plots of the design showing (a) main effects plot and (b) 
interactions plot for work of adhesion 
 
4.3.6.3. Maximum Detachment Force 
The main effects (Figure 4.17a) and interactions (Figure 4.17b) plots for MDF displayed 
similar trends to that of WA regarding the effects of the three variables on the response 
and on each other’s effects on the response (refer to Figure 4.16 and the discussion on 
WA). The most significant effect on MDF was from HPMC concentration (p = 0.003). 
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Figure 4.17: Diagnostic plots of the design showing (a) main effects plot and (b) 
interactions plot for maximum detachment force 
 
4.3.6.4. AUCD at 1 minute 
On analysis of the main effects plot (Figure 4.18a) of AUCD at 1 minute, it was observed 
that AUCD was appreciably high for large fill volumes, high HPMC concentration and 
glycerol concentration above and below 12.5%w/w. AUCD was affected significantly by fill 
volume (p = 0.265). The interactions plot (Figure 4.18b) suggested that the effect of all 
three individual variables on AUCD depended on the other independent variables. 
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Figure 4.18: Diagnostic plots of the design showing (a) main effects plot and (b) 
interactions plot for AUCD at 1 minute 
 
4.3.6.5. AUCP at 3 minutes 
The main effects plot for AUCP at 3 minutes (Figure 4.19a) revealed that AUCP was 
greatest at low fill volumes, high glycerol concentration and an HPMC concentration of 
0.25%w/v. Fill volume had the most significant effect on AUCP (p = 0.585). The 
interactions plot (Figure 4.19b) suggested that the effect of all three individual variables 
on AUCP depended on the other independent variables. 
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Figure 4.19: Diagnostic plots of the design showing (a) main effects plot and (b) 
interactions plot for AUCP at 3 minutes 
 
4.3.7. Analysis of the Box-Behnken Experimental Design 
Residuals are useful for the fitting of data to regression models and residual plots can 
be employed to analyze the fit of such models (Deschepper et al., 2006) in a Box-
Behnken experimental design. Residual plots are plots of the differences between 
observed values and predictions for a particular response (Stewardson and Whitfield, 
2004). The residual plots for the responses analyzed using the Box-Behnken 
experimental design are depicted in Figures 4.20, 4.21, 4.22, 4.23 and 4.24.  
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Figure 4.20: Diagnostic plots of the design showing residual plots for disintegration time 
 
 
Figure 4.21: Diagnostic plots of the design showing residual plots for work of adhesion 
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Figure 4.22: Diagnostic plots of the design showing residual plots for maximum 
detachment force 
 
 
Figure 4.23: Diagnostic plots of the design showing residual plots for AUCD at 1 minute 
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Figure 4.24: Diagnostic plots of the design showing residual plots for AUCP at 3 minutes 
 
Table 4.5: ANOVA analysis for the measured responses investigated in the Box-
Behnken experimental design 
Term p-value 
DT WA MDF AUCD AUCP 
FV 0.699 0.340 0.615 0.054 0.285 
[HPMC] 0.724 0.102 0.245 0.055 0.376 
[Glycerol] 0.840 0.272 0.601 0.062 0.736 
FV*FV 0.746 0.578 0.929 0.092 0.859 
[HPMC]*[HPMC] 0.204 0.666 0.820 0.843 0.020 
[Glycerol]*[Glycerol] 0.883 0.190 0.556 0.078 0.490 
FV*[HPMC] 0.093 0.931 0.728 0.285 0.954 
FV*[Glycerol] 0.508 0.106 0.526 0.099 0.163 
[HPMC]*[Glycerol] 0.181 0.160 0.426 0.092 0.772 
Where DT = disintegration time, WA = work of adhesion, MDF = maximum detachment 
force, AUCD = AUCD at 1 minute, AUCP = AUCP at 3 minutes and FV = fill volume. 
 
On residual analysis of disintegration time (Figure 4.20), WA (Figure 4.21), MDF (Figure 
4.22), AUCD at 1 minute (Figure 4.23) and AUCP at 3 minutes (Figure 4.24), it was 
observed that there was a random distribution of data. The normal probability plots for 
all responses exhibited a linear curve, indicating normality. The residuals versus fitted 
values plots demonstrated a random arrangement of data points, signifying an 
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acceptable and normal fit with a linear regression model. The residual histograms 
exhibited bell-shaped or nearly bell-shaped curves, suggesting that the data is normally 
distributed. The residual versus observation order plots displayed a random fluctuation 
about the center line, suggesting that the error terms are not correlated with one 
another. An ANOVA analysis with the p-values for the various responses is outlined in 
Table 4.5. 
 
The regression equations that were generated for five responses are outlined below: 
 
Disintegration time = 40.764 – 0.374(FV) + 34.333[HPMC] – 3.517[glycerol] – 
0.0015(FV2) + 94.000[HPMC]2 + 0.100[glycerol]2 + 1.067(FV)[HPMC] + 
0.0367(FV)[glycerol] – 9.600[HPMC][glycerol]    (Equation 4.3) 
 
Work of adhesion = 2.235 + 0.0148(FV) -2.828[HPMC] – 0.315[glycerol] + 0.00004(FV2) 
+ 0.455[HPMC]2 + 0.0150[glycerol]2 – 0.00072(FV)[HPMC] – 0.00157(FV)[glycerol] + 
0.157[HPMC][glycerol]       (Equation 4.4) 
 
Maximum detachment force = 0.943 + 0.00550(FV) – 1.360[HPMC] – 0.104[glycerol] – 
0.000(FV2) + 0.174[HPMC]2 + 0.00457[glycerol]2 + 0.00213(FV)[HPMC] – 
0.00040(FV)[glycerol] + 0.0604[HPMC][glycerol]    (Equation 4.5) 
 
AUCD = 2.504 – 0.0179(FV) + 1.785[HPMC] – 0.310[glycerol] + 0.00007(FV
2) – 
0.105[HPMC]2 + 0.0111[glycerol]2 – 0.00482(FV)[HPMC] + 0.00081(FV)[glycerol] – 
0.100[HPMC][glycerol]       (Equation 4.6) 
 
AUCP = 1.460 +0.0351(FV) + 2.868[HPMC] – 0.190[glycerol] – 0.00003(FV
2) – 
6.967[HPMC]2 + 0.0154[glycerol]2 + 0.00100(FV)[HPMC] – 0.00270(FV)[glycerol] + 
0.0608[HPMC][glycerol]       (Equation 4.7) 
 
4.3.8. Response Optimization 
Response optimization was performed using Minitab®, V15 (Minitab® Inc, Pennsylvania, 
USA). The film formulation was optimized according to the measured responses of 
disintegration time, WA, MDF, AUCD at 1 minute and AUCP at 3 minutes, which were 
targeted as outlined in Table 4.6. Maximizing and minimizing responses, where 
appropriate, resulted in a low desirability for the optimized formulation and the values 
were therefore targeted within the limits of acceptability. Figure 4.25 displays the final 
optimization plot, revealing a composite desirability of 95.23%. 
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Table 4.6: Targeted response values employed in formulation optimization 
Response Lower Target Upper 
Disintegration time (seconds) 12 13 20 
Work of Adhesion (mJ) 0.3 0.4 0.7 
Maximum Detachment Force (N) 0.2 0.3 0.45 
AUCD at 1 minute 0.3 0.35 0.45 
AUCP at 3 minutes 1.6 1.9 2 
 
 
Figure 4.25: Final optimization plot for the response optimization of the polymeric film 
formulation 
 
Table 4.7 displays the predicted values acquired from formulation optimization with the 
observed experimental values for the various responses.  
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Table 4.7: Predicted and experimental values for optimization of the responses 
Response Predicted 
Value 
Experimental 
Value 
Desirability 
Disintegration time (seconds) 13.2457 12.8 96.6% 
Work of Adhesion (mJ) 0.3885 0.335 86.2% 
Maximum Detachment Force (N) 0.3043 0.2705 88.9% 
AUCD at 1 minute 0.3491 0.4179 83.5% 
AUCP at 3 minutes 1.8885 2.0860 90.5% 
 
4.4. Concluding Remarks 
 
Mucoadhesive, drug-loaded electrospun fibers were incorporated directly onto polymeric 
backing films that were prepared and optimized according to a 3-level, 3-factor Box-
Behnken experimental design. The effects of the independent variables on the 
dependent response variables were analyzed and an optimized formulation was 
mathematically produced. The optimized formulation was found to have a desirable 
disintegration time, mucoadhesiveness and rapid drug release and permeation. The 
rapid drug release may be attributed to the exceedingly large surface area of the 
electrospun fibers. However, drug-loading was somewhat irregular due to asymmetrical 
fiber deposition and it would therefore be necessary to conduct further studies in order 
to temper the regularity of the fiber layer. Notwithstanding the uneven drug-loading, the 
FMS displays a favorable propensity to be employed as a rapidly releasing, 
mucoadhesive buccal drug delivery system. 
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CHAPTER 5 
PHYSICOCHEMICAL AND PHYSICOMECHANICAL INVESTIGATION 
OF AN OPTIMIZED FIBROUS MATRIX SYSTEM FOR RAPID 
ORAMUCOSAL DRUG DELIVERY 
 
5.1. Introduction 
 
During electrospinning, the polymer chain orientation that occurs during fiber formation 
has a significant effect on the physicomechanical properties of the fibrous matrix that is 
formed (Baji et al., 2010). The fiber diameter has been found to affect the mechanical 
properties of electrospun materials (Tan and Lim, 2006), where fibers with smaller 
diameters displayed a greater strength, but were less pliable than larger fibers (Tan et 
al., 2005). The physicomechanical properties of a material have a significant effect on 
drug release (Coviello et al., 2005), patient acceptability (Malone et al., 2003) and 
residence time at the site of absorption (Zaman et al., 2008; Andrews et al., 2009) and it 
is thus necessary to investigate the physicomechanical properties of a drug delivery 
system. 
 
In the work outlined in this chapter, drug-loaded fibers were electrospun directly onto an 
optimized polymeric backing film in order to form a porous, rapidly disintegrating fibrous 
matrix system (FMS) for oramucosal drug delivery. Polyvinylalcohol (PVA) fibers were 
produced and loaded with model drug, diphenhydramine (DPH). The polymeric backing 
film was produced according to an optimized formula determined by a Box-Behnken 
experimental design, in Chapter 4. Drug-loaded films, serving as a comparison, were 
produced according to the same formula as the backing film and using the same 
constituents as the electrospinning solution. This chapter details the investigation into 
drug release, ex vivo permeation, mucoadhesion, micro-environmental pH variation and 
mechanical properties of the optimized FMS. 
 
5.2. Materials and Methods 
 
5.2.1. Materials 
The materials used in this phase of the study were the same as in Chapter 4. 
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5.2.2. Preparation of Polymeric Backing Films by Film-Casting 
A film intended as a backing and mucoadhesive layer for electrospun fibers was 
prepared according to an optimized formula using a Box-Behnken experimental design 
in as described in Chapter 4. Polymer solutions were prepared by dissolving 136.5mg of 
glycerol, 794mg of polyvinylalcohol (PVA) and 116mg of hydroxypropylmethylcellulose 
(HPMC) in 79.39mL of a 4:1 mixture of deionized water and propan-2-ol. The solution 
was syringed into a rectangular flat-bottomed mould and left in a fume hood for 48 hours 
in order that complete solvent evaporation and film-formation could occur. For 
comparative purposes, a DPH-loaded film (FD) containing the same polymeric and 
plasticizer constituents was prepared. 
 
5.2.3. Preparation of Fibers by Electrospinning 
A drug-loaded solution for electrospinning was produced by dissolving PVA, citric acid, 
DPH and glycerol in a 2:1 deionized water:propan-2-ol mixture at concentrations of 
25%w/v, 2%
 w/v, 10%
 w/v and 0.5%
v/v, respectively. These quantities were based on 
optimal fiber production, reproducibility and drug-loading efficiency. The solution was 
placed in a 5mL pipette, which was fitted into the adjustable supporting bracket of an 
electrospinning device. Electrospinning of the solution was performed as outlined in 
Chapter 4. Fibers were collected on the polymeric backing film secured on aluminum 
foil-lined board. Samples were cut into 1.5cm2 sections. For comparative purposes, a 
film (FE) was prepared with the same drug/polymer ratio as the electrospinning solution. 
 
5.2.4. Morphological and Surface Structure Analysis of the Drug-loaded Fiber 
Layer 
The surface structure of the electrospun fibers was analyzed by images produced by 
scanning electron microscopy (SEM), using a Phenom Microscope (FEI Company, 
Hillsboro, Oregon, USA). Samples were mounted on stubs and sputter-coated with gold 
prior to examination. 
 
5.2.5. Drug Entrapment of the Optimized FMS and Drug-Loaded Films 
Samples of the FMS and the two drug-loaded films (FD and FE) were cut into sections, 
dissolved in simulated saliva (pH 6.75) and the drug content of each section was 
analyzed by UV spectrophotometry.  
 
5.2.6. Disintegration Time of the Optimized FMS and Drug-Loaded Films 
The in vitro disintegration time of FMS samples and drug-loaded films (FD and FE) was 
determined as outlined in Chapter 4. 
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5.2.7. In vitro Drug Release by Dissolution Testing 
In vitro drug release was tested according to the method outlined in Chapter 4. As a 
branded product comparison, the in vitro dissolution testing of Sleepeze-PM® tablets 
was performed using a USP rotating paddle apparatus (Model 7ST, Caleva, Frankfurt, 
Germany) and employing 900mL phosphate buffered saline (PBS) (pH 6.8, 37°C). 5mL 
samples were drawn at 1, 3, 5, 10, 15, 30, 60 and 90 minutes and analyzed by UV 
spectrophotometry. 
 
5.2.8. Drug Permeation by ex vivo Studies 
Ex vivo drug permeation testing was performed according to the method outlined in 
Chapter 4. After equilibration, the PBS in the donor compartment was removed and was 
replaced with an FMS, FD, or FE sample in simulated saliva (pH 6.75). A 2mg/mL DPH in 
simulated saliva solution was also tested for comparative purposes.  
 
5.2.9. Mucoadhesion of the Optimized FMS and Drug-Loaded Films 
Mucoadhesion testing was performed according to the method outlined in Chapter 4.  
 
5.2.10. Determination of Micro-Environmental Surface pH Variation within the FMS 
Extreme changes in pH on the surface of the matrix can cause irritation to mucous 
membranes within the oral cavity (Patel et al., 2007). Measurement of the surface pH is 
therefore essential. Matrices were allowed to swell in contact with 1mL of simulated 
saliva (pH 6.75). The surface pH was measured by glass micro-electrode (Mettler 
Instruments, Giessen, Germany). Measurements were taken after the matrices had 
been hydrated for 20 seconds and at 1, 3, 5, 10 and 15 minutes thereafter. 
 
5.2.11. Determination of FMS Toughness and Bi-Axial Extensibility 
Bi-axial extensibility was determined from Force-Distance profiles generated using a 
TA.XTplus Texture Analyser (Stable Micro Systems, London, England) fitted with a 2mm 
flat cylindrical probe and a 5kg loadcell. The method of testing the extensibility was 
based on work by Sibeko and co-workers (2009). The sample was secured onto a ring 
assembly with a central hole (5mm diameter), which was attached to a supportive, 
hollow, raised platform. The setup was placed such that the cylindrical probe of the 
textural analyzer was centralized over the hole. The probe was lowered and penetrated 
into the sample according to the test parameters outlined in Table 5.1. 
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Table 5.1: Test parameters employed in bi-axial extensibility testing 
Parameter Setting 
Test mode Compression 
Pre-test speed 1mm/s 
Test speed 1mm/s 
Post-test speed 1mm/s 
Target mode Distance 
Distance 10mm 
Trigger force 0.5N 
 
5.2.12. Determination of Tensile Properties of the Optimized FMS and Drug-
Loaded Films 
The tensile properties of samples were measured using a nanoTensileTM 5000 (Hysitron 
Incorporated, Minneapolis, Minnesota, USA). Samples were cut into thin 1 × 22mm 
(approximately) strips and mounted, with cyanoacrylate-based adhesive, onto specially 
designed mounting brackets held together with rigid strips of cardboard. Once the 
sample had cured completely, the width, length and thickness were measured with 
digital calipers. The sample and sample bracket were secured in the upper sample 
gripper on the nanotensile (NT) Head and the mass was measured. The NT Head was 
lowered and the axes were aligned in order to secure the bottom of the sample bracket 
in the sample stage (lower) sample gripper. The mounting brackets were moved apart at 
a constant rate of displacement and the tensile properties of the sample were measured 
and recorded. 
 
5.2.13. Analysis of the Stress-Strain Rheological Parameters of the Components 
of the FMS 
The rheological properties of polymer solutions and hydrated FMS, FD and FE samples 
were determined with the use of a Haake Modular Advanced Rheometer System 
(ThermoFisher Scientific, Karlsruhe, Germany). The stress-strain rheological 
parameters of the polymer solution have an influence on drug release, electrospinning, 
palatability and effect on saliva, and are important factors when considering the desired 
characteristics of the system. Samples were analyzed by placing the polymer solution or 
FMS/film sample, hydrated in 1mL simulated saliva (pH 6.75), on the sample stage and 
immersing the spindle in the fluid. The shear rate was ramped from 0 to 500/s and the 
shear forces and viscosities of the samples were measured at 37°C for the FMS and 
film samples and at 25°C for the electrospinning solution. The thixotropy of the 25%w/v 
PVA electrospinning solution was determined by ramping the shear rate from 0 to 50/s 
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over 60 seconds, holding for 60 seconds and then decreasing back to 0/s over 60 
seconds. Oscillation studies were carried out by subjecting samples to oscillating 
stresses or strains. Oscillation measurements were used to determine the storage 
modulus, G’, and the loss modulus, G”, as a function of angular frequency, ω. 
Oscillation tests provide information on sample elasticity and viscosity related to the 
applied frequency. 
 
5.2.14. Vibrational Chemical Structure Analysis 
Fourier Transform Infrared (FTIR) Spectroscopy was performed in order to assess 
structural changes that may have occurred in the polymeric backbone due to 
interactions of excipients, drugs or polymers during film or fiber formation. A Spectrum 
100 FT-IR Spectrometer (PerkinElmer Inc., Waltham, Massachusetts, USA) was used to 
assess vibration characteristics of chemical functional groups.  
 
5.3. Results and Discussion 
 
5.3.1. Physical Dimensions of the Films and Fiber Layer 
The films produced were even, thin, transparent and pliable. The fibers formed a white 
layer on the films. The FMS backing layer film was 80µm thick, while the complete FMS 
was 460µm thick, and hence the fiber layer was 380µm thick. The FE film was 110µm 
thick and the FD film was approximately 90µm thick, but was somewhat uneven in 
places. 
 
5.3.2. Morphological and Surface Structure Analysis of the Electrospun Fiber 
Layer 
On SEM analysis, it was observed that the fibers produced were randomly arranged and 
had uniform diameters on average. The fiber diameter was approximately 0.36µm and 
the average visible pore size ranged between approximately 0.69 and 1.91µm, as 
depicted in Figure 5.1. 
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Figure 5.1: SEM image of the electrospun fiber layer, showing average fiber diameter of 
0.36µm and visible pore size of 0.69-1.91µm 
 
5.3.3. Drug Entrapment of the Optimized FMS and Drug-Loaded Films 
The average drug entrapment of the FMS and the FD and FE films was determined along 
with standard deviation, and is outlined in Table 5.2.  
 
Table 5.2: Drug entrapment per 1.5cm2 section of fibrous matrix system (FMS), drug-
loaded optimized film (FD) and film produced from ratios in electrospinning solution (FE) 
Formulation Drug Entrapment 
(mg) ± SD 
FMS 2.3 ± 0.44 
FD 8.8 ± 0.11 
FE 5.5 ± 0.48 
 
5.3.4. Disintegration Time of the Optimized FMS and Drug-Loaded Films 
The time taken for the FMS and the FD and FE films to disintegrate was 12.8 seconds, 
15.8 seconds and 52.6 seconds, respectively, and is depicted in Figure 5.2. The DPH-
loaded fiber layer of the FMS took an average of 3.6 seconds to disintegrate, which is 
considerably shorter than the time taken for the drug-loaded films to disintegrate. 
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Figure 5.2: Vertical bar chart depicting the disintegration times of the fibrous matrix 
system (FMS), fiber layer of the FMS, drug-loaded optimized film (FD) and film formed 
from the same components as the electrospinning solution (FE) (in all cases SDs < 0.02, 
N = 3) 
 
5.3.5. In vitro Drug Release by Dissolution 
The optimized FMS exhibited a rapid dissolution rate, with an average of 63% of the 
loaded dose releasing after 1 minute and 86% after 3 minutes. In comparison, the FD 
and FE films released 27% and 17% of the loaded dose after 1 minute and 48% and 
46% at 3 minutes, respectively. Drug release profiles are depicted in Figure 5.3. It is 
apparent that the dissolution rate of the FMS is significantly more rapid than that of 
either of the drug-loaded films, owing to the extremely high surface area of the fibrous 
layer in comparison to films (Agarwal et al., 2008; Reneker and Yarin, 2008), which 
enhances the rate of disintegration and dissolution (Dokoumetzidis and Macheras, 
2006). Figure 5.4 displays the drug release profiles of the FMS and the branded 
comparator product. The branded comparator product, Sleepeze-PM®, displayed a 
relatively rapid drug release, with 31% and 55% of the loaded dose releasing after 1 and 
3 minutes, respectively. However, the optimized FMS exhibited a superior drug release 
profile in a considerably smaller volume of buffer, which makes it preferable to the 
conventional system on the market in terms of its rapid action.  
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Figure 5.3: Drug release profiles of the fibrous matrix system (FMS), DPH-loaded film 
formulation (FD) and film formed from the same components as the electrospinning 
solution (FE) (in all cases SDs < 0.02, N = 3) 
 
Figure 5.4: Drug release profiles of the fibrous matrix system (FMS) and Sleepeze-PM® 
tablets (in all cases SDs < 0.02, N = 3) 
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The area under the curve (AUCD) at 1 minute was calculated for the FMS, FD and FE 
films and Sleepeze-PM® tablets, and is illustrated as a bar chart in Figure 5.5. The 
AUCD of the FMS is nearly 3 times greater than that of the FD film and Sleepeze-PM
® 
tablets, and approximately 5 times greater than the AUCD of the FE film. Hence it can be 
deduced that drug release from the FMS occurs more rapidly than from any of the 
comparison test formulations. 
 
Figure 5.5: Dissolution AUC (AUCD) comparison between the FMS, comparator DPH-
loaded film formulations (FD and FE) and Sleepeze-PM
® tablets (in all cases SDs < 0.02, 
N = 3) 
 
5.3.6. Drug Permeation by ex vivo Studies 
Figure 5.6 depicts the flux profiles of the FMS, a 2mg/mL DPH solution and the drug-
loaded films, FD and FE. The DPH solution exhibited a slightly greater flux than the FMS, 
with 79% and 78% of the loaded dose permeated at 3 minutes, respectively. The FD and 
FE films displayed a lower flux than the FMS, where 74% and 55% of the loaded dose 
had permeated after 3 minutes, respectively. This is in agreement with the in vitro 
dissolution data. Permeation AUC (AUCP) at 3 minutes was calculated for the tested 
formulations and plotted as in Figure 5.7. AUCP of the 2mg/mL DPH solution was 
slightly greater than that for the FMS, suggesting that the rate of permeation of drug 
from solution was only marginally faster than from the FMS. The FE film exhibited the 
smallest AUCP value and the value for the FD film was between that of the FMS and FE 
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film. The rate of drug permeation from the DPH-loaded films was somewhat slower than 
from the FMS or the drug solution. 
 
Figure 5.6: Flux profiles of the fibrous matrix system (FMS), DPH solution, DPH-loaded 
film formulation (FD) and film formed from the same components as the electrospinning 
solution (FE) 
 
Figure 5.7: Scatter plot depicting AUCP at 3 minutes for the fibrous matrix system 
(FMS), DPH solution, DPH-loaded film formulation (FD) and film formed from the same 
components as the electrospinning solution (FE) 
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The apparent permeability coefficient (Papp) and steady-state flux (Jss) values were 
calculated for the tested formulations and are outlined in Table 5.3. These values were 
in accordance with those for AUCP of the various formulations, with the FE film exhibiting 
the smallest Papp and Jss values and the DPH solution having the largest Papp and Jss 
values. 
 
Table 5.3: Calculated apparent permeability coefficient (Papp) and steady-state flux (Jss) 
values for the FMS, DPH solution, FD and FE 
Formulation Papp Jss 
FMS 4.9 × 10-4 5.88 
DPH Solution 5.0 × 10-4 5.95 
FD 4.7 × 10
-4 5.60 
FE 3.4 × 10
-4 4.11 
 
5.3.7. Mucoadhesion of the Optimized FMS and Drug-Loaded Films 
The average maximum detachment force (MDF) and work of adhesion (WA) were 
determined from the peak and AUC, respectively, of the Force-Distance profiles (Figure 
5.8) generated by textural profiling. Table 5.4 outlines the values of MDF and WA for the 
FMS film, fibrous layer and the drug-loaded films (FD and FE). The backing film of the 
FMS exhibited an adequate MDF and WA. The fibrous layer was observed to be 
apparently more mucoadhesive than the film; however, due to the rapid disintegration 
rate of the fibers, the backing film is required to hold the system in place and ensure that 
the released drug is detained at the buccal mucosa until absorption occurs. The FE film 
was found to have a considerably larger MDF than the fibrous layer of the FMS. This 
may be attributed to the rapid disintegration rate of the fibers. In comparison to the FMS 
film layer, the FD film displayed an exceedingly smaller MDF and WA. From this, it can 
be deduced that the addition of drug to the film formulation resulted in a reduction in 
mucoadhesiveness. The disparity between the MDF and WA values of the FMS backing 
film and the FE film may be due to the presence of HPMC in the FMS film formulation. 
As discussed in Chapter 4, HPMC has poorly flexible chains due to a high glass 
transition temperature and is therefore poorly mucoadhesive (Karavas et al., 2006), and 
hence the addition of HPMC to the film formulation will decrease the mucoadhesive 
strength of the resulting film. 
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Figure 5.8: Typical textural profile used to determine MDF (peak) and WA (AUCFD) for 
assessing mucoadhesion 
 
Table 5.4: Maximum detachment force (MDF) and work of adhesion (WA) for the FMS 
film, fiber layer of the FMS and the drug-loaded films, FE and FD 
Formulation MDF (N) WA (mJ) 
FMS Film 0.2705 0.335 
FMS Fibrous Layer 0.2982 0.601 
FD 0.0468 0.041 
FE 0.3867 0.599 
 
5.3.8. Micro-Environmental Surface pH Variation within the FMS 
It has been observed that extreme changes in surface pH may cause damage to 
mucosal surfaces (Bottenberg et al., 1991). The evaluation of surface pH variation is 
therefore an important factor to consider (Munasur et al., 2006). The surface pH values 
ranged between 6.63 and 6.75 over the 15 minutes in which measurements were taken 
(Figure 5.9). There was an initial drop in pH to 6.63 at the 20 second time point, possibly 
due to dissolution and subsequent solubilization of citric acid, which was employed as a 
taste-masking component. At the 3 minute time point, the pH had increased to 6.73, 
which may be due to the buffering effect of the simulated saliva or the dissolving of the 
polymeric components of the formulation. The variation of pH was less than 0.5 units 
and considered acceptable for an oramucosally administered drug delivery system as it 
can be deduced that minimal irritation to the buccal mucosa would occur. 
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Figure 5.9: Average pH variation over time for the FMS hydrated in simulated saliva (pH 
6.75) 
 
5.3.9. FMS Toughness and Bi-Axial Extensibility 
Extensibility is the degree of extension or stretching that a material can withstand before 
fracture occurs and polymer linkages have a substantial effect on the 
physicomechanical strength of materials (Sibeko et al., 2009). Figure 5.10 is a typical 
textural profile obtained during extensibility testing. The maximum force (Fmax) and 
distance (Dmax) values for the FMS, optimized FMS film, FD film and FE film were plotted 
as a vertical bar chart in Figure 5.11. The complete FMS was found to be slightly 
stronger than the FMS film (Fmax = 5.29N and 5.17N, respectively), but also less 
extensible (Dmax = 4.435 and 4.957mm, respectively). It can therefore be deduced that 
the presence of electrospun fibers resulted in a slight increase in film strength and a 
decrease in extensibility. When electrospun fibers are produced, there is a thinning and 
extending process that takes place (Kalayci et al., 2005), and this may result in the 
fibers being less extensible than the film. The presence of drug in the FMS film (FD) 
brought about a decrease in both Fmax and Dmax. This may also partially explain the 
reduction in extensibility with the presence of a drug-loaded fiber layer. The FE film had 
a significantly larger Fmax and Dmax than the FMS, which may be due to the absence of 
the more rigid polymer, HPMC, and formation by film-casting, which does not result in 
thinning, of the former.  
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Figure 5.10: Typical textural extensibility profile for the FMS, showing 3 distinct regions: 
linear extensibility (A), maximum extensibility (B) and fracture point (C) 
 
Figure 5.11: Vertical bar chart outlining average maximum force and distance values for 
the film of the fibrous matrix system (FMS), the complete FMS, drug-loaded FMS film 
(FD) and film containing the same components as the electrospinning solution (FE) (in all 
cases SDs < 0.02, N = 3) 
 
5.3.10. Determination of Tensile Properties by Nanotensile Testing 
The stress-strain relationship of a material is highly dependent on the flexibility of the 
polymer chains and the strength of the material. When only a small amount of stress is 
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required to produce a large amount of strain, the material is considered to be flexible 
and the Young’s modulus, which is the slope of the linear portion of the stress-strain 
curve, will be relatively small (Wu and McGinity, 2000). The average experimental 
values for Young’s modulus (E), yield stress (σy), ultimate strength (σu), ultimate strain 
(εu) and toughness (uf) are outlined in Table 5.5. The samples tested were the fiber layer 
of the FMS (Figure 5.12a), the FMS film (Figure 5.12b), the complete FMS (Figure 
5.12c), the FD film (Figure 5.12d) and the FE film (Figure 5.12e).  
 
The drug-loaded fiber layer (Figure 5.12a) exhibited the smallest yield stress, ultimate 
strain and toughness. The Young’s modulus of the fiber layer was greater than that of 
the FE film (Figure 5.12e) but smaller than the other tested samples, suggesting that it 
was more flexible than the film onto which it was incorporated but less flexible than the 
FE film. When compared to the FE film, which was prepared using the same components 
at the same ratios, the fiber layer was found to have a larger Young’s modulus and a 
considerably smaller yield stress, ultimate strength, ultimate strain and toughness, as 
well as a smaller elastic region (green portion of nanotensile profile), which may be 
attributed to the elongating forces experienced by polymer chains during electrospinning 
(Lu et al., 2008; Baji et al., 2010). When a polymer is exposed to greater elongating 
forces, the fibers that are formed will have smaller diameters, which have also been 
associated with a larger Young’s modulus and hence a greater stiffness (Arinstein et al., 
2007). It can therefore be deduced that the differences between the tensile properties of 
the fiber layer and the FE film are due to polymer chain stretching during fiber formation.  
 
Table 5.5: Experimental values obtained from nanotensile analysis of the FMS and 
various films 
Sample E (MPa) σy (MPa) σu (MPa) εu uf (J/cm
3) 
Fiber Layer 26.09 0.49 2.98 0.227 0.38 
FMS Film 36.01 1.675 3.33 0.242 0.62 
FMS 30.31 1.18 2.79 0.238 0.48 
FD 56.35 1.13 2.73 0.314 0.71 
FE 20.34 1.10 3.52 0.731 2.10 
 
The FMS film (Figure 5.12b) revealed slightly larger values than the fiber layer for the 
various responses determined during nanotensile testing. This may be due to the 
presence of the more rigid polymer, HPMC, in the film. The profile for the FMS (Figure 
5.12c) revealed two distinct points of fracture – the first one being the point at which the 
fiber layer fractured and the second where the film layer fractured. The FD film (Figure 
 104 
5.12d), which is the DPH-loaded FMS film, featured a substantially larger Young’s 
modulus than the FMS film, suggesting that the presence of DPH in the formulation 
enhanced the rigidity of the film.  
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Figure 5.12: Stress-strain nanotensile profiles of the (a) drug-loaded fiber layer, (b) 
FMS film, (c) FMS, (d) drug-loaded FD film and (e) drug-loaded FE film  
 
The results of nanotensile testing were in agreement with the extensibility results in the 
previous section. However, the two tests were performed disparately and with varying 
sensitivity. The extensibility test utilized a large sample area, imbedded a probe into the 
sample until fracture and measured the force-distance relationship. Whereas the 
nanotensile test employed only a small sample area, pulled the sample apart until 
fracture and measured the stress-strain relationship, from which various parameters, 
such as Young’s modulus, yield stress and toughness, could be calculated. While both 
tests are useful, the nanotensile test was more applicable for this particular formulation 
due to the method of testing, type of results produced and the augmented sensitivity of 
the test. 
 
5.3.11. Analysis of the Stress-Strain Rheological Parameters of the Components 
of the FMS 
5.3.11.1. Rheological Analysis of the Optimized FMS and Drug-Loaded Film 
Formulations 
The rheological properties of a hydrated sample play an important role in the retention 
of that sample within the buccal cavity (Eouani et al., 2001; Zaman et al., 2008). The 
hydrated film and FMS samples were investigated for the effect of an increasing shear 
rate ( ) on shear force (τ) and viscosity (η). The average values over the shear rate 
range for these parameters are outlined in Table 5.6. Linear rheological profiles are 
depicted in Figure 5.13. The FE film (Figure 5.13c) exhibited an exceedingly larger 
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average viscosity and shear force than the FMS (Figure 5.13a) and FD film (Figure 
5.13b), which correlates with the greater mucoadhesive properties and slower 
disintegration rate evinced by this film. However, such a high viscosity may result in an 
unpleasant mouth-feel in vivo (Malone et al., 2003). The large disparity between the 
parameters of the FMS and FE film may be due to the more rapid disintegration rate of 
the former. Nevertheless, the rheological properties of the FMS suggest that it would 
have an adequate retention time, which is in agreement with the mucoadhesion data. 
 
Table 5.6: Average rheological parameters of the FMS, FD film and FE film in 1mL 
simulated saliva (pH 6.75) 
Sample Shear Rate 
(1/s) 
Shear Force 
(Pa) 
Viscosity 
(mPa.s) 
FMS 254.3 7.44 32.29 
FD 252.3 7.39 30.49 
FE 253.2 82.71 1616.67 
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Figure 5.13: Linear rheological profiles of the (a) FMS, (b) FD film and (c) FE film  
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5.3.11.2. Rheological Analysis of the Electrospinning Solution 
The rheological properties of a solution employed for electrospinning can have a 
substantial effect on the process of electrospinning as well as the quality and 
morphology of fibers that are formed (Tao and Shivkumar, 2007). The degree of 
polymer chain entanglements, and hence the polymer concentration, has a considerable 
influence over the viscosity of a solution (Ramakrishna et al., 2005). The actual 
conformation of individual polymer chains also has a significant influence on solution 
viscosity, considering that solutions containing coiled chains have a lower viscosity than 
those with extended chains (Ramakrishna et al., 2005). It is therefore important to 
investigate the rheological properties of polymeric solutions employed in 
electrospinning. 
 
The 25%w/v PVA solution that was electrospun to form the fiber layer of the FMS was 
analyzed for responses to rheological stresses, both linear and oscillating. The average 
shear force (τ) and viscosity (η) was 186.40Pa and 737.5mPa.s, respectively, for an 
average shear rate ( ) of 252.3/s. Figure 5.14 displays the rheological profile. The linear 
rheological properties of the 25%w/v solution were deemed acceptable for 
electrospinning because adequate fiber formation occurred at that polymer 
concentration.  
 
 
Figure 5.14: Linear rheological profile of the 25%w/v PVA electrospinning solution 
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Thixotropy is when the viscosity of a material, that was at rest, decreases on exposure 
to a mechanical stress and consequently increases again upon removal of the stress 
(Barnes, 1997; Mewis and Wagner, 2009). The thixotropy of the 25%w/v PVA 
electrospinning solution was determined by calculating the difference between the AUC 
values of the increasing shear and decreasing shear rate curves and was determined to 
be -1.229Pa.s-1. This difference is relatively small when compared to the average AUC, 
which was 757.4Pa.s-1 and it was deduced that the electrospinning solution underwent 
adequate recovery. Figure 5.15 displays the thixotropy curve for the 25% PVA solution. 
The curves of shear stress as a function of shear rate (blue line) for both increasing and 
decreasing rates follow an almost identical path and appear as one thick line, 
suggesting a favorable recovery of the sample. 
 
 
Figure 5.15: Thixotropy curve for the 25%w/v PVA solution used for electrospinning 
 
Viscoelasticity is an important factor to be considered for the electrospinning of a 
polymer solution as the polymer is required to be stretched in order to produce fibers. It 
is necessary for the elastic properties of a solution to be great enough so that the fiber 
jet will not break up before reaching the collector surface (Eggers and Villermaux, 
2008). Oscillation rheology testing is a useful tool for assessing the viscoelastic 
behavior of materials intended for electrospinning. The yield stress (τo) was determined 
for the 25%w/v PVA electrospinning solution at 25°C by measuring the deformation (γ) 
over a range of controlled stress (τ). The average yield stress was 0.3782Pa and the 
rheological plot is depicted in Figure 5.16. In order to determine the viscoelastic region 
of the 25%w/v PVA electrospinning solution, a stress sweep was performed at various 
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frequencies to ascertain the yield point. The yield point was found to be 6.36Pa at a 
frequency of 0.1Hz and is depicted graphically in Figure 5.17. A frequency sweep was 
performed in order to determine the stability of the 25%w/v PVA solution. The frequency 
of oscillations was ranged from 8 to 0.008Hz at a constant stress. The resulting plot is 
depicted in Figure 5.18. 
 
 
Figure 5.16: Rheology plot depicting the yield stress (at 0.3782Pa) of a 25%w/v PVA 
solution intended for electrospinning 
 
 
Figure 5.17: Rheological plot depicting the yield point in a stress sweep of a 25%w/v 
PVA solution 
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Figure 5.18: Stress sweep of 25%w/v PVA solution intended for electrospinning 
 
5.3.12. Vibrational Chemical Structure Analysis 
FTIR spectroscopy is a propitious tool for determining whether two or more components 
exist together as a mixture or if there is a chemical interaction (Bourtoom and Chinnan, 
2008). FTIR is the analysis of the infrared spectrum, which is formed by measuring the 
absorption of electromagnetic radiation over a range of frequencies. The radiation is 
absorbed by molecules at the frequencies of the vibrations of the chemical bonds within 
(Coates, 2000). FTIR analysis was performed in order to determine whether any 
chemical changes occurred to the drug and/or polymer during the process of 
electrospinning. 
 
The molecular structures of DPH and PVA are depicted in Figure 5.19. The FTIR 
spectra for the DPH-loaded fiber layer (DF), DPH and non-drug-loaded PVA placebo 
fibers (PF) are depicted in Figure 5.20. The broad O-H stretching vibration of PVA 
(Figure 5.19b) can clearly be seen for both DF and PF at 3295cm-1. DPH and DF both 
show a small peak at 3033cm-1, characteristic of the phenyl groups present in the DPH 
molecule (Figure 5.19a). The phenyl groups are also identified by the presence of large 
peaks at 755cm-1 and 702cm-1 in both profiles where DPH was present. The peak 
associated with the stretching vibration of the alkoxy substituent in the DPH molecule at 
2955cm-1 is obscured by the slightly broader band of the alkyl group of the PVA 
molecule at 2913cm-1 in the DF spectrum, which can also be seen in the PF spectrum. 
The broad peaks at 2594cm-1, 2524cm-1 and 2487cm-1 in the DPH spectrum, 
representative of the tertiary amine group, are also visible in the DF spectrum, but not in 
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the PF spectrum. The peak at 1598cm-1, indicating the absorption from the phenyl 
groups, is visible in both the DPH and DF spectra. From the FTIR data, it can be 
concluded that no significant chemical changes occurred to the drug during solution 
preparation and electrospinning.  
       
    
Figure 5.19: Molecular structures of (a) DPH and (b) PVA 
 
Figure 5.20: FTIR profiles of the drug-loaded fibers (DF), placebo fibers (PF) and DPH 
 
5.4. Concluding Remarks 
 
An optimized FMS formulation was prepared by electrospinning drug-loaded PVA fibers 
directly onto a thin polymeric film consisting of PVA and HPMC. The physicochemical 
and physicomechanical characteristics of the FMS were assessed. The FMS exhibited 
rapid disintegration and drug release, mucoadhesion, oramucosal retention, flexibility 
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and minimal mucosal irritation due to pH variation. The FMS was found to be flexible 
and extensible on physicomechanical analysis. Furthermore, upon FTIR analysis, it was 
elucidated that no significant chemical interactions occurred between drug, polymer and 
excipients during the process of formulation preparation. The FMS may therefore be 
deemed suitable for rapid oramucosal drug delivery. 
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CHAPTER 6 
CONCLUSIONS AND RECOMMENDATIONS 
 
6.1. Conclusions 
 
This study designed, developed and analyzed a porous Fibrous Matrix System (FMS), 
consisting of drug-loaded electrospun fibers incorporated directly onto a polymeric 
backing film, which has been evidenced to possess considerable potential in rapid oral 
transmucosal drug delivery.  
 
Preliminary studies were conducted and polyvinylalcohol (PVA) was found to be the 
most suitable polymer for the formation of the drug-loaded fiber layer for the purposes of 
this study. Diphenhydramine (DPH) and zidovudine (AZT) were employed as the model 
drugs. Ideal DPH-loaded PVA fibers were produced by dissolving DPH (10%w/v), citric 
acid (2%w/v) and glycerol (5%
v/v) directly in the 25%
w/v PVA solution and subsequently 
electrospinning. Preliminary studies on the polymeric backing film layer of the FMS 
revealed that combinations of PVA and hydroxypropylmethylcellulose (HPMC) were 
optimal for film-formation for the purposes of this study. Variables for the formulation of 
adequate films were obtained and employed in a 3-factor Box-Behnken experimental 
design in order to optimize the backing film layer in terms of drug release from the fiber 
layer, mucoadhesion and disintegration time. The effects of the independent variables 
on the dependent response variables were assessed and an optimized formulation was 
mathematically determined. 
 
The optimized FMS exhibited mucoadhesiveness, a rapid rate of disintegration and 
accelerated drug release. Favorable rheological properties, flexibility, extensibility, 
minimal pH variation and an absence of significant chemical changes characterized the 
optimized FMS. From the results of physicochemical and physicomechanical analysis, 
the FMS was deemed suitable for application in rapid oramucosal drug delivery. 
 
The FMS developed in this study may be regarded as suitable for rapid oramucosal 
drug delivery and is considered able to overcome some of the inherent disadvantages of 
oral drug delivery, particularly for pediatric and geriatric patients, who experience 
difficulty in swallowing large tablets and capsules. The FMS may also be capable of 
overcoming some of the limitations of current rapidly dissolving systems such as wafers. 
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6.2. Recommendations 
 
Although the FMS was developed and optimized employing DPH as a model drug, it is 
not limited in its application to the delivery of this drug, but may be relevant for the 
oramucosal delivery of a variety of drugs, particularly those requiring a rapid onset of 
action. Such drugs may include, but should not necessarily be limited to, sleep inducers, 
anxiolytics, antihistamines, antiemetics, analgesics and antianginal agents. The FMS 
may also find application in the delivery of drugs that do not necessarily require a rapid 
onset of action, but tend to be problematic for administration to pediatric or geriatric 
patients due to poor stability in a liquid formulation as the FMS is a solid delivery system 
that does not require swallowing. Such drugs may include antibiotics, antiretrovirals and 
other antiviral agents. 
 
Large variations in drug-loading were observed for the FMS, which were due to the 
uneven deposition of the drug-loaded fibers during electrospinning. Further 
electrospinning method and formulation development is therefore required in order to 
temper the regularity of the fiber layer and, hence, achieve more accurate drug dosing.  
 
Furthermore, the drug-loading capability of the FMS was relatively low and additional 
studies would thus need to be conducted in order to increase the potential dosing 
capacity of the FMS. 
 
The present study did not include an in vivo component and future work should 
therefore focus on assessing the FMS for in vivo drug release characteristics and 
suitability. 
 
Zidovudine (AZT), the model drug that was originally applied in this study, exhibited 
poor permeability, and incorporation of penetration enhancing agents was complicated 
by their detrimental effect on fiber formation by electrospinning. Further studies involving 
the incorporation of penetration enhancers into the electrospun fiber layer should 
therefore be conducted in order to improve the permeation of less permeable drugs. 
 
 117 
REFERENCES 
 
1. Abrams, J., 1983. New nitrate delivery systems: Buccal nitroglycerin. American 
Heart Journal, 105, 848-854. 
2. Agarwal, S., Wendorff, J.H., Greiner, A., 2008. Use of electrospinning technique 
for biomedical applications. Polymer, 49, 5603-5621. 
3. Ahn, Y.C., Park, S.K., Kim, G.T., Hwang, Y.J., Lee, C.G., Shin, H.S., Lee, J.K., 
2006. Development of high efficiency nanofilters made of nanofibers. Current 
Applied Physics, 6, 1030-1035. 
4. Ali, A.A., 2008. New generation of super absorber nano-fibroses hybrid fabric by 
electro-spinning. Journal of Materials Processing Technology, 199, 193-198. 
5. Allaoui, A., Hoa, S.V., Pugh, M.D., 2008. The electronic transport properties and 
microstructure of carbon nanofiber/epoxy composites. Composites Science and 
Technology, 68, 410-416. 
6. Andrews, G.P., Laverty, T.P., Jones, D.S., 2009. Mucoadhesive polymeric 
platforms for controlled drug delivery. European Journal of Pharmaceutics and 
Biopharmaceutics, 71, 505-518. 
7. Arinstein, A., Burman, M., Gendelman, O., Zussman, E., 2007. Effect of 
supramolecular structure on polymer nanofiber elasticity. Nature Nanotechnology, 
2, 59-62. 
8. Aungst, B.J., 1999. P-glycoprotein, secretory transport, and other barriers to the 
oral delivery of anti-HIV drugs. Advanced Drug Delivery Reviews, 39, 105-116. 
9. Azarmi, S., Roa, W., Löbenberg, R., 2007. Current perspectives in dissolution 
testing of conventional and novel dosage forms. International Journal of 
Pharmaceutics, 328, 12-21. 
10. Bai, J., Li, Y., Li, M., Wang, S., Zhang, C., Yang, Q., 2008. Electrospinning method 
for the preparation of silver chloride nanoparticles in PVP nanofiber. Applied 
Surface Science, 254, 4520-4523. 
11. Baji, A., Mai, Y.-W., Wong, S.-C., Abtahi, M., Chen, P., 2010. Electrospinning of 
polymer nanofibers: Effects on oriented morphology, structures and tensile 
properties. Composites Science and Technology, 70, 703-718. 
12. Barnes, H.A., 1997. Thixotropy – a review. Journal of Non-Newtonian Fluid 
Mechanics, 70,1-33. 
13. Baumgarten, P.K., 1971. Electrostatic spinning of acrylic microfibers. Journal of 
Colloid and Interface Science, 36, 71-79. 
 118 
14. Beachley, V., Wen, X., 2009. Effect of electrospinning parameters on the nanofiber 
diameter and length. Materials Science and Engineering C, 29, 663-668. 
15. Bhardwaj, N., Kundu, S.C., 2010. Electrospinning: A fascinating fiber fabrication 
technique. Biotechnology Advances, 28, 325-347. 
16. Bottenberg, P., Cleymaet, R., De Muynck, C., Remon, J.P., Coomans, D., 
Michotte, Y., Slop, D., 1991. Development and testing of bioadhesive, fluoride-
containing slow-release tablets for oral use. Journal of Pharmacy and 
Pharmacology, 43, 457-464. 
17. Bourtoom, T., Chinnan, M.S., 2008. Preparation and properties of rice starch-
chitosan blend biodegradable film. LWT – Food Science and Technology, 41, 
1633-1641. 
18. Box, G.E.P., Behnken, D.W., 1960. Some new three level designs for the study of 
quantitative variables. Technometrics, 2, 455-475. 
19. Bredenberg, S., Duberg, M., Lennernäs, B., Lennernäs, H., Pettersson, A., 
Westerberg, M., Nyström, C., 2003. In vitro and in vivo evaluation of a new 
sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as 
the active substance. European Journal of Pharmaceutical Sciences, 20, 327-334. 
20. Bruner, L., Tolloczko, St., 1901. Über die Auflösungsgeschwindigkeit fester 
Körper. Zeitschrift für Anorganische Chemie, 28, 314-330. 
21. Cappello, B., De Rosa, G., Giannini, L., La Rotonda, I.M., Mensitieri, G., Miro, A., 
Quaglia, F., Russo, R., 2006. Cyclodextrin-containing poly(ethylene oxide) tablets 
for the delivery of poorly soluble drugs: Potential as buccal delivery system. 
International Journal of Pharmaceutics, 319, 63-70. 
22. Carli, F., Capone, G., Colombo, I., Magarotto, L., Motta, A., 1984. Surface and 
transport properties of acrylic polymers influencing drug release from porous 
matrices. International Journal of Pharmaceutics, 21, 317-329. 
23. Casper, C.L., Stephens, J.S., Tassi, N.G., Chase, D.B., Rabolt, J.F., 2004. 
Controlling surface morphology of electrospun polystyrene fibers: Effect of 
humidity and molecular weight on the electrospinning process. Macromolecules, 
37, 573-578. 
24. Chan, B.P., Leong, K.W., 2008. Scaffolding in tissue engineering: general 
approaches and tissue-specific considerations. European Spine Journal, 17, 
S467-S479. 
25. Chandrasekhar, R., Hassan, Z., AlHusban, F., Smith, A.M., Mohammed, A.R., 
2009. The role of formulation excipients in the development of lyophilised fast-
disintegrating tablets. European Journal of Pharmaceutics and Biopharmaceutics, 
72, 119-129. 
 119 
26. Chen, Q.Z., Thompson, I.D., Boccaccini, A.R., 2006. 45S5 Bioglass®-derived 
glass-ceramic scaffolds for bone tissue engineering. Biomaterials, 27, 2414-2425. 
27. Chen, J.-P., Chang, G.-Y., Chen, J.-K., 2008. Electrospun collagen/chitosan 
nanofibrous membrane as wound dressing. Colloids and Surfaces A: 
Physicochemical and Engineering Aspects, 313-314, 183-188. 
28. Chew, S.Y., Wen, J., Yim, E.K.F., Leong, K.W., 2005. Sustained release of 
proteins from electrospun biodegradable fibers. Biomacromolecules, 6, 2017-
2024.  
29. Chew, S.Y., Mi, R., Hoke, A., Leong, K.W., 2008. The effect of the alignment of 
electrospun fibrous scaffolds on Schwann cell maturation. Biomaterials, 29, 653-
661.  
30. Chopra, S., Motwani, S.K., Iqbal, Z., Talegaonkar, S., Ahmad, F.J., Khar, R.K., 
2007. Optimisation of polyherbal gels for vaginal drug delivery by Box-Behnken 
statistical design. European Journal of Pharmaceutics and Biopharmaceutics, 67, 
120-131. 
31. Chu, B., Liang, D., Hadjiargyrou, M., Hsiao, B.S., 2006. A new pathway for 
developing in vitro nanostructured non-viral gene carriers. Journal of Physics: 
Condensed Matter, 18, S2513-S2525. 
32. Chunder, A., Sarkar, S., Yu, Y., Zhai, L., 2007. Fabrication of ultrathin 
polyelectrolyte fibers and their controlled release properties. Colloids and Surfaces 
B: Biointerfaces, 58, 172-179. 
33. Coates, J., 2000. Interpretation of infrared spectra, a practical approach. In: 
Meyers, R.A. (Ed.), Encyclopedia of Analytical Chemistry, John Wiley and Sons, 
Ltd, Chichester, pp. 10815-10837. 
34. Coviello, T., Alhaique, F., Parisi, C., Matricardi, P., Bocchinfuso, G., Grassi, M., 
2005. A new polysaccharidic gel matrix for drug delivery: preparation and 
mechanical properties. Journal of Controlled Release, 102, 643-656. 
35. Deitzel, J.M., Kleinmeyer, J., Harris, D., Beck Tan, N.C., 2001. The effect of 
processing variables on the morphology of electrospun nanofibers and textiles. 
Polymer, 42, 261-272. 
36. Deng, X.-L., Sui, G., Zhao, M.-L., Chen, G.-Q., Yang, X.-P., 2007. Poly(L-lactic 
acid)/hydroxyapatite hybrid nanofibrous scaffolds prepared by electrospinning. 
Journal of Biomaterials Science. Polymer Edition, 18, 117-130.  
37. Deschepper, E., Thas, O., Ottoy, J.P., 2006. Regional residual plots for assessing 
the fit of linear regression models. Computational Statistics and Data Analysis, 50, 
1995-2013. 
 120 
38. Ding, B., Kim, J., Miyazaki, Y., Shiratori, S., 2004. Electrospun nanofibrous 
membranes coated quartz crystal microbalance as gas sensor for NH3 detection. 
Sensors and Actuators B, 101, 373-380. 
39. Dixit, R.P., Puthli, S.P., 2009. Oral strip technology: Overview and future potential. 
Journal of Controlled Release, 139, 94-107. 
40. Dokoumetzidis, A., Macheras, P., 2006. A century of dissolution research: From 
Noyes and Whitney to the Biopharmaceutics Classification System. International 
Journal of Pharmaceutics, 321, 1-11. 
41. Doshi, J., Reneker, D.H., 1995. Electrospinning process and applications of 
electrospun fibers. Journal of Electrostatics, 35, 151-160. 
42. Eggers, J., Villermaux, E., 2008. Physics of liquid jets. Reports on Progress in 
Physics, 71, 036601. 
43. Eouani, C., Piccerelle, Ph., Prinderre, P., Bourret, E., Joachim, J., 2001. In-vitro 
comparative study of buccal mucoadhesive performance of different polymeric 
films. European Journal of Pharmaceutics and Biopharmaceutics, 52, 45-55. 
44. Ferreira, S.L.C., Bruns, R.E., Ferreira, H.S., Matos, G.D., David, J.M., Brandão, 
G.C., da Silva, E.G.P., Portugal, L.A., dos Reis, P.S., Souza, A.S., dos Santos, 
W.N.L., 2007. Box-Behnken design: An alternative for the optimization of analytical 
methods. Analytica Chimica Acta, 597, 179-186. 
45. Figueiras, A., Hombach, J., Veiga, F., Bernkop-Schnürch, A., 2009. In vitro 
evaluation of natural and methylated cyclodextrins as buccal permeation 
enhancing system for omeprazole delivery. European Journal of Pharmaceutics 
and Biopharmaceutics, 71, 339-345.  
46. Fong, H., Chun, I., Reneker, D.H., 1999. Beaded nanofibers formed during 
electrospinning. Polymer, 40, 4585-4592. 
47. Formhals, A., 1934. Process and apparatus for preparing artificial threads. US 
Patent 1 975 504, 2 Oct. 
48. Formhals, A., 1939. Method and apparatus for spinning. US Patent 2 160 962, 6 
Jun. 
49. Formhals, A., 1940. Artificial thread and method of producing same. US Patent 2 
187 306, 16 Jan. 
50. Formhals, A., 1943. Production of artificial fibers from fiber forming liquids. US 
Patent. 2 323 025, 29 Jun. 
51. Frenot, A., Chronakis, I.S., 2003. Polymer nanofibers assembled by 
electrospinning. Current Opinion in Colloid and Interface Science, 8, 64-75. 
52. Giannola, L.I., De Caro, V., Giandalia, G., Siragusa, M.G., Tripodo, C., Florena, 
A.M., Campisi, G., 2007. Release of naltrexone on buccal mucosa: Permeation 
 121 
studies, histological aspects and matrix system design. European Journal of 
Pharmaceutics and Biopharmaceutics, 67, 425-433. 
53. Gong, J., Shao, C.-L., Yang, G.-C., Pan, Y., Qu, L.-Y., 2003. Preparation of ultra-
fine fiber mats contained H4SiW12O40. Inorganic Chemistry Communications, 6, 
916-918. 
54. He, C.-L., Huang, Z.-M., Han, X.-J., Liu, L., Zhang, H.-S., Chen, L.-S., 2006. 
Coaxial electrospun poly(L-lactic acid) ultrafine fibers for sustained drug delivery. 
Journal of Macromolecular Science, Part B: Physics, 45, 515-524. 
55. He, C.-L., Huang, Z.-M., Han, X.-J., 2009. Fabrication of drug-loaded electrospun 
aligned fibrous threads for suture applications. Journal of Biomedical Materials 
Research Part A, 89A, 80-95. 
56. Hogan Jr., C.J., Biswas, P., 2008. Narrow size distribution nanoparticle production 
by electrospray processing of ferritin. Aerosol Science, 39, 432-440. 
57. Hoogstraate, J.A.J., Wertz, P.W., 1998. Drug Delivery via the Buccal Mucosa. 
Pharmaceutical Science and Technology Today, 1, 309-316. 
58. Huang, Z.-M., Zhang, Y.-Z., Kotaki, M., Ramakrishna, S., 2003. A review on 
polymer nanofibers by electrospinning and their applications in nanocomposites. 
Composites Science and Technology, 63, 2223-2253. 
59. Huang, Z.-M,. He, C.-L., Yang, A., Zhang, Y., Han, X.-J., Yin, J., Wu, Q., 2006. 
Encapsulating drugs in biodegradable ultrafine fibers through co-axial 
electrospinning. Journal of Biomedical Materials Research Part A, 77A, 169-179. 
60. Jarusuwannapoom, T., Hongrojjanawiwat, W., Jitjaicham, S., Wannatong, L., 
Nithitanakul, M., Pattamaprom, C., Koombhongse, P., Rangkupan, R., Supaphol, 
P., 2005. Effect of solvents on electro-spinnability of polystyrene solutions and 
morphological appearance of resulting electrospun polystyrene fibers. European 
Polymer Journal, 41, 409-421. 
61. Jaworek, A., 2007. Micro- and nanoparticle production by electrospraying. Powder 
Technology, 176, 18-35. 
62. Ju, Y.-W., Park, J.-H., Jung, H.-R., Cho, S.-J., Lee, W.-J., 2008. Electrospun 
MnFe2O4 nanofibers: Preparation and morphology. Composites Science and 
Technology, 68, 1704-1709. 
63. Kalayci, V.E., Patra, P.K., Kim, Y.K., Ugbolue, S.C., Warner, S.B., 2005. Charge 
consequences in electrospun polyacrylonitrile (PAN) nanofibers. Polymer, 46, 
7191-7200. 
64. Kang, X., Pan, C., Xu, Q., Yao, Y., Wang, Y., Qi, D., Gu, Z., 2007. The 
investigation of electrospun polymer nanofibers as a solid-phase extraction 
 122 
sorbent for the determination of trazodone in human plasma. Analytica Chimica 
Acta, 587, 75-81. 
65. Karavas, E., Georgarakis, E., Bikiaris, D., 2006. Application of PVP/HPMC 
miscible blends with enhanced mucoadhesive properties for adjusting drug release 
in predictable pulsatile chronotherapeutics. European Journal of Pharmaceutics 
and Biopharmaceutics, 64, 115-126. 
66. Kenawy, E.-R., Bowlin, G.L., Mansfield, K., Layman, J., Simpson, D.G., Sanders, 
E.H., Wnek, G.E., 2002. Release of tetracycline hydrochloride from electrospun 
poly(ethylene-co-vinylacetate), poly(lactic acid), and a blend. Journal of Controlled 
Release, 81, 57-64. 
67. Kenawy, E.-R., Abdel-Hay, F.I., El-Newehy, M.H., Wnek, G.E., 2007. Controlled 
release of ketoprofen from electrospun poly(vinyl alcohol) nanofibers. Materials 
Science and Engineering A, 459, 390-396. 
68. Kenawy, E.-R., Abdel-Hay, F.I., El-Newehy, M.H., Wnek, G.E., 2009. Processing 
of polymer nanofibers through electrospinning as drug delivery systems. Materials 
Chemistry and Physics, 113, 296-302. 
69. Khil, M.-S., Cha, D.-I., Kim, H.-Y., Kim, I.-S., Bhattarai, N., 2003. Electrospun 
nanofibrous polyurethane membrane as wound dressing. Journal of Biomedical 
Materials Research Part B: Applied Biomaterials, 67B, 675-679. 
70. Kim, K., Luu, Y.K., Chang, C., Fang, D., Hsiao, B.S., Chu, B., Hadjiargyrou, M., 
2004. Incorporation and controlled release of a hydrophilic antibiotic using 
poly(lactide-co-glycolide)-based electrospun nanofibrous scaffolds. Journal of 
Controlled Release, 98, 47-56. 
71. Kim, T.G., Lee, D.S., Park, T.G., 2007. Controlled protein release from electrospun 
biodegradable fiber mesh composed of poly(ε-caprolactone) and poly(ethylene 
oxide). International Journal of Pharmaceutics, 338, 276-283. 
72. Langoth, N., Bernkop-Schnürch, A., Kurka, P., 2005. In vitro evaluation of various 
buccal permeation enhancing systems for PACAP (pituatary adenylate cyclase-
activating polypeptide). Pharmaceutical Research, 22, 2045-2050. 
73. Lee, C.H., Shin, H.J., Cho, I.H., Kang, Y.-M., Kim, I.A., Park, K.-D., Shin, J.-W., 
2005. Nanofiber alignment and direction of mechanical strain affect the ECM 
production of human ACL fibroblast. Biomaterials, 26, 1261-1270. 
74. Li, D., Xia, Y., 2004. Electrospinning of nanofibers: Reinventing the wheel? 
Advanced Materials, 16, 1151-1170. 
75. Li, M., Han, G., Yang, B., 2008a. Fabrication of the catalytic electrodes for 
methanol oxidation on electrospinning-derived carbon fibrous mats. 
Electrochemistry Communications, 10, 880-883. 
 123 
76. Li, X., Zhang, H., Li, H., Tang, G., Zhao, Y., Yuan, X., 2008b. Self-accelerated 
biodegradation of electrospun poly(ethylene glycol)-poly(L-lactide) membranes by 
loading proteinase K. Polymer Degradation and Stability, 93, 618-626. 
77. Li, Z.-F., Blum, F.D., Bertino, M.F., Kim, C.-S., Pillalamarri, S.K., 2008c. One-step 
fabrication of a polyaniline nanofiber vapor sensor. Sensors and Actuators B, 134, 
31-35. 
78. Liang, D., Luu, Y.K., Kim, K., Hsiao, B.S., Hadjiargyrou, M., Chu, B., 2005. In vitro 
non-viral gene delivery with nanofibrous scaffolds. Nucleic Acids Research, 33, 
e170. 
79. Liang, D., Hsiao, B.S., Chu, B., 2007. Functional electrospun nanofibrous scaffolds 
for biomedical applications. Advanced Drug Delivery Reviews, 59, 1392-1412.  
80. Liao, S., Wang, W., Uo, M., Ohkawa, S., Akasaka, T., Tamura, K., Cui, F., Watari, 
F., 2005. A three-layered nano-carbonated hydroxyapatite/collagen/PLGA 
composite membrane for guided tissue regeneration. Biomaterials, 26, 7564-7571.  
81. Liao, S., Murugan, R., Chan, C.K., Ramakrishna, S., 2008. Processing 
nanoengineered scaffolds through electrospinning and mineralization suitable for 
biomimetic bone tissue engineering. Journal of the Mechanical Behaviour of 
Biomedical Materials, 1, 252-260. 
82. Liu, X., Won, Y., Ma, P.X., 2006. Porogen-induced surface modification of nano-
fibrous scaffolds for tissue engineering. Biomaterials, 27, 3980-3987. 
83. Llabot, J.M., Palma, S.D., Manzo, R.H., Allemandi, D.A., 2007. Design of novel 
antifungal mucoadhesive films Part II. Formulation and in vitro biopharmaceutical 
evaluation. International Journal of Pharmaceutics, 336, 263-268. 
84. Loh, X.J., Peh, P., Liao, S., Sng, C., Li, J., 2010. Controlled drug release from 
biodegradable thermoresponsive physical hydrogel nanofibers. Journal of 
Controlled Release, 143, 175-182. 
85. Lu, J.-W., Zhang, Z.-P., Ren, X.-Z., Chen, Y.-Z., Yu, J., Guo, Z.-X., 2008. High-
elongation fiber mats by electrospinning of polyoxymethylene. Macromolecules, 
41, 3762-3764. 
86. Luong-Van, E., Grøndal, L., Chua, K.N., Leong, K.W., Nurcombe, V., Cool, S.M., 
2006. Controlled release of heparin from poly(ε-caprolactone) electrospun fibers. 
Biomaterials, 27, 2042-2050. 
87. Ma, Z., Kotaki, M., Yong, T., He, W., Ramakrishna, S., 2005. Surface engineering 
of electrospun polyethylene terephthalate (PET) nanofibers towards development 
of a new material for blood vessel engineering. Biomaterials, 26, 2527-2536. 
 124 
88. Ma, K., Chan, C.K., Liao, S., Hwang, W.Y.K., Feng, Q., Ramakrishna, S., 2008. 
Electrospun nanofibers scaffolds for rapid and rich capture of bone marrow-
derived hematopoietic stem cells. Biomaterials, 29, 2096-2103. 
89. MacDiarmid, A.G., Jones Jr., W.E., Norris, I.D., Gao, J., Johnson Jr., A.T., Pinto, 
N.J., Hone, J., Han, B., Ko, F.K., Okuzaki, H., Llaguno, M., 2001. Electrostatically-
generated nanofibers of electronic polymers. Synthetic Materials, 119, 27-30.  
90. Madhav, N.V.S., Shakya, A.K., Shakya, P., Singh, K., 2009. Orotransmucosal drug 
delivery systems: A review. Journal of Controlled Release, 140, 2-11. 
91. Malone, M.E., Appelqvist, I.A.M., Norton, I.T., 2003. Oral behaviour of food 
hydrocolloids and emulsions. Part 1. Lubrication and deposition considerations. 
Food Hydrocolloids, 17, 763-773. 
92. Maquet, V., Boccaccini, AR.,  Pravata, L.,  Notingher, I., Jérôme, R., 2004. Porous 
poly(α-hydroxyacid)/Bioglass® composite scaffolds for bone tissue engineering. I: 
preparation and in vitro characterisation. Biomaterials, 25, 4185-4194. 
93. Maretschek, S., Greiner, A., Kissel, T., 2008. Electrospun biodegradable nanofiber 
nonwovens for controlled release of proteins. Journal of Controlled Release, 127, 
180-187. 
94. McCarron, P.A., Donnelly, R.F., Zawislak, A., Woolfson, A.D., Price, J.H., 
McClelland, R., 2005. Evaluation of a water-soluble bioadhesive patch for 
photodynamic therapy of vulval lesions. International Journal of Pharmaceutics, 
293, 11-23. 
95. McKee, M.G., Wilkes, G.L., Colby, R.H., Long, T.E., 2004. Correlations of solution 
rheology with electrospun fiber formation of linear and branched polyesters. 
Macromolecules, 37, 1760-1767. 
96. Meechaisue, C., Dubin, R., Supaphol, P., Hoven, V.P., Kohn, J., 2006. 
Electrospun mat of tyrosine-derived polycarbonate fibers for potential use as 
tissue scaffolding material. Journal of Biomaterials Science. Polymer Edition, 17, 
1039-1056. 
97. Megelski, S., Stephens, J.S., Chase, D.B., Rabolt, J.F., 2002. Micro- and 
nanostructured surface morphology on electrospun polymer fibers. 
Macromolecules, 35, 8456-8466. 
98. Mewis, J., Wagner, N.J., 2009. Thixotropy. Advances in Colloid and Interface 
Science, 147-148, 214-227. 
99. Miao, X., Tan, D.M., Li, J., Xiao, Y., Crawford, R., 2008. Mechanical and biological 
properties of hydroxyapatite/tricalcium phosphate scaffolds coated with poly(lactic-
co-glycolic acid). Acta Biomaterialia, 4, 638-645.  
 125 
100. Munasur, A.P., Pillay, V., Chetty, D.J., Govender, T., 2006. Statistical optimisation 
of the mucoadhesivity and characterisation of multipolymeric propranolol matrices 
for buccal therapy. International Journal of Pharmaceutics, 323, 43-51.  
101. Munir, M.M., Suryamas, A.B., Iskandar, F., Okuyama, K., 2009. Scaling law on 
particle-to-fiber formation during electrospinning. Polymer, 50, 4935-4943. 
102. Nafee, N.A., Ismail, F.A., Boraie, N.A., Mortada, L.M., 2003. Mucoadhesive buccal 
patches of miconazole nitrate: in vitro/in vivo performance and effect of ageing. 
International Journal of Pharmaceutics, 264, 1-14. 
103. Nicolazzo, J.A., Reed, B.L., Finnin, B.C., 2005. Buccal penetration enhancers – 
How do they really work? Journal of Controlled Release, 105, 1-15. 
104. Nieh, S., Nguyen, T., 1988. Effects of humidity, conveying velocity, and particle 
size on electrostatic charges of glass beads in a gaseous suspension flow. Journal 
of Electrostatics, 21, 99-114. 
105. Oh, G.-Y., Ju, Y.-W., Kim, M.-Y., Jung, H.-R., Kim, H.J., Lee, W.-J., 2008. 
Adsorption of toluene on carbon nanofibers prepared by electrospinning. Science 
of the Total Environment, 393, 341-347. 
106. Park, S.H., Kim, C., Choi, Y.O., Yang, K.S., 2003. Preparations of pitch-based 
CF/ACF webs by electrospinning. Carbon, 41, 2655-2657. 
107. Patel, V.M., Prajapati, B.G., Patel, M.M., 2007. Formulation, evaluation and 
comparison of bilayered and multilayered mucoadhesive buccal devices of 
propranolol hydrochloride. AAPS PharmSciTech, 8, E147-E154. 
108. Pawlowski, K.J., Belvin, H.L., Raney, D.L., Su, J., Harrison, J.S., Siochi, E.J., 
2003. Electrospinning of a micro-air vehicle wing skin. Polymer, 44, 1309-1314. 
109. Perioli, L., Ambrogi, V., Angelici, F., Ricci, M., Giovagnoli, S., Capuccella, M., 
Rossi, C., 2004. Development of mucoadhesive patches for buccal administration 
of ibuprofen. Journal of Controlled Release, 99, 73-82. 
110. Pillay, V., Danckwerts, M.P., Bhatt, R., Setshedi, R., Patel, R., 2005. Preparation 
of hydroxypropylcellulose membranes using slow ionotropic reactions configured 
in an experimental design. Journal of Bioactive and Compatible Polymers, 20, 
395-414. 
111. Ponchel, G., 1994. Formulation of oral mucosal drug delivery systems for the 
systemic delivery of bioactive materials. Advanced Drug Delivery Reviews, 13, 75-
87. 
112. Qi, H., Hu, P., Xu, J., Wang, A., 2006. Encapsulation of drug reservoirs in fibers by 
emulsion electrospinning: morphology characterization and preliminary release 
assessment. Biomacromolecules, 7, 2327-2330. 
 126 
113. Ramakrishna, S., Fujihara, K., Teo, W.-E., Lim, T.-C., Ma, Z., 2005. An 
introduction to electrospinning and nanofibers, World Scientific Publishing Co., 
London. 
114. Ranganath, S.H., Wang, C.-H., 2008. Biodegradable microfiber implants delivering 
paclitaxel for post-surgical chemotherapy against malignant glioma. Biomaterials, 
29, 2996-3003. 
115. Rathbone, M.J., Drummond, B.K., Tucker, I.G., 1994. The oral cavity as a site for 
systemic drug delivery. Advanced Drug Delivery Reviews, 13, 1-22. 
116. Reneker, D.H., Chun, I., 1996. Nanometre diameter fibres of polymer, produced by 
electrospinning. Nanotechnology, 7, 216-223. 
117. Reneker, D.H., Yarin, A.L., 2008. Electrospinning jets and polymer nanofibers. 
Polymer, 49, 2387-2425. 
118. Rodriguez, C.F., Bruneau, N., Barra, J., Alfonso, D., Doelker, E., 2000. Hydrophilic 
cellulose derivatives as drug delivery carriers: influence of substitution type on the 
properties of compressed matrix tablets. In: Wise, D.L. (Ed.), Handbook of 
Pharmaceutical Controlled Release Technology, Marcell Dekker, New York, pp. 1–
30. 
119. Rossi, S., Sandri, G., Caramella, C.M., 2005. Buccal drug delivery: A challenge 
already won? Drug Discovery Today: Technologies, 2, 59-65. 
120. Sahoo, S., Ouyang, H., Goh, J.C.-H., Tay, T.E., Toh, S.L., 2006. Characterization 
of a novel polymeric scaffold for potential application in tendon/ligament tissue 
engineering. Tissue Engineering, 12, 91-99. 
121. Sastry, S.V., Nyshadham, J.R., Fix, J.A., 2000. Recent technological advances in 
oral drug delivery – a review. Pharmaceutical Science and Technology Today, 3, 
138-145. 
122. Sawicka, K., Gouma, P., Simon, S., 2005. Electrospun biocomposite nanofibers 
for urea biosensing. Sensors and Actuators B, 108, 585-588. 
123. Schek, R.M., Taboas, J.M., Hollister, S.J., Krebsbach, P.H., 2005. Tissue 
engineering osteochondral implants for temporomandibular joint repair. 
Orthodontics & Craniofacial Research, 8, 313-319.  
124. Schnell, E., Klinkhammer, K., Balzer, S., Brook, G., Klee, D., Dalton, P., Mey, J., 
2007. Guidance of glial cell migration and axonal growth on electrospun 
nanofibers of poly-ε-caprolactone and a collagen/poly-ε-caprolactone blend. 
Biomaterials, 28, 3012-3025. 
125. Scholz, O.A., Wolff, A., Schumacher, A., Giannola, L.I., Campisi, G., Ciach, T., 
Velten, T., 2008. Drug delivery from the oral cavity: focus on a novel mechatronic 
delivery device. Drug Discovery Today, 13, 247-253. 
 127 
126. Şenel, S., Hıncal, A.A., 2001. Drug permeation enhancement via buccal route: 
possibilities and limitations. Journal of Controlled Release, 72, 133-144. 
127. Shenoy, S.L., Bates, W.D., Frisch, H.L., Wnek, G.E., 2005. Role of chain 
entanglements on fiber formation during electrospinning of polymer solutions: 
good solvent, non-specific polymer-polymer interaction limit. Polymer, 46, 3372-
3384. 
128. Shukla, S., Brinley, E., Cho, H.J., Seal, S., 2005. Electrospinning of hydroxypropyl 
cellulose fibers and their application in synthesis of nano and submicron tin oxide 
fibers. Polymer, 46, 12130-12145. 
129. Sibeko, B., Pillay, V., Choonara, Y.E., Khan, R.A., Modi, G., Iyuke, S.E., Naidoo, 
D., Danckwerts, M.P., 2009. Computational molecular modeling and structural 
rationalization for the design of a drug-loaded PLLA/PVA biopolymeric membrane. 
Biomedical Materials, 4, 015014. 
130. Sill, T.J., von Recum, H.A., 2008. Electrospinning: Applications in drug delivery 
and tissue engineering. Biomaterials, 29, 1989-2006. 
131. Simpson, D.M., Messina, J., Xie, F., Hale, M., 2007. Fentanyl buccal tablet for the 
relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic 
pain: a multicenter, randomized, double-blind, placebo-controlled study. Clinical 
Therapeutics, 29, 588-601. 
132. Singh, B., Kumar, R., Ahuja, N., 2004. Optimizing drug delivery systems using 
systematic “Design of Experiments.” Part I: Fundamental aspects. Critical 
ReviewsTM in Therapeutic Drug Carrier Systems, 22, 27-105. 
133. Sjökvist, E., Nyström, C., 1991. Physicochemical aspects of drug release. XI. 
Tableting properties of solid dispersions, using xylitol as carrier material. 
International Journal of Pharmaceutics, 67, 139-153. 
134. Son, W.K., Youk, J.H., Lee, T.S., Park, W.H., 2004. The effects of solution 
properties and polyelectrolyte on electrospinning of ultrafine poly(ethylene oxide) 
fibers. Polymer, 45, 2959-2966.  
135. Song, M., Pan, C., Li, J., Zhang, R., Wang, X., Gu, Z., 2008. Blends of TiO2 
nanoparticles and poly(N-isopropylacrylamide)-co-polystyrene nanofibers as a 
means to promote the biorecognition of an anticancer drug. Talanta, 75, 1035-
1040. 
136. Standing, J.F., Tuleu, C., 2005. Paediatric formulations – Getting to the heart of 
the problem. International Journal of Pharmaceutics, 300, 56-66. 
137. Stanley, T.H., Ashburn, M.A., 1992. Novel delivery systems: Oral transmucosal 
and intranasal transmucosal. Journal of Pain and Symptom Management, 7, 163-
171. 
 128 
138. Stewardson, D.J., Whitfield, R.I., 2004. A demonstration of the utility of fractional 
experimental design for finding optimal genetic algorithm parameter settings. 
Journal of the Operational Research Society, 55, 132-138. 
139. Sudhakar, Y., Kuotsu, K., Bandyopadhyay, A.K., 2006. Buccal bioadhesive drug 
delivery – A promising option for orally less efficient drugs. Journal of Controlled 
Release, 114, 15-40. 
140. Suwantong, O., Opanasopit, P., Ruktanonchai, U., Supaphol, P., 2007. 
Electrospun cellulose acetate fiber mats containing curcumin and release 
characteristic of the herbal substance. Polymer, 48, 7546-7557. 
141. Szepes, A., Ulrich, J., Farkas, Z., Kovács, J., Szabó-Révész, P., 2007. Freeze-
casting technique in the development of solid drug delivery systems. Chemical 
Engineering and Processing, 46, 230-238. 
142. Taepaiboon, P., Rungsardthong, U., Supaphol, P., 2006. Drug-loaded electrospun 
mats of poly(vinyl alcohol) fibers and their release characteristics of four model 
drugs. Nanotechnology, 17, 2317-2329. 
143. Taepaiboon, P., Rungsardthong, U., Supaphol, P., 2007. Vitamin-loaded 
electrospun cellulose acetate nanofiber mats as transdermal and dermal 
therapeutic agents of vitamin A acid and vitamin E. European Journal of 
Pharmaceutics and Biopharmaceutics, 67, 387-397. 
144. Tan, E.P.S., Ng, S.Y., Lim, C.T., 2005. Tensile testing of a single ultrafine 
polymeric fiber. Biomaterials, 26, 1453-1456. 
145. Tan, E.P.S., Lim, C.T., 2006. Mechanical characterization of nanofibers – A 
review. Composites Science and Technology, 66, 1102-1111. 
146. Tan, S., Feng, X., Zhao, B., Zou, Y., Huang, X., 2008. Preparation and 
photoluminescence properties of electrospun nanofibers containing PMO-PPV and 
Eu(ODBM)3phen. Materials Letters, 62, 2419-2421. 
147. Tao, J., Shivkumar, S., 2007. Molecular weight dependent structural regimes 
during the electrospinning of PVA. Materials Letters, 61, 2325-2328. 
148. Taylor, G., 1969. Electrically driven jets. Proceedings of the Royal Society of 
London. Series A, Mathematical and Physical Sciences, 313, 453-475. 
149. Theron, S.A., Zussman, E., Yarin, A.L., 2004. Experimental investigation of the 
governing parameters in the electrospinning of polymer solutions. Polymer, 45, 
2017-2030. 
150. Tiwari, S.K., Tzezana, R., Zussman, E., Venkatraman, S.S., 2010. Optimizing 
partition-controlled drug release from electrospun core-shell fibers. International 
Journal of Pharmaceutics, 392, 209-217. 
 129 
151. Tripatanasuwan, S., Zhong, Z., Reneker, D.H., 2007. Effect of evaporation and 
solidification of the charged jet in electrospinning of poly(ethylene oxide) aqueous 
solution. Polymer, 48, 5742-5746. 
152. Tsai, P.P., Schreuder-Gibson, H., Gibson, P., 2002. Different electrostatic 
methods for making electret filters. Journal of Electrostatics, 54, 333-341. 
153. Tungprapa, S., Jangchud, I., Supaphol, P., 2007. Release characteristics of four 
model drugs from drug-loaded electrospun cellulose acetate fiber mats. Polymer, 
48, 5030-5041. 
154. US Pharmacopeia 32, 2009. US Pharmacopeial Convention, Rockville, MD. 
155. Vaz, C.M., van Tuijl, S., Bouten, C.V.C., Baaijens, F.P.T., 2005. Design of 
scaffolds for blood vessel tissue engineering using a multi-layering electrospinning 
technique. Acta Biomateriala, 1, 575-582. 
156. Verreck, G., Chun, I., Rosenblatt, J., Peeters, J., Van Dijck, A., Mensch, J., Noppe, 
M., Brewster, M.E., 2003a. Incorporation of drugs in an amorphous state into 
electrospun nanofibers composed of a water-insoluble, nonbiodegradable 
polymer. Journal of Controlled Release, 92, 349-360. 
157. Verreck, G., Chun, I., Peeters, J., Rosenblatt, J., Brewster, M.E., 2003b. 
Preparation and characterization of nanofibers containing amorphous drug 
dispersions generated by electrostatic spinning. Pharmaceutical Research, 20, 
810-817. 
158. Vidaurre, A., Cortázar, I.C., Ribelles, J.L.G., 2007. Polymeric scaffolds with a 
double pore structure. Journal of Non-Crystalline Solids, 353, 1095-1100. 
159. Viswanath, B., Ravishankar, N., 2007. Porous biphasic scaffolds and coatings for 
biomedical applications via morphology transition of nanorods. Nanotechnology, 
18, 475604. 
160. Viswanathamurthi, P., Bhattarai, N., Kim, H.Y., Lee, D.R., 2003. Vanadium 
pentoxide nanofibers by electrospinning. Scripta Materiala, 49, 577-581. 
161. Winfield, A.J., 2004. Solutions. In: Winfield, A.J., Richards, R.M.E. (Ed.), 
Pharmaceutical practice, 3rd ed., Churchill Livingstone, London, p. 18. 
162. World Health Organization, 2007. Antiretroviral therapy for HIV infection in infants 
and children: Towards universal access. Recommendations for a public health 
approach. WHO Press, World Health Organization, Switzerland. 
163. World Health Organization, 2008. The International Pharmacopoeia, 4th ed. 
164. Wu, C., McGinity, J.W., 2000. Influence of relative humidity on the mechanical and 
drug release properties of theophylline pellets coated with an acrylic polymer 
containing methylparaben as a non-traditional plasticizer. European Journal of 
Pharmaceutics and Biopharmaceutics, 50, 277-284. 
 130 
165. Xin, Y., Huang, Z., Li, W., Jiang, Z., Tong, Y., Wang, C., 2008. Core-sheath 
functional polymer nanofibers prepared by co-electrospinning. European Polymer 
Journal, 44, 1040-1045. 
166. Xu, C.Y., Inai, R., Kotaki, M., Ramakrishna, S., 2004. Aligned biodegradable 
nanofibrous structure: a potential scaffold for blood vessel engineering. 
Biomaterials, 25, 877-886. 
167. Xu, X., Yang, L., Xu, X., Wang, X., Chen, X., Liang, Q., Zeng, J., Jing, X., 2005. 
Ultrafine medicated fibers electrospun from W/O emulsions. Journal of Controlled 
Release, 108, 33-42. 
168. Xu, X., Chen, X., Liu, A., Hong, Z., Jing, X., 2007. Electrospun poly(l-lactide)-
grafted hydroxyapatite/poly(L-lactide) nanocomposite fibers. European Polymer 
Journal, 43, 3187-3196. 
169. Xu, X., Chen, X., Ma, P., Wang, X., Jing, X., 2008. The release behavior of 
doxorubicin hydrochloride from medicated fibers prepared by emulsion-
electrospinning. European Journal of Pharmaceutics and Biopharmaceutics, 70, 
165-170. 
170. Yang, Q., Li, Z., Hong, Y., Zhao, Y., Qiu, S., Wang, C., Wei, Y., 2004. Influence of 
solvents on the formation of ultrathin uniform poly(vinyl pyrrolidone) nanofibers 
with electrospinning. Journal of Polymer Science: Part B: Polymer Physics, 42, 
3721-3726. 
171. Yang, F., Murugan, R., Wang, S., Ramakrishna, S., 2005. Electrospinning of 
nano/micro scale poly(L-lactic acid) aligned fibers and their potential in neural 
tissue engineering. Biomaterials, 26, 2603-2610. 
172. Yang, D., Li, Y., Nie, J., 2007. Preparation of gelatin/PVA nanofibers and their 
potential application in controlled release of drugs. Carbohydrate Polymers, 69, 
538-543. 
173. Yang, F., Wolke, J.G.C., Jansen, J.A., 2008. Biomimetic calcium phosphate 
coating on electrospun poly(ε-caprolactone) scaffolds for bone tissue engineering. 
Chemical Engineering Journal, 137, 154-161. 
174. Yao, W.-L., Wang, J.-L., Yang, J., Du, G.-D., 2008a. Novel carbon nanofiber-
cobalt oxide composites for lithium storage with large capacity and high 
reversibility. Journal of Power Sources, 176, 369-372. 
175. Yao, W., Yang, J., Wang, J., Tao, L., 2008b. Synthesis and electrochemical 
performance of carbon nanofiber-cobalt oxide composites. Electrochimica Acta, 
53, 7326-7330. 
 131 
176. Yoshimoto, H., Shin, Y.M., Terai, H., Vacanti, J.P., 2003. A biodegradable 
nanofiber scaffold by electrospinning and its potential for bone tissue engineering. 
Biomaterials, 24, 2077-2082. 
177. Zaman, M.A., Martin, G.P., Rees, G.D., 2008. Mucoadhesion, hydration and 
rheological properties of non-aqueous delivery systems (NADS) for the oral cavity. 
Journal of Dentistry, 36, 351-359. 
178. Zeleny, J., 1914. The electrical discharge from liquid points, and a hydrostatic 
method of measuring the electric intensity at their surfaces. The Physical Review, 
3, 69-91. 
179. Zeleny, J., 1917. Instability of electrified liquid surfaces. The Physical Review, 10, 
1-7. 
180. Zeleny, J., 1935. The role of surface instability in electrical discharges from drops 
of alcohol and water in air at atmospheric pressure. Journal of the Franklin 
Institute, 219, 659-675. 
181. Zeng, J., Xu, X., Cheng, X., Liang, Q., Bian, X., Yang, L., Jing, X., 2003. 
Biodegradable electrospun fibers for drug delivery. Journal of Controlled Release, 
92, 227-231. 
182. Zeng, J., Yang, L., Liang, Q., Zhang, X., Guan, H., Xu, X., Chen, X., Jing, X., 
2005. Influence of the drug compatibility with polymer solution on the release 
kinetics of electrospun fiber formulation. Journal of Controlled Release, 105, 43-
51. 
183. Zong, X., Kim, K., Fang, D., Ran, S., Hsiao, B.S., Chu, B., 2002. Structure and 
process relationship of electrospun bioabsorbable nanofiber membranes. Polymer, 
43, 4403-4412. 
184. Zong, X., Li, S., Chen, E., Garlick, B., Kim, K.-S., Fang, D., Chiu, J., Zimmerman, 
T., Brathwaite, C., Hsiao, B.S., Chu, B., 2004. Prevention of postsurgery-induced 
abdominal adhesions by electrospun bioabsorbable nanofibrous poly(lactide-co-
glycolide)-based membranes. Annals of Surgery, 240, 910-915.  
 
 
